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Abstract 
This thesis describes the development of novel homogeneous asymmetric 
hydrogenation catalysts that are all based on chiral non-racemic ferrocene derivatives 
as the catalyst ligands. For this purpose, phosphino-substituted ferrocenyloxazoline 
ligands were prepared and tested in ruthenium-catalyzed asymmetric hydrogenations 
and transfer hydrogenations. Furthermore, two novel and optimized synthesis 
procedures for such ligands were established. Moreover, a very general and highly 
modular synthesis procedure for chiral non-racemic 1,2-di- and 1,2,3-trisubstituted 
ferrocene derivatives has been developed. 
All novel phosphino-oxazoline ligands were prepared in good yields by applying 
two different and highly modular synthesis strategies. One synthesis route started from 
commercially available Ugi-amine and allowed to build up the desired phosphino-
oxazoline ligand in a five step sequence. With use of the second methodology, the 
desired phosphino-oxazoline ligands could be obtained in only two steps from 
commercially available ferrocenyloxazoline. Ruthenium complexes [RuCl2(PPh3)(L)] of 
all ligands were prepared. The application of these complexes as catalysts in 
asymmetric hydrogenations and transfer hydrogenations of ketones delivered excellent 
results and product with up to 99% e.e. was obtained in hydrogenation and with 98% 
e.e. in transfer hydrogenation reactions. 
In order to further ease the synthesis procedure of such ligands, two additional 
complementary synthesis routes were worked out and optimized. Both routes started 
from easily accessible ferrocenyloxazolines and in both cases the phosphino-
substituted side chain was build up diastereoselectively. In the first sequence, 2-
oxazolinyl substituted ferrocene aldehydes were directly phenylated or alkylated 
through an auto-activated transfer from diphenyl zinc or dialkyl zinc reagents to the 
aldehyde functionality and provided alcohols with 94% d.e. and in very high chemical 
yield. In a further two-step sequence, these alcohols were transformed into the desired 
phosphino-oxazolines. Alternatively, the ligand side chain could be built up by applying 
a diastereoselective -deprotonation reaction to diphenylphosphinylmethyl substituted 
ferrocene precursors. With this methodology the stereogenic center of the side-chain 
was introduced with 95% d.e. and 93% chemical yield. Moreover, from a number of 
additional asymmetric transfer hydrogenations it was concluded that for these ligands 
the (S,SOx,SFc) relative configuration constitutes the matching configuration while both a 
change of the side-chain or of the oxazoline configuration leads to less efficient transfer 
hydrogenation catalysts. 
Furthermore, a number of chiral, non-racemic 1,2-di- and 1,2,3-trisubstituted 
ferrocene derivatives were synthesized in a highly modular three-step sequence, 
starting from well-established diastereoselectively ortho-directing ferrocenyl amines. 
Ortho-lithiation followed by reaction with electrophiles and subsequent reductive 
removal of the amino substituents led to enantiopure 1,2-disubstituted ferrocenes. A 
further ortho-lithiation of these products followed by reaction with another electrophile 
allowed to generate chiral non-racemic 1,2,3-trisubstituted ferrocenes which are 
inclined to be useful starting materials for the synthesis of chiral, non-racemic ferrocene 
derivatives such as phosphino- or oxazoline-based catalysts ligands.  
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Zusammenfassung 
Diese Dissertation beschreibt die Weiterentwicklung homogener, 
asymmetrischer Hydrierkatalysatoren, die alle chirale, nichtrazemische Ferrocen-
derivate als Katalysatorliganden aufweisen. Zu diesem Zwecke wurden phosphino-
substituierte Ferrocenyloxazoline dargestellt und in Ruthenium-katalysierten 
asymmetrischen Hydrierungen und Transferhydrierungen getestet. In diesem Rahmen 
wurden auch zwei neue Wege zur einfacheren Synthese solcher Liganden, sowie eine 
sehr allgemeine und modulare Synthesesequenz für chirale, nichtrazemische 1,2-di- 
and 1,2,3-trisubstituierte Ferrocenderivate ausgearbeitet. 
Alle neuen Phosphinooxazolin-Liganden wurden auf zwei hochmodularen 
Synthesewegen hergestellt. Die erste Synthesesequenz beginnt mit kommerziell 
erhältlichem Ugi-Amin und erlaubt es, die gewünschten Phosphinooxazoline in fünf 
Schritten darzustellen. Mit Hilfe der zweiten Synthesemethode können solche Liganden 
– ausgehend von kommerziell erhältichem Ferrocenyloxazolin – in zwei Stufen 
hergestellt werden. Von allen dargestellten Liganden konnten Komplexe des Typs 
[RuCl2(PPh3)(L)] erhalten und in asymmetrischen Hydrierungen und Transfer-
hydrierungen von Ketonen getestet werden. Mit beiden Methoden waren Produkte mit 
einem enantiomeren Überschuss von  98%  zugänglich.  
Zur Vereinfachung der Darstellung solcher Oxazolin-Liganden wurden zwei 
neue komplementäre und optimierte Synthesesequenzen ausgearbeitet. Beide 
Synthesemethoden begannen mit leicht zugänglichen Ferrocenyloxazolinen und in 
jedem Fall wurde die benötigte Seitenkette auf einem diastereoselektiven Weg 
aufgebaut. In der ersten Synthesesequenz wurde von 2-Oxazoliny-substituierten 
Ferrocenylaldehyden ausgegangen und diese jeweils in einer autoaktivierten Reaktion 
mittels Diphenylzink oder Dialkylzink-Reagenzien phenyliert beziehungsweise alkyliert. 
Die dabei entstandenen Alkohole konnten in zwei weiteren Schritten zu den 
gewünschten Liganden umgesetzt werden. In einer alternativen Synthesesequenz 
konnten die Seitenkettensubstituenten durch -Deprotonierung von geeigneten 
Ferrocenylmethyl-substituierten Phosphinoxiden mit 95% diastereoselektivem 
Überschuss und 93% chemischer Ausbeute eingeführt werden. Aus den Resultaten 
weiterer Transferhydrierungen konnte geschlossen werden, dass die besten 
Ergebnisse dann erhalten werden, wenn Liganden mit (S,SOx,SFc) Relativkonfiguration 
eingesetzt werden. Änderungen sowohl der relativen Seitenketten- als auch der 
Oxazolinkonfiguration führten zu Katalysatorliganden mit geringerer Effizienz.  
In einem weiteren Teil dieser Arbeit wird die Synthese von chiralen, 
nichtrazemischen 1,2-di- und 1,2,3-trisubstitubstituierten Ferrocenderivaten 
beschrieben, wobei jeweils von etablierten diastereoselektiv ortho-dirigierenden 
Ferrocenylaminen ausgegangen wurde. Durch ortho-Lithiierung derartiger Ferrocene, 
einer nachfolgenden Reaktion mit Elektrophilen und anschließender partieller 
Entfernung der dirigierenden Gruppe konnten enantiomerenreine 1,2-disubstituierte 
Ferrocene hergestellt werden. Wurden Elektrophile verwendet, die selber ortho-
dirigierend wirken, konnten durch nochmalige ortho-Lithiierung und Reaktion mit 
weiteren Elektrophilen 1,2,3-trisubstituierte Ferrocene erhalten werden, die als 
Ausgangsmaterialien für die Synthese von chiralen, nichtrazemischen 
Ferrocenderivaten, wie etwa Katalysatorliganden, verwendet werden können. 
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1. Introduction 
1.1.  General Introduction 
The term “catalyst” was raised for the first time by Berzelius in 1836 and in 1894 
Ostwald defined a catalyst as a substance that increases the rate of a chemical reaction 
without itself being substantially consumed. The function of a catalyst usually depends 
significantly on the type of chemical reaction. A catalyst may either change the rate of a 
chemical reaction by altering its activation energy or may open up reaction pathways 
that otherwise are inaccessible. In the case of an equilibrium reaction, a catalyst will 
accelerate both the forward and the backward reaction without changing the position of 
equilibrium. In those cases where the reactions can follow simultaneously more than 
one reaction pathway, a catalyst may accelerate selectively one reaction over the 
others and this may result in a different product distribution.1 
A catalytic reaction usually consists of a series of transformations to which a 
catalyst enters in one step and is regenerated in another step. Such sequences are 
frequently depicted in a cyclic graph which is called a „catalytic cycle‟ (Figure 1). The 
notable difference between a catalytic and a stoichiometric reaction ensues from the 
fact that – as compared to the reagent – in a catalytic reaction only a substoichiometric 
amount of the catalyst is required. 
Generally, catalysts are categorized either in accordance to their physical state 
(gas, solid, liquid), their chemical nature (metals, oxides, proteins), the type of catalyzed 
reaction (oxidation, reduction, cracking, etc.) or according to the number of phases 
(homogeneous, heterogeneous).2 
Heterogeneous and homogeneous catalysis constitute two main types of 
catalysis, which are characterized by significantly different properties and applications. 
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Figure 1. Schematic representation of a catalytic cycle. 
In homogeneous catalysis, the catalyst is present in the same phase as the 
other reaction components and this fact is associated with a number of advantages and 
disadvantages. Advantages of homogeneous catalysts include (i) high diffusion rates 
for all reaction components, (ii) the possibility of investigating the progress of reaction 
by utilizing spectroscopic methods such as NMR spectroscopy (iii) higher reactivity and 
selectivity. Disadvantages include difficulties in separating catalyst and products as well 
as the regeneration of catalyst.  
In heterogeneous catalysis (surface catalysis), catalyst and reagents are 
present in different phases. These types of reaction usually occur on the surface of 
solid catalysts. The advantages of heterogeneous catalysts include low cost, ease of 
separation, high stability and the possibility of catalyst recycling. Disadvantages include 
slow rates – and as compared to homogeneous catalysis – lower regio- and 
stereoselectivity. 
Like with stoichiometric reagents also with use of chiral catalysts, chiral non-
racemic products can be obtained from prochiral substrates. Such compounds are 
typically formed in biological systems in which enzymes act as the enantioselective 
catalysts.3 
Since usually biological systems constitute a chiral non-racemic environment, 
enantiomers may act significantly different from each other. For example, one 
enantiomer could cause a beneficial therapeutic action while the other one could be 
highly toxic. Hence, the synthesis of enantiomerically pure or highly enriched 
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biologically active compounds has become an important task in organic chemistry. 
Several methods have been applied for the synthesis of enantiomerically pure 
compounds such as resolution of racemates, chromatographic separation of 
enantiomers, enzymatic resolution, chemical kinetic resolution, asymmetric synthesis 
and enantioselective catalysis. Amongst these methodologies, frequently, asymmetric 
catalysis has proved to be superior since a small amount of a chiral non-racemic 
catalyst can produce a large amount of chiral non-racemic product. Therefore, 
asymmetric catalysis has become a powerful tool for synthesizing chiral non-racemic 
compounds.1,4,5 
Historically, enantioselective catalysis dates back to 1904 when Marckwald 
reported his pioneering work on the enantioselective decarboxylation of properly 
substituted malonic acids with use of brucine.6 
Later on in 1908, Bredig synthesized mandelonitrile from benzaldehyde and 
HCN in the presence of an alkaloid (quinine or quinidine) as the catalyst.7 Prelog and 
Wilhelm continued along this line and in 1954 proposed a mechanistic picture.8 In the 
late 1950s in Japan, Izumi and co-workers reported on the impregnation of silk with 
palladium dichloride and its application in the enantioselective hydrogenation of some 
dehydroamino acid derivatives.9 In a further attempt, Izumi modified Raney nickel with 
tartaric acid derivatives and these modified catalysts were applied in the hydrogenation 
of methyl acetoacetate.10 Products were obtained with up to 80% enantiomeric excess.  
Since then the development of homogeneous and heterogeneous as well as 
enantioselective catalysts has progressed enormously and this work has been awarded 
by several Nobel prizes (Ziegler, Natta 1963; Wilkinson, Fischer, 1973; Knowles, 
Noyori, Sharpless 2001; Chauvin, Grubbs, Schrock, 2005; Ertl, 2007; Heck, Negishi, 
Suzuki, 2010). 
Nowadays, a great variety of highly selective catalysts is available for 
applications ranging from the small laboratory to the large industrial scale. From an 
industrial point of view, hydrogenations including enantioselective hydrogenations with 
use of hydrogen gas belong to the most mature synthesis methodologies available and 
are used for the large scale production of many achiral as well as chiral products. For 
enantioselective applications, especially homogenous catalysts11 are used while for the 
production of achiral or racemic derivatives heterogeneous catalysts2 are preferred. 
In certain cases, hydrogen gas in hydrogenations can be replaced by other 
hydrogen sources. These so called transfer hydrogenations are in some respects 
3
  
complementary to hydrogenations with hydrogen gas and are especially useful for the 
reduction of polar substrates such as ketones, aldehydes or imines.2 However, due to 
some limitations large scale industrial applications are rare. Like hydrogenations, also 
transfer hydrogenations can be carried out enantioselectively and in many cases 
products with very high enantiomeric excess can be obtained. 
1.2. Asymmetric Transfer Hydrogenation 
Asymmetric transfer hydrogenation of ketones and imines with chiral non-
racemic catalysts is recognized as an efficient methodology for the preparation of 
enantiopure or highly enantiomerically enriched alcohols and amines.12 In catalytic 
transfer hydrogenation reactions, hydrogen is transferred from a donor to the substrate 
to yield reduced substrate and oxidized donor (Scheme 1). Common donors include 
cyclohexadiene, ammonium formate and 2-propanol. Chiral Ru, Rh and Ir catalysts are 
particularly useful in these reactions and have been intensively studied.13 
 
Scheme 1. Schematic representation of transfer hydrogenation reactions. 
The first report on asymmetric transfer hydrogenation describes an asymmetric 
version of the Meerwein-Pondorf-Verley reduction (MPV) (Scheme 2).9a,14 
 
Scheme 2. Asymmetric Meerwein-Pondorf-Verley (MPV) reduction. 
In this case, a chiral non-racemic alcohol was used as the source of chirality. 
Although the enantioselectivity of this type of MPV reduction was rather low, it is 
considered a milestone in the development of many chiral catalysts for the asymmetric 
transfer hydrogenation of ketones and imines. In 1991 Chowdhury and Backvall 
showed that RuCl2(PPh3)3 in the presence of NaOH acts as an effective catalyst for this 
transformation.15 A breakthrough came about when Noyori reported the development of 
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a class of well-designed chiral Ruװ-arene complexes that were modified with chiral 
diamine derivatives (Scheme 3). With applying these catalysts, asymmetric transfer 
hydrogenation of ketones and imines in the presence of an organic hydrogen donor 
solvent such as 2-propanol gave products with excellent conversion and enantiomeric 
excess.16 
 
Scheme 3. Asymmetric transfer hydrogenation of aromatic ketones. 
Later on in 1997, Sammakia and co-workers applied chiral ferrocenyloxazoline 
complexes with planar chirality to the asymmetric transfer hydrogenation of aryl 
ketones. They prepared catalysts in situ from RuCl2(PPh3)3 and a variety of 
ferrocenyloxazolines. In the presence of these catalysts, products with up to 94% e.e. 
were obtained (Scheme 4).17 
In 1999 Nishibayashi and co-workers isolated diastereomerically pure ruthenium 
complexes [RuCl2(PPh3)3L] of oxazolinyl ferrocenylphoshphine ligands. By applying 
these complexes, extremely high enantionselectivities were obtained in the transfer 
hydrogenation of alkyl aryl ketones and dialkyl ketones when 2-propanol was used as 
the hydrogen donor (up to 99% e.e. for acetophenone).18 
 
Scheme 4. Asymmetric transfer hydrogenation of aryl ketones catalyzed by 
RuCl2(PPh3)3 and ferrocenyloxazolines. 
5
  
Some chiral Schiff bases have also been applied as catalyst in asymmetric 
transfer hydrogenations. In 1999 Kwong and co-workers used P,N,O ligand 1 (Chart 1) 
for the asymmetric transfer hydrogenation of ketones and reported up to 81% e.e.19 
Later on in 2003, Zheng and co-workers reported on a series of P,N,O ligands (2, Chart 
1) for ruthenium catalyzed asymmetric transfer hydrogenation of ketones (up to 94% 
e.e.).20 
Generally, chiral PN, NN, NO and P,N,O ligands have shown to be very 
successful in asymmetric transfer hydrogenations. Chart 1 summarizes the most 
effective ligands for the transfer hydrogenation of ketones.9d,10 
In the last two decades, asymmetric transfer hydrogenation has evolved as a 
complementary methodology to the well-established asymmetric hydrogenation, 
especially for producing enantiopure or highly enantiomerically enriched secondary 
alcohols and amines. Contrary to hydrogenation reactions, the use of transfer 
hydrogenations does not require hydrogen gas as the reagent and in addition high 
pressure equipment can be avoided. In most cases isopropanol is used as the 
hydrogen source.21 
However, besides some advantages like high stereo- and regioselectivity, there 
are some disadvantages related to asymmetric transfer hydrogenations that until now 
have prevented large scale industrial applications: (i) in order to reach reasonable 
reaction rates, addition of a strong base to the reaction mixture is required and this may 
result in side reactions of both substrates and products (e.g. aldol reactions of substrate 
or racemisation of product); (ii) in many cases the reactions have to be carried out at 
low substrate concentrations, a fact that severely limits up-scaling; and (iii) if 
isopropanol is used as the hydrogen source, at large scale huge amounts of 
commercially unusable acetone is produced. 
6
  
 
Chart 1. The most effective ligands for transfer hydrogenations of ketones. 
1.3 Asymmetric Hydrogenation 
Asymmetric hydrogenation of prochiral unsaturated compounds such as 
alkenes, ketones and imines has been intensively studied and is considered a versatile 
methodology for the synthesis of chiral compounds ranging from the laboratory to the 
industrial scale. The discovery of homogenous catalysts for the asymmetric 
hydrogenation of prochiral olefins, ketones and imines is well recognized as one of the 
most significant developments in organotransition metal chemistry.2 
 Low valent Ru, Rh or Ir complexes bearing at least one chiral ligand belong to 
the most effective homogeneous hydrogenation catalyst precursors.4a,22 
The term “homogeneous hydrogenation” was used for the first time in 1938 by 
Calvin.23 He reported on copper based catalysts and used it for the reduction of p-
benzoquinone. Rhodium amine complexes and later on cyanocobaltate complexes 
were described by Iguchi.24 With his discovery of [RhCl(PPh3)3] in 1965 Wilkinsons 
made a very important breakthrough in homogeneous catalysis.25 Independently, 
Coffey26 discovered and also applied this complex in the hydrogenation of a variety of 
alkenes. The reactions could be carried out under very mild conditions and with high 
selectivity. In 1968 Horner27 and Knowles28 independently published on chiral non-
racemic rhodium catalysts all containing P-chiral monodentate ligands. In 
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hydrogenations, these rhodium complexes resulted in measurable but low product 
enantioselectivities (less than 30%). In 1971 Kagan introduced his rhodium complexes 
containing the C2-symmetric diphosphine DIOP [(4R,5R)-(–)-O-isopropylidene-2,3-
dihydroxy-1,4-bis(diphenylphosphino)butane] as the chiral ligand (3, Chart 2).29,30 His 
studies resulted in significantly higher product enantioselectivities (up to 88%) for the 
hydrogenation of alkenes. With Kagan‟s study about C2-symmetric chelating 
diphosphine ligands in view, Knowles synthesized DIPAMP (R,R)-(-)-1,2-bis[(o-
methoxy-phenyl)(phenyl)phosphino]ethane; a second generation of P-chiral ligands (4, 
Chart 2).31 Rhodium complexes of this C2-symmetric ligand catalyzed the hydrogenation 
of dehydroamino acids and L-DOPA (3,4-dihydroxy-L-phenylalanine), a drug for treating 
Parkinson‟s disease, with high enantioselectivity (up to 95% e.e.).32 
The next outstanding ligand was BINAP [2,2‟-bis(diphenylphosphino)-1,1‟-
binaphtyl] which was developed by Noyori in the 1980s (5, Chart 2).33,34 Unlike the 
previously described ligands, BINAP does not contain carbon stereocenters but belongs 
to the group of axially chiral compounds. Interestingly, the most active and selective 
catalysts containing BINAP as the chiral ligand are based on ruthenium rather than on 
rhodium (e.g. [Ru(BINAP)(OAc)2]). BINAP also belongs to the group of so called 
privileged ligands, since BINAP based catalysts can be used for a wide range of 
catalysis reactions as well as for a broad range of substrates. 
Ligands containing alkylphosphines such as the DuPhos ligand family (6, Chart 
2) have been developed by Burk.35 Catalysts from DuPhos and rhodium precursors 
show excellent results in enantiosective hydrogenation of many olefins and imines. 
 
Chart 2. C2-symmetric bidentate diphosphine ligands. 
During the last 25 years, hundreds of chiral non-racemic ligands have been 
synthesized and applied in enantioselective catalysis. Among all of these ligands, the 
group of ferrocene based ligands has been applied most successfully in hydrogenation 
and transfer hydrogenation reactions. 
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1.4. Chiral, non-racemic ferrocene ligands 
A great number of properly substituted ferrocene derivatives has been 
synthesized in chiral non-racemic form and such planar chiral derivatives have been 
applied in a variety of different fields including homogeneous enantioselective catalysis, 
bioorganometallic chemistry, polymers and dendrimers, electrooptical materials as well 
as thermotropic liquid crystals.36 
In 1959 the first optically active planar chiral ferrocene was prepared by 
Thomson via chemical resolution (7, Chart 3).37 
Fe
NMe2
(R)-8
Fe
7
O
 
Chart 3. First optically active planar chiral ferrocene, 7, and Ugi‟s amine, 8. 
In 1970 Nozaki and Ugi independently used a diastereoselective ortho-directing 
group (2-methylpyrrolidine) in the synthesis of chiral non-racemic 1,2-disubstituted 
ferrocenes. In the same year, Ugi and co-workers also reported on N,N-
dimethylferrocenylethylamine (Ugi‟s amine) (8, Chart 3), a ferrocene derivative that 
bears a highly diastereoselective ortho-directing group.38 Ugi‟s amine marks a turning 
point in the synthesis of chiral 1,2-disubstituted ferrocenes since by reaction with butyl 
lithium and subsequent trapping with electrophiles a variety of substituents can be 
introduced in the ortho-position (Scheme 5). 
 
Scheme 5. Synthesis of chiral ferrocenyl derivatives with planar chirality. 
Chiral ferrocenylphosphines were prepared for the first time in 1974 by Hayashi 
and Kumada with use of Ugi‟s methodology.39 Diastereoselective ortho-lithiation of (R)-8 
yielded (R,RFc)-9 with high diastereoselectivity (92% d.e.) and subsequent quenching 
with chlordiphenylphosphine resulted in PPFA (11, Chart 4). In addition to 
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aminophosphine PPFA, diphosphine BPPFA (12, Chart 4) was synthesized. It turned 
out that these derivatives are very valuable ligands in a variety of catalytic asymmetric 
transformations such as cross-coupling reactions and asymmetric hydrosilylations of 
olefins.40 
 
Chart 4. First ferrocenyl-based chiral ligands. 
Further stereospecific SN1-type reactions of the dimethylamino moiety with 
different nucleophiles such as acetate, R2PH, pyrazoles and others, which take place 
with retention of configuration, have led to a wide variety of chiral non-racemic 
ferrocene ligands. Among the huge number of ferrocene based catalyst ligands the so 
called Josiphos ligand family (14, Scheme 6) – developed by Togni, Spindler and co-
workers – holds a dominant role amongst C1-symmetric ferrocene-based ligands. In 
Scheme 6 the synthesis approach of Joshiphos ligands is depicted. This method starts 
from readily available Ugi‟s amine and follows Ugi‟s original diastereoselective ortho-
lithiation procedure. Then by quenching with chlorodiphenylphosphine the first 
phosphino substituent is added. In a second step, by replacing the ortho-directing N,N-
dimethyl-amino group by another phosphine the second substituent is introduced. This 
short and highly modular approach has allowed the synthesis of a huge number of 
Josiphos type ligands.12d,41 
Josiphos ligands proved to be excellent ligands in the asymmetric 
hydrogenation of alkenes, ketones, imines and enamines.2,42 Especially Xyliphos43 
(14b) represents an outstanding example of the Josiphos family and is intensively 
applied in an industrial process. The iridium catalyzed large scale hydrogenation of 
imine 15 yields amine 16 which is an intermediate in the synthesis of herbicide (S)-
metolachlor (17, Scheme 7). This herbicide is produced on a 10.000 ton scale per year. 
To date this is considered to be the most successful asymmetric hydrogenation process 
on industrial scale with exceptional turnover numbers (2.000.000) and turnover 
frequencies (400.000 h-1) as well as acceptable product enantioselectivity (80% e.e.).44 
Josiphos-type ligands are also applied by industry for the preparation of β-amino 
acid derivatives, which are important intermediates in the synthesis of biologically active 
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molecules. For this purpose, unprotected prochiral enamines are enantioselectively 
hydrogenated with use of a diphosphine-modified rhodium catalyst. PPF-t-Bu2 (14c) 
proved to act as the most effective diphosphine ligand in this process (Scheme 8).45,46 
 
Scheme 6. Synthesis of Josiphos ligands. 
 
 
Scheme 7. Synthesis of (S)-metolachlor. 
 
 
Scheme 8. Synthesis of β-amino acid derivatives. 
Like Josiphos, Walphos-type ligands, (18, Chart 5) were prepared in a highly 
modular approach from Ugi‟s amine.47 Walphos derivatives were found to be promising 
catalyst precursors for the enantioselective hydrogenation of olefins and ketones, as 
well as for C–C bond forming reactions.48 As an industrial application of one Walphos 
ligand, the preparation of Synthon A, an intermediate in the synthesis of the rennin 
inhibitor Aliskiren, should be mentioned. On a large scale, it was prepared quantitatively 
11
  
and with high enantioselectivity from the appropriately substituted 2-isopropyl cinnamic 
acid (Scheme 9).12d,49  
 
Chart 5. Structure of C1-symmetric ferrocenyl-based Walphos and Taniaphos 
ligands. 
 
 
Scheme 9. Application of a Walphos ligand (18e) on large scale. 
Taniaphos-type ligands50 (19, Chart 5) constitute another class of C1-symmetric 
ferrocene-based diphosphines that proved superior in the rhodium and ruthenium 
catalyzed hydrogenation.51 Within this class of ligands the product enantioselectivity 
strongly depends on the nature of the backbone substituent R attached to the benzylic 
methylene position. For example, in the hydrogenation of β-dicarbonyl compounds, 
ligand 19b (R = Me) and 19d (R = NMe2) resulted in product of opposite absolute 
configuration. 
Furthermore, ferrocenyl diphosphine ligands with planar chirality as the sole 
source of chirality (20 and 21, Chart 6)52 – originally developed by Kagan‟s group – 
have been screened in hydrogenations of a variety of alkenes, however, only in the 
12
  
hydrogenation of dimethyl itaconate high enantioselectivities could be obtained (98 and 
92% e.e. for ligand 20, R = Cy and cyclopentyl).16 
 
Chart 6. Exclusively planar chiral diphosphine ligands. 
As mentioned above, for the synthesis of 1,2-disubstituted ferrocene derivatives 
different ortho-directing groups can be applied. Besides amines also sulfoxides, acetals, 
oxazolines and miscellaneous chiral auxiliaries are in use. 
Amongst all stereogenic ortho-directing groups, Kagan‟s p-tolylsulfinyl group53 is 
a unique directing group since it can be fully replaced by reaction of tBuLi and 
subsequent quenching with an electrophile (Scheme 10). Although this exchange 
reaction is very efficient on the laboratory scale, up-scaling to the large industrial scale 
was not possible.  
 
Scheme 10. Synthesis of planar chiral 1,2-disubstituted ferrocenes by 
sulfoxide/lithium exchange. 
1.5. Phosphino-substituted ferrocenyloxazolines 
In 1993, aryl based phosphinooxazolines – the so called PHOX ligands54 – ((S)-
22, Chart 7) were independently synthesized by Pfaltz, Helmchen and Williams and 
have been applied in a variety of catalysis reactions.55 Their outstanding results raised 
the idea of extending this concept to ferrocene derivatives ((S,SFc)-23, Chart 7). 
These FOXAP ((S,SFc)-23) type derivatives were synthesized independently by 
Sammakia,56 Richards57 and Ahn58 almost at the same time and are now recognized to 
13
  
be versatile ligands in a wide variety of enantioselectively catalyzed reactions, including 
enantioselective hydrogenations,59 transfer hydrogenations,40k,60 hydrosilylations,40k,61 
cross-coupling reactions,62 Heck-reactions,63 alkylations of aldehydes,64 allylic 
substitutions,40k,43c,65 and many other transformations.49d,66  
 
Chart 7. Aryl and ferrocene-based phosphine-oxazoline ligands. 
Several routes for the synthesis of these FOXAP ligands have been reported 
which differ only in the preparation procedure of ferrocenyl oxazolines (S)-24 (Scheme 
11). These intermediates are accessible either from esters of ferrocenecarbonic acid 
(route 11a)56, from the acid chloride of ferrocenecarbonic acid (route 11b),67 or from 
cyanoferrocene (route 11c).68 In the latter cases reaction of cyanoferrocene with a 
suitable amino alcohol in the presence of ZnCl2 leads directly to the oxazolines (S)-24. 
In the former cases an amide is formed as the intermediate which can be cyclised with 
use of different methodologies to the desired ferrocenyl oxazolines. 
As already reported by Richards55,65, Sammakia54a and Uemura69 
ferrocenyloxazolines (S)-24 can be diastereoselectively ortho-deprotonated with butyl 
lithium (Scheme 13). In the presence of nBuLi or sBuLi and diethyether as the solvent 
diastereomeric ratios of up to 39:1 of (S,SFc)-25 were obtained (Scheme 12). Later on, 
Sammakia and co-workers increased this ratio to >500:1 by adding 
tetramethylethylendiamine and by changing the solvent to hexane.54b Finally, trapping of 
the lithiated species ((S,SFc)-25) with chlorodiphenylphosphine as the electrophile 
results in the planar chiral FOXAP ligands (S,SFc)-23. 
14
  
 
Scheme 11. Synthesis of optically active ferrocenyloxazoline. 
 
 
Scheme 12. Diastereoselective ortho-lithiation of ferrocenyloxazolines and 
synthesis of the FOXAP ligand family. 
Generally, FOXAP ligands show a good performance in both hydrogenation and 
transfer hydrogenation catalysis. In 1997 Sammakia13 and later on Uemura70 (1999) 
reported that ruthenium complexes of FOXAP ligands ([RuCl2(PPh3)(L)], L = FOXAP 
ligands) perform very efficiently as catalysts for transfer hydrogenations of ketones in 
the presence of isopropanol as the hydrogen source and a sodium or potassium 
alkoxide as the base. Especially aryl-alkyl ketones and in some cases also dialkyl 
ketones could be transformed at room temperature into secondary alcohols with almost 
15
  
quantitative conversion and with excellent enantioselectivity. In 2006 Naud63c and co-
workers found that [RuCl2(PPh3)(FOXAP)] complexes are not only able to catalyze 
transfer hydrogenations but also hydrogenations in the presence of hydrogen gas even 
when transfer hydrogenation conditions such as isopropanol as the solvent and KOtBu 
as the base are applied. With these conditions the limitation of transfer hydrogenations 
(high dilution and product racemisation) could be overcome without losing product 
enantiomeric excess. Hence, up-scaling even to the large industrial scale became 
possible and as a result a few industrial pilot projects have been carried out.65b 
Very recently, the backbone of FOXAP type ligands was further modified in our 
group by replacing the ferrocene unit by a ferrocenylethyl unit (Chart 8). A preliminary 
high throughput screening of ruthenium complexes of these ligands ([RuCl2(PPh3)(L)] L 
= 26–28) in the hydrogenation of a small set of three aryl-alkyl ketones provided 
products in nearly quantitative conversion and with an enantiomeric excess of 97–99%. 
Because of their excellent performance, these ligands were called with reference to one 
inventor Raffa-FOX ligands.71  
 
Chart 8. Ferrocenylethyl based phosphinooxazolines. 
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2 Aim and scope of this thesis 
The main intention of this thesis was (i) to develop further phosphino-substituted 
ferrocenyloxazolines based catalysts, (ii) to test and to compare their performance in 
asymmetric hydrogenations and transfer hydrogenations, (iii) to develop additional 
straightforward and easy to handle synthesis routes for Raffa-FOX ligands and (iv) to 
explore methodologies for the synthesis of enantiopure 1,2-di- and 1,2,3-trisubstituted 
ferrocenes that could serve as starting material for the synthesis of ferrocene based 
ligands including oxazoline derivatives. 
These topics are summarized in Chapter 3 of this thesis. In the first part 
(Chapter 3.1), the synthesis of additional Raffa-FOX ligands and their performance in 
the asymmetric transfer hydrogenation of ketones is described. Moreover, a quantitative 
comparison between asymmetric transfer hydrogenation and asymmetric hydrogenation 
reactions is reported. The second part (Chapter 3.2) reports on a novel and optimised 
synthesis procedure for Raffa-FOX ligands that starts from well-known and easily 
accessible ferrocenyloxazolines. The third part (Chapter 3.3) describes a simplified 
methodology for removing ortho-directing amines in the presence of various 
substituents. With use of this methodology a number of enantiopure 1,2-di- and 1,2,3-
trisubstituted ferrocenes could be synthesized. 
2.1 Phosphino-substituted ferrocenyloxazolines: asymmetric 
hydrogenation and asymmetric transfer hydrogenation of 
ketones 
As described in the introduction, preliminary test reactions of our newly 
developed Raffa-FOX ligands (26–28, Chart 9) provided excellent results in the 
asymmetric hydrogenation of a small set of ketones. Nearly quantitative conversion and 
product e.e.s of 97–99% were observed when ruthenium complexes [RuCl2(PPh3)(L)] of 
ligands L = 26–28 were used as the catalyst precursors. It was therefore obvious to 
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extend this concept towards several directions. First of all, we questioned whether 
structural changes of these ligands could improve the catalysts performance or could 
ease and shorten the original preparation procedures. For this purpose novel synthesis 
routes for ligands 29–31 were developed. Like ligand 26, ligand 29 lacks the 
stereogenic center of the oxazoline unit while ligands 30 and 31 lack the stereogenic 
center of the side-chain carbon. Secondly, it was of interest to explore the scope of 
substrates with respect to asymmetric hydrogenations and transfer hydrogenations. In 
addition we questioned whether ruthenium complexes of type [RuCl2(PPh3)(L)] could be 
used for both hydrogenations and transfer hydrogenations and how these results would 
compare to each other. Results related to this topic are presented in Chapter 3.1. 
 
Chart 9. Raffa-FOX ligands 26–28 and newly proposed analogs 29–31. 
2.2 Diastereoselective synthesis of phosphino-substituted 
ferrocenyloxazolines 
Amongst all ligands tested in the ruthenium catalysed hydrogenation and 
transfer hydrogenation of alkyl-aryl ketones ([RuCl2(PPh3)(L)], L= 26–31) ligand 
(R,ROx,RFc)-27 performed best. Additionally, in certain cases ligand (R,ROx,RFc)-28 
provided comparable results while (SOx,SFc)-23 always led to slightly lower product e.e. 
values. 
The original synthesis route for ligands of type 27 not only requires several 
steps but also two enantiopure reagents are needed (Scheme 13).  
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Scheme 13. Original synthesis route for ligand 27 and analogs. 
For example, for the synthesis of the (R,ROx,RFc)-27 enantiopure starting 
materials (R)-8 and (R)-valinol, (R)-33, are required. Therefore, we questioned whether 
this synthesis route for ligands with either (ROx,RFc) or (SOx,SFc) configuration could be 
significantly simplified and shortened. For this purpose two different methodologies 
were considered. 
The first methodology is based on a report of Marr who showed that ferrocenyl 
phosphine oxides can be α-deprotonated and reacted with electrophiles such as methyl 
iodide (Scheme 14). Recently, a diastereoselective version of this reaction has been 
published by Stepnicka. It was therefore our intention to investigate whether this 
methodology could be applied for the synthesis of ligands 27 and 28 when the easily 
accessible derivatives 24a and 39 (Scheme 15) are used as the precursors (Scheme 
16).  
 
Scheme 14. α-Deprotonation of a ferrocenyl phosphine oxide. 
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Scheme 15. Synthesis of ligands (SOx,SFc)-30 and (SOx,SFc)-42. 
 
 
Scheme 16. Diastereoselective side-chain alkylation. 
The second methodology relates to work of Brocard who has shown that alkyl 
groups from dialkyl zinc reagents can be transferred autocatalytically to aldehydes. 
Based on this report, we considered to autocatalytically alkylate amino-aldehydes 
(S,SFc)-37 and 40 with dialkylzinc reagents and to transform the alcohol intermediates 
into the desired phosphino-oxazolines (Scheme 17). 
 
Scheme 17. Autocatalytic alkylation of oxazolinyl-aldehydes with dialkylzinc 
reagents. 
Results related to this topic are presented in Chapter 3.2. 
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2.3. Synthesis of chiral, non-racemic ferrocene derivatives via 
ortho-metallation and partial reductive removal of ortho-directing 
amino groups.  
As mentioned in the introduction, chiral non-racemic 1,2-disubstituted ferrocene 
derivatives have found widespread application in homogeneous catalysis. Among the 
prevalent methodologies for the preparation of 1,2-disubstituted ferrocene derivatives, 
the p-tolylsulfinyl group (57) holds a unique position since it is the only diastereosective 
ortho-directing ferrocene substituent that undergoes full sulphur/lithium exchange with 
tBuLi. However, replacement of the sulfinyl group by other electrophiles works well only 
on the laboratory scale but up-scaling to the larger industrial scale has proved to be 
very difficult (Scheme 18). 
In order to circumvent this problem, other strategies have been reported by 
industrial researchers. One approach was to use an ortho-directing group and to only 
partially remove it. For example, 2-bromo-(N,N-dimethylaminoethyl)-ferrocene, (R,SFC)-
58, was prepared from Ugi’s amine and subsequently, in a two-step sequence, the 
ortho-directing group was transformed into a non-coordinating ethyl group, (SFc)-60. 
Since the ortho-position next to the bromide can also be deprotonated, various 
phosphino units could be introduced, (RFc)-61. A further exchange of bromide by a 
second set of phosphino groups allowed the synthesis of a variety of ferrocenyl 
diphosphines (62, Scheme 19).  
 
Scheme 18. Preparation of 1,2-disubstituted ferrocene derivatives via the p-
tolylsulfinyl directing group. 
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Scheme 19. Preparation of 1,2-disubstituted ferrocene derivatives from Ugi’s 
amine. 
Due to the importance of these types of ligands, we anticipated that simplifying 
this procedure and by using additional ortho-directing groups and substituents others 
than bromide a much broader applicability of this methodology could be achieved.  
Therefore this project is aiming for an extention of this methodology with respect 
to the type of ortho-directing groups, (R)-8 and 63-65, as well as with focus on the 
synthesis of 1,2-di- and 1,2,3-trisubstiuted ferrocenes (Scheme 20). 
 
Scheme 20. Synthesis of non-racemic 1,2-di- and 1,2,3-trisubstituted 
ferrocenes. 
Details of this work are reported in Chapter 3.3. 
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3. Results 
This thesis is based on the following papers and manuscripts. 
 
Ruthenium complexes of phosphino-substituted ferrocenyloxazolines in the 
asymmetric hydrogenation and transfer hydrogenation of ketones: a comparison. 
Afrooz Zirakzadeh, Raffael Schuecker, Kurt Mereiter, Felix Spindler, and Walter 
Weissensteiner 
Organometallics, submitted 
 
The use of -deprotonation- and autoactivated alkylation-reactions in the 
diastereoselective synthesis of phosphino-substituted ferrocenyloxazolines.  
Afrooz Zirakzadeh, Kurt Mereiter, and Walter Weissensteiner 
Manuscript prepared 
 
Synthesis of chiral, nonracemic ferrocene derivatives via ortho-metallation and 
partial reductive removal of ortho-directing amino groups. 
Afrooz Zirakzadeh, Raffael Schuecker, Walter Weissensteiner  
Tetrahedron: Asymmetry 2010, 21, 1494–1502 
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3.1. Ruthenium complexes of phosphino-substituted 
ferrocenyloxazolines in the asymmetric hydrogenation and 
transfer hydrogenation of ketones: a comparison. 
 
Afrooz Zirakzadeh, Raffael Schuecker, Kurt Mereiter, Felix Spindler, and Walter 
Weissensteiner 
Organometallics, submitted 
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Afrooz Zirakzadeh,a Raffael Schuecker,a Kurt Mereiter,b Felix Spindler,c and 
Walter Weissensteinera,* 
 
a University of Vienna, Institute of Organic Chemistry, Währinger Straße 38, A-1090 
Wien, Austria 
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c Solvias AG, Synthese & Katalyse, Römerpark 2, CH-4303 Kaiseraugst, Switzerland 
 
Abstract 
Ruthenium complexes of the type [RuCl2PPh3(L)] with eight novel bidentate 
ferrocene-based phosphine-oxazoline ligands were prepared and tested as catalysts in 
the asymmetric hydrogenation and transfer hydrogenation of fourteen ketones. The 
molecular structures of two catalyst precursors and of two corresponding acetonitrile 
complexes were studied by X-ray diffraction. Two catalysts delivered products in high 
yield and with enantiomeric excesses of up to 99%. The transfer hydrogenation results 
obtained with all novel ligands were compared to those of one well-established and 
commercially available FOXAP ligand. Furthermore, a qualitative comparison with the 
hydrogenation data was carried out. In both cases surprising similarities in product 
enantiomeric excess and product absolute configuration were found. Attempts were 
made with use of a transition state model to rationalize these features. 
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 Introduction 
For more than two decades phosphino-oxazolines such as the so called PHOX-
type ligands[1] (Chart 1) have been successfully used in a huge number of asymmetric 
transformations as hetero-bidentate ligands of transition metal-based catalysts.[2] In 
1995 several groups independently extended the concept of PHOX-type ligands by 
replacing the ligand aryl backbone by a ferrocene unit.[3] The resulting FOXAP ligands 
(Chart 1) were found to perform excellently in a wide variety of enantioselectively 
catalyzed reactions,[4] including hydrogenations,[5] transfer hydrogenations,[5i,6] 
hydrosilylations,[3d,7] cross-coupling reactions,[3b,8] Heck reactions,[9] alkylations of 
aldehydes,[10] allylic substitutions,[5i,8c,11] and many other transformations.[12]  
Fe
PPh2
N
O
R
PPh2
N
O
R
PHOX FOXAP  
Chart 1. 
Sammakia[6e] (1997), Dai[6d] (1998) and Uemura[6b] (1999) reported that 
ruthenium complexes of FOXAP ligands ([RuCl2(PPh3)(L)], L = FOXAP ligands) 
performed very efficiently as catalyst precursors in the transfer hydrogenation of 
ketones when 2-propanol was used as the hydrogen source and sodium hydroxide or a 
sodium (potassium) alkoxide was used as the base. In particular, aryl-alkyl ketones – 
and in some cases also dialkyl ketones – could be transformed at room temperature 
into secondary alcohols with almost quantitative conversion and with excellent 
enantioselectivity. In 2006 Naud and co-workers found that [RuCl2(PPh3)(FOXAP)] 
complexes are not only able to catalyze transfer hydrogenations but also 
hydrogenations in the presence of hydrogen gas, even when transfer hydrogenation 
conditions such as the use of 2-propanol as the solvent and KOtBu as the base were 
applied.[13] On using these conditions some limitations of transfer hydrogenations (high 
dilution, product racemization) could be overcome without losing product enantiomeric 
excess and scale-up even to the large industrial scale became possible.[13a] 
Within this framework, and as a continuation of our search for novel chiral non-
racemic catalysts and catalyst ligands,[14] we very recently made further modifications to 
the ligand backbone of FOXAP ligands by replacing the ferrocene unit by a 
ferrocenylethyl unit (derivatives 2–4, Chart 2). This structural modification led to the 
addition of a further stereogenic unit to the ligand system and for the corresponding 
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 ruthenium complexes to an increase in chelate ring size from six to seven.[15] A 
preliminary high throughput screening of ruthenium complexes of these ‘Raffa-FOX’ 
ligands ([RuCl2(PPh3)(L)] L = 2–4) in the hydrogenation of a small set of three aryl-alkyl 
ketones gave products with nearly quantitative conversion and with an enantiomeric 
excess of 97–99%.  
Fe
Ph2P
O
N R
(R,RFc)-2
(R,SOx,RFc)-3
(R,ROx,RFc)-3
R =
(R,SOx,RFc)-4
(R,ROx,RFc)-4
CHMe2
CHMe2
Ph
Ph
H
Fe
Ph2P
O
N
(R,RFc)-5
Fe
(SOx,SFc)-6
PPh2
N
O
R =
3,5-(CH3)2C6H2
Ph
(SOx,SFc)-7
(SOx,SFc)-1
Fe
N
O
PR2
 
Chart 2. 
In this contribution we report the synthesis of three additional ligands (5, 6, and 
7), all of which feature structural modifications of our previously described ligands 2–
4[15]. Like 2, ligand 5 lacks a stereogenic center at the oxazoline ring while ligands 6 and 
7 represent analogs of 3 lacking the stereogenic center of the side chain.  Complexes 
[RuCl2(PPh3)(L)] of all ligands (L = 2–7) have been extensively tested in transfer 
hydrogenations and hydrogenations of fourteen ketones. The transfer hydrogenation 
results obtained with 2–7 are compared to those of FOXAP ligand 1. In addition, a 
qualitative comparison of the results obtained for transfer hydrogenations and 
hydrogenations under transfer hydrogenation conditions is given. Attempts are also 
made to identify structural features responsible for product enantioselectivity as well as 
for the experimentally determined product absolute configuration. 
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 Results and Discussion 
Synthesis of Ligands 5–7 and Complexes 19–23 
Ligand 5 was prepared by the same synthesis route as ligands 2–4 (Scheme 1). 
Amino-ester (R,SFc)-9,
[16] which is easily accessible from Ugi’s amine, (R)-8, was 
reacted in the presence of trimethylaluminium[8g] with 1,1-dimethyl-2-hydroxyethylamine 
to give amide (R,SFc)-10. In the next step this compound was transformed according to 
the methodology of Appel[17] to oxazoline (R,SFc)-11. Oxazoline 11 was treated with 
methyl iodide in acetonitrile and the crude ammonium salt was subsequently reacted 
with diphenylphosphinyl lithium to give the phosphinyl-substituted derivative (R,RFc)-
12.[18] Reduction of this phosphine oxide with polymethylhydrosiloxane (PMHS) in the 
presence of titanium isopropoxide[19] gave the desired phosphine-oxazoline (R,RFc)-5. 
 
Scheme 1. 
The synthesis of ligands 6 and 7 was achieved in only two steps from 
commercially available ferrocenyl oxazoline (SOx)-13 (Scheme 2). Alcohol (SOx,RFc)-14 
was obtained from (SOx)-13 in analogy to a reported procedure.
[20] Subsequent 
reactions with diphenylphosphine or bis(3,5-dimethylphenyl)phosphine in the presence 
of chlorotrimethylsilane and sodium iodide gave ligands (SOx,SFc)-6 and (SOx,SFc)-7, 
respectively.[21]  
Complexes [RuCl2(PPh3)(L)] of ligands 5–7 (19–21) were prepared in exactly the 
manner as the complexes of ligands 1–4 (Scheme 3, 16–18). Reaction of phosphino-
oxazoline ligands 5–7 with [RuCl2(PPh3)3] in toluene at r.t. gave the desired unsaturated 
green complexes 19–21. Two of these complexes, (ROx,RFc)-17 and (SOx,SFc)-21, were 
further treated at r.t. with acetonitrile and the coordinatively saturated yellow-orange 
acetonitrile complexes (ROx,RFc)-22 and (SOx,SFc)-23 were obtained (Scheme 3, bottom).  
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Scheme 2. 
 
+ L [RuCl2(PPh3)(L)][RuCl2(PPh3)3] toluene
(R,ROx,RFc)-4
(R,SOx,RFc)-4
(R,ROx,RFc)-3
(R,SOx,RFc)-3
(R,RFc)-2
L =
(SOx,SFc)-7
(SOx,SFc)-6
(R,RFc)-5
complex =
(SOx,SFc)-15(SOx,SFc)-1
(ROx,RFc)-18
(SOx,RFc)-18
(ROx,RFc)-17
(SOx,RFc)-17
(RFc)-16
(SOx,SFc)-21
(SOx,SFc)-20
(RFc)-19
[RuCl2(PPh3)(L)] [RuCl2(CH3CN)(PPh3)(L)]
(R,ROx,RFc)-3 (ROx,RFc)-22
L = complex =
(SOx,SFc)-7 (SOx,SFc)-23
CH3CN
 
Scheme 3. 
Single crystals were obtained for two unsaturated, (ROx,RFc)-17 and (RFc)-19, 
and two coordinatively saturated, (ROx,RFc)-22 and (SOx,SFc)-23, complexes and their 
molecular structures in the solid state were studied by X-ray diffraction. Details of these 
X-ray crystallography studies are given in the Experimental section and in the 
Supporting Information (Table S4). The absolute configuration of each compound was 
determined from the X-ray anomalous dispersion effects and was consistent with the 
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 chemical evidence. Views of the molecular structures of these compounds are shown in 
Figures 1 and 2 (for selected geometric data see Supporting Information, Tables S5–
S8). The molecular structure of (SOx,SFc)-15 had been determined previously
[6c] and the 
data for this compound were used for comparative purposes (retrieved from Cambridge 
Structural Database, refcode MAPLUK; for a view of the molecular structure see 
Supporting Information, Figure S5). 
As in the case of (SOx,SFc)-15, complexes (ROx,RFc)-17 and (RFc)-19 adopt a 
square pyramidal rather than a trigonal bipyramidal molecular structure. In all cases the 
free coordination site is well shielded by either a PPh3 phenyl (15 and 17) or an 
oxazoline methyl (19) group. However, as compared to 15 the overall molecular 
structures and the ligand arrangements differ significantly in 17 and 19. In 15 the 
chlorides adopt a cis disposition while in 17 and 19 the chlorides are located trans to 
each other. Furthermore, in 15 the triphenylphosphino phosphorus is cis to the 
oxazoline nitrogen but is trans in 17 and 19. 
 
Figure 1. Molecular structures of complexes (ROx,RFc)-17 (left) and (RFc)-19 
(right). Hydrogen atoms omitted for clarity. 
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Figure 2. Molecular structures of complexes (ROx,RFc)-22 (left) and (SOx,SFc)-23 
(right). Hydrogen atoms omitted for clarity. 
As expected, the acetonitrile complexes (ROx,RFc)-22 and (SOx,SFc)-23 adopt an 
octahedral geometry, but – in contrast to 17 and 19 – the chlorides are positioned in a 
cis rather than in a trans arrangement and the acetonitrile nitrogen is trans to one of the 
chlorides. 
 
Catalysis 
Complexes 16–21 were screened in asymmetric hydrogenations (HY) and 
transfer hydrogenations (THY) of a total of fourteen ketones (Chart 3). All catalysis 
reactions were carried out with the isolated and fully characterized catalyst precursors 
16–21. Complex 15 was used as the reference.  
Transfer Hydrogenations (THY) 
Transfer hydrogenations of thirteen ketones were carried out with complexes 
15–21. It was our initial intention to compare the performance of the newly synthesized 
complexes 16–21 with that of the well-established FOXAP ligand 15. In order to ensure 
maximum comparability, all complexes (15–21) were synthesized according to the 
same protocol.  
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Chart 3. 
The THY conditions were first optimized with respect to the type and amount of 
base, the substrate concentration, the substrate-to-catalyst ratio (S/C), and the reaction 
temperature (for details see Supporting Information). Based on this optimization 
procedure, the majority of all screening reactions were carried out at r.t. using 1 mmol 
of substrate in 51 mL of 2-propanol (19.6 mM), 0.5% catalyst and 2% base (S/C/base = 
200/1/4). In an effort to ensure consistency and reproducibility, all transfer 
hydrogenations were carried out at least twice. 
The THY results obtained with acetophenone (ACP) as the substrate and 
complexes 15–21 as the catalyst precursors are summarized in Table 1. It is important 
to note that as a result of the availability of ligands for these THY reactions, complexes 
with a different absolute configuration at the ferrocene unit were applied. Complexes 
15, 20 and 21 had the (SFc) absolute configuration and derivatives 16–19 had the (RFc) 
configuration.  
In all THYs carried out, we observed that the product enantiomeric excess was 
significantly dependent on the reaction time due to product racemization. After reaching 
a maximum value, the product e.e. dropped continuously. Therefore, in all Tables the 
maximum product e.e. values obtained at the given reaction time are listed together 
with the corresponding conversion data. 
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 Table 1. THY results for acetophenone obtained with complexes 15–21. 
entry substrate complex time 
% 
conv. 
% 
e.e. 
abs. 
conf. 
1 ACP (SOx,SFc)-15 20 min 99 96 R 
2 ACP (RFc)-16 20 min 98 92 S 
3 ACP (ROx,RFc)-17 10 min 99 98 S 
4 ACP (SOx,RFc)-17 5 h 18 69 R 
5 ACP (ROx,RFc)-18 15 min >99 97 S 
6 ACP (SOx,RFc)-18 6 h 90 73 R 
7 ACP (RFc)-19 4 h 78 95 S 
8 ACP (RFc)-19
a 
1 h 85 95 S 
9 ACP (SOx,SFc)-20 30 min 96 93 R 
10 ACP (SOx,SFc)-21 20 min 97 89 R 
a pre-prepared catalyst 
For example, with reference (SOx,SFc)-15 as the catalyst precursor the reaction 
was essentially finished after 20 min (99% conversion) and the product (R)-1-
phenylethanol was formed with 96% e.e. (Table 1, entry 1). In order to estimate the 
effect of product racemization, enantiopure (S)-1-phenylethanol was treated for 24 
hours in 2-propanol either with base only (KOiPr) or it was exposed to the actual 
catalysis conditions [KOiPr/(SOx,SFc)-15]. The treatment with base only led to a loss of 
5% e.e. while under catalysis conditions this process took place much faster and after 
24 hours a reduction of 30% e.e. was observed. 
The results obtained for complexes 16–21 to some extent depended on the 
substitution pattern and relative configuration of the ligands used (2–7). The best results 
were obtained with ligands (R,ROx,RFc)-3 and (R,ROx,RFc)-4 [complexes (ROx,RFc)-17 and 
(ROx,RFc)-18], both of which bear a mono-substituted oxazoline ring and have the 
(ROx,RFc) relative configuration. As compared to the reference, both complexes gave 
rise to slightly higher product e.e.s in a shorter reaction time (17: 98%; 18: 97%; Table 
1, entries 3 and 5). Removal of the oxazoline substituent or the side chain methyl group 
[ligands (R,RFc)-2 and (SOx,SFc)-6; complexes (RFc)-16 and (SOx,SFc)-20] resulted mainly 
in a decrease in the product e.e. (92% and 93%, Table 1, entries 2 and 9). 
Replacement of the diphenylphosphino group of (SOx,SFc)-6 by a dixylylphosphino unit 
[ligand (SOx,SFc)-7, complex (SOx,SFc)-21] led to a further reduction in the product 
enantiomeric excess (89%, Table 1, entry 10). 
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 Interestingly, the use of ligand (R,RFc)-5 [complex (RFc)-19], which bears two 
methyl groups at the oxazoline position 4, led to a significant decrease in the rate of the 
reaction and after 4 hours a conversion of only 78% was achieved. However, this 
problem could be partly overcome without loss of product e.e. (95%) when the catalyst 
precursor (RFc)-19 was reacted for 2 hours with base in 2-propanol before the substrate 
was added. The use of such a pre-prepared catalyst led to a markedly faster THY 
process and after 1 hour the product was obtained with 85% conversion and 95% e.e. 
(after 2 h: 97% conversion and 94% e.e.; Table 1, entries 7 and 8). It is clear that with 
catalyst precursor (RFc)-19 the formation of the active catalyst is slowed down 
significantly. From the chemical and structural evidence it is plausible to assume that 
the transformation of the ruthenium dichloride complex into the active ruthenium hydride 
catalyst is slowed down by steric hindrance caused by one of the oxazoline methyl 
substituents, which efficiently shields the free coordination site at the metal center 
[Figure 1 (right) and Supporting Information, Figure S2, C47]. 
The strongest influences on the THY reactions were observed when, instead of 
complexes (ROx,RFc)-17 and (ROx,RFc)-18, the diastereomers (SOx,RFc)-17 and (SOx,RFc)-
18 [ligands (R,SOx,RFc)-3 and (R,SOx,RFc)-4] were applied – both of which have the (S) 
configuration at the oxazoline carbon C4. In these cases, not only did the reaction 
become very slow but the product absolute configuration also changed from (S) to (R).  
Generally, the product of (S) absolute configuration was obtained either when 
ligands were used that adopted an (RFc) absolute configuration at the ferrocene unit but 
lacked a further stereogenic unit at the oxazoline ring (16 and 19) or when ligands with 
(ROx,RFc) relative and absolute configuration were applied (15, 17, 18, 20 and 21). 
However, with phenyl or 2-propyl substituents a change in the configuration at the 
oxazoline carbon C4 led to ligands having the (SOx,RFc) relative configuration and this 
resulted in a change of product absolute configuration from (S) to (R) (Table 1, entries 4 
and 6). Interestingly, an identical dependence of the product absolute configuration on 
the relative configuration of the ligand was reported by Dai and co-workers.[6d] In the 
transfer hydrogenation of acetophenone with the diastereomeric complexes (SOx,SFc)-15 
and (SOx,RFc)-15 [ligands (SOx,SFc)-1 and (SOx,RFc)-1] the product with the same (R) 
absolute configuration was formed. This means that – as with 17 and 18 – the use of 
diastereomers (ROx,RFc)-15 and (SOx,RFc)-15 leads to products of opposite absolute 
configuration. 
Since the THY of acetophenone was best accomplished with complex (ROx,RFc)-
17, the dependence of this process on the substrate concentration as well as on the 
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 substrate-to-catalyst ratio was investigated. The dependence on the substrate 
concentration was found to be rather small. While a 0.02 molar solution was 
transformed within 10 minutes into the product with 98% e.e. (99% conversion), a 0.2 
molar solution gave the product with 95% e.e. (90% conversion) within 5 minutes. Only 
when a 0.02 molar solution was used and the S/C ratio was increased from 200/1 to 
1000/1 did the conversion become slow and the maximum product e.e. dropped from 
98% to 81%.  
In summary, with the exception of complexes (SOx,RFc)-17 and (SOx,RFc)-18, all 
catalyst precursors gave results that are comparable to those of the reference. 
Surprisingly, for these complexes the type of oxazoline substituent as well as the 
oxazoline substitution pattern [non- (16), mono- (17, 18) or di-substitution (19)] hardly 
had any influence on the product enantiomeric excess (16: 92%; 17: 98%; 18: 97%; 19: 
95% e.e.).  
In order to study the influence of steric and electronic effects, 2- and 4-
substituted acetophenones (2-F-ACP, 2-Cl-ACP, 4-CF3-ACP, 4-MeO-ACP, and 4-Me-
ACP) together with additional phenyl-alkylketones (phenyl-ethylketone, PEK; phenyl-
benzylketone, PBK; 1,3-diphenylpropan-1-one, DPP) were tested. Furthermore, a 
bicyclic system (1-tetralone, TETN), acetylferrocene (AcFc), and one dialkylketone (tert-
butylmethylketone, tBMK) were used. For these transfer hydrogenations only those 
catalyst precursors were used that gave the best results with acetophenone as the 
substrate [reference (SOx,SFc)-15, (ROx,RFc)-17, (ROx,RFc)-18, (RFc)-19, and (SOx,SFc)-20].  
In the majority of test reactions (Table 2) nearly quantitative conversion could be 
achieved within 5–30 minutes. Only with the electron-rich substrates 4-MeO-ACP and 
AcFc, with the sterically more demanding bicyclic 1-tetralone (TETN) and, especially, 
with dialkyl ketone tBMK was a prolonged reaction time required. The best results were 
obtained with complex (ROx,RFc)-17 [ligand (R,ROx,RFc)-3]. In a few cases comparable 
(Table 2, entries 2/3, 13/14, 18/19, 21/22, and 24/25) or even better (entries 27/28 and 
30/31) results could be obtained on using complex (ROx,RFc)-18. In particular, the THY 
of acetylferrocene gave the product with significantly higher enantiomeric excess, albeit 
with a very low level of conversion (entry 31). 
As for acetophenone, when the THY reactions were carried out with catalyst 
precursors of (RFc) or (ROx,RFc) configuration and with aryl-alkyl ketones as the 
substrates, products with the (S) absolute configuration were obtained consistently. As 
one might expect, the product enantiomeric excess was also dependent on the 
substrate substitution pattern (Figure 3). On employing reference 15 and ACP as the 
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 substrates, products with 96% e.e. were obtained. Substitution of the ACP phenyl ring 
with electron-donating or electron-withdrawing substituents led – with the exception of 
4-Me-ACP (96% e.e.) – to a small reduction in the e.e. values (90–93%) but replacing 
the methyl group of ACP with other alkyl substituents did not significantly affect the 
product e.e. (95–97%; PEK, PBK, DPP). Even the bicyclic compound 1-tetralone 
(TETN) was reduced with an enantiomeric excess of 93%.  
Similar trends were seen when the best performing complex (ROx,RFc)-17 was 
used (Figure 3). As compared to the reference, slightly better product e.e.s were 
obtained with seven substrates (ACP, 4-Cl-ACP, 4-MeO-ACP, 4-Me-ACP, PBK, DPP, 
and AcFc) while slightly lower product e.e.s were found in the THY reactions of 
substrates 4-CF3-ACP and PEK. Interestingly, with both 2-substituted acetophenones 
(2-F-ACP and 2-Cl-ACP) and with tetralone a sharp drop in product e.e. was found (2-
F-ACP: 50%, 2-Cl-ACP: 75%, TETN: 74%).  
In summary, in a number of cases complex (ROx,RFc)-17 gave slightly better 
results than the original FOXAP analog 15. However, we noticed with surprise that 
although complexes 15 and 17 adopt totally different molecular structures (15: 
Supporting Information, Figure S5 and 17: Figure 1, left) their performance in THY 
reactions was found to be remarkably similar. Except for the 2-substituted 
acetophenones and 1-tetralone, structural changes in the substrates were comparably 
reflected in changes of product e.e. values. For complexes 15 and 17 as the catalyst 
precursors, we consider these findings to be the result of similar asymmetric induction 
mechanisms.[22] 
In their original report on THYs of aryl-alkyl and dialkyl ketones with FOXAP 
ruthenium dichloride complexes such as [RuCl2((SOx,SFc)-1)], Uemura and co-workers 
commented on mechanistic features and presented some NMR evidence for a 
ruthenium dihydride-based reaction mechanism.[6b] Furthermore, for aryl-alkyl ketones a 
transition state model was presented (Figure 4, top). Based on this report we 
questioned whether the THY reactions with complex (ROx,RFc)-17 or similar complexes 
could be explained in terms of a related transition state model. Like Uemura’s proposal, 
our suggestion is based on structural and chemical evidence. Our model was mainly 
derived from the molecular structures of complexes (ROx,RFc)-22 and (SOx,SFc)-23 
(Figure 2) and is shown in Figure 4 (bottom).  
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 Table 2. Best THY results obtained for all substrates screened. 
entry substrate complex time 
% 
conv. 
% 
e.e. 
abs. 
conf. 
1 ACP (SOx,SFc)-15 20 min 99 96 R 
2 ACP (ROx,RFc)-17 10 min 99 98 S 
3 ACP (ROx,RFc)-18 15 min >99 97 S 
4 2-F-ACP (SOx,SFc)-15 5 min 99 91 R 
5 2-F-ACP (ROx,RFc)-17 30 min 99 50 S 
6 2-Cl-ACP (SOx,SFc)-15 20 min >99 90 R 
7 2-Cl-ACP (ROx,RFc)-17 5 min >99 75 S 
8 4-Cl-ACP (SOx,SFc)-15 10 min >99 93 R 
9 4-Cl-ACP (ROx,RFc)-17 5 min 98 94 S 
10 4-CF3-ACP (SOx,SFc)-15 5 min 99 90 R 
11 4-CF3-ACP (ROx,RFc)-17 20 min >99 87 S 
12 4-MeO-ACP (SOx,SFc)-15 20 min 80 90 R 
13 4-MeO-ACP (ROx,RFc)-17 20 min 82 95 S 
14 4-MeO-ACP (ROx,RFc)-18 20 min 75 95 S 
15 4-Me-ACP (SOx,SFc)-15 10 min 97 96 R 
16 4-Me-ACP (ROx,RFc)-17 10 min 97 98 S 
17 PEK (SOx,SFc)-15 10 min 99 97 R 
18 PEK (ROx,RFc)-17 20 min 99 96 S 
19 PEK (ROx,RFc)-18 15 min 94 96 S 
20 PBK (SOx,SFc)-15 10 min >99 95 R 
21 PBK (ROx,RFc)-17 20 min >98 97 S 
22 PBK (ROx,RFc)-18 2 h >99 95 S 
23 DPP (SOx,SFc)-15 10 min >99 94 R 
24 DPP (ROx,RFc)-17 15 min 99 96 S 
25 DPP (ROx,RFc)-18 20 min >99 94 S 
26 TETN (SOx,SFc)-15 5 min 71 93 R 
27 TETN (ROx,RFc)-17 30 min 32 74 S 
28 TETN (ROx,RFc)-18 20 min 21 81 S 
29 AcFc (SOx,SFc)-15 30 min 24 80 R 
30 AcFc (ROx,RFc)-17 30 min 10 81 S 
31 AcFc (ROx,RFc)-18 30 min 16 93 S 
32 tBMK (SOx,SFc)-15 24 h 85 >99 S 
33 tBMK (SOx,SFc)-20 24 h 36 21 R 
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Figure 3. Best product enantiomeric excesses (% e.e.) obtained in THYs and 
HYs. 
 
 
Figure 4. Transition state models for the THYs of aryl-alkyl ketones with systems 
[RuH2((ROx,RFc)-1)]/ACP (top; adopted from Cambridge Structural Database, refcode 
MAPLUK and reference [6c]), and [RuH2((ROx,RFc)-3)]/ACP (bottom). 
This model is able to explain why acetophenone or similar ketones coordinate to 
the (ROx,RFc)-configured metal hydride with their (Si) side and therefore the product of 
(S) absolute configuration is obtained. Furthermore, unlike with the FOXAP-type 
ligands, phenyl ortho- and meta-substituents are more prone to interfere with the 
oxazoline-substituted ferrocenyl Cp-ring and this view correlates well with the observed 
drop in product enantiomeric excess when substrates 2-F-ACP, 2-Cl-ACP and TETN 
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 were used. On the other hand, the steric influence of phenyl para-substituents or of 
different side chain alkyl groups is expected to be much smaller.  
It is also clear from this model that, unlike with FOXAP-type catalysts, the 
oxazoline substituents at carbon C4 and the substrate are located far from each other 
and therefore in most cases a change in this substituent only leads to a rather small 
change of the product enantiomeric excess. However, when the phenyl groups of the 
diphenylphosphino unit are replaced by xylyl groups a greater steric interaction between 
one xylyl group and the substrate is expected and this is again consistent with the 
experimentally observed drop in enantioselectivity when catalyst precursor 20 was 
replaced by 21 (Table 1, entries 9 and 10). 
Hydrogenations (HY) 
Since complexes of the type [RuCl2(FOXAP)] are known to be very efficient 
catalyst precursors for asymmetric hydrogenation reactions,[13] the full set of novel 
complexes 16–21 was screened against seven aryl-alkyl ketones on a customized 
Symyx high throughput screening system.[23] Typical results are listed in Table 3. 
As for the THYs, all hydrogenations were carried out with isolated and fully 
characterized catalyst precursors. Reactions were run for 16 hours at a temperature of 
25 °C under hydrogen gas at a pressure of 25 bar, a substrate concentration of 41.67 
µmol/500 µL (83 mM), and a substrate-to-catalyst ratio of 25:1. Different combinations 
of solvents and bases were tested. Either 2-propanol in combination with KOtBu or 
toluene/water (9:1) with bases K2CO3 or NaOH were applied. The former solvent/base 
system is typically used in transfer hydrogenation reactions[22] while the latter conditions 
were found to give excellent results in the hydrogenation of ketones using ruthenium-
FOXAP-based catalysts, even on a large industrial scale.[13] 
For all substrates screened, reaction conditions were identified that gave 
products with quantitative or nearly quantitative conversion and – with the exception of 
bis(3,5-trifluoromethyl)acetophenone – with an enantiomeric excess equal to or better 
than 90%.  
As in transfer hydrogenations, catalyst precursor (ROx,RFc)-17 gave the best 
results (Table 3, entries 2, 9, 12, 15, and 17), especially when it was used in 
combination with the solvent/base system toluene/H2O/K2CO3.  
Only in the case of phenyl benzyl ketone, PBK, did the iPrOH/KOtBu system 
prove to be superior to the toluene/H2O system, resulting in quantitative conversion and 
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 a product enantiomeric excess of 99% (entry 20). Once again, in a few cases complex 
(ROx,RFc)-18 gave equally good results to (ROx,RFc)-17 [Table 3, entries 2/6 (ACP), and 
17/19 (4-Me-ACP)]. 
With respect to the substrate substitution pattern and to the relative 
configuration of ligands and complexes, the hydrogenation and transfer hydrogenation 
results obtained with (ROx,RFc)-17 showed almost identical trends (Figure 3). Only in the 
hydrogenation of the 2-substituted acetophenones 2-F-ACP and 2-Cl-ACP were 
significantly better results obtained in comparison to transfer hydrogenations. 
Interestingly, the hydrogenation reactions of substrates 2-F-ACP and 2-Cl-ACP showed 
a very strong dependence on the solvent/base system used. When the reactions were 
carried out in the 2-PrOH/KOtBu system instead of the toluene/H2O/K2CO3 system – as 
in transfer hydrogenations – a very significant drop in product enantiomeric excess was 
seen [Table 3, entries 10/11 (2-F-ACP) and 13/14 (2-Cl-ACP)].  
Comparison of Transfer Hydrogenation and Hydrogenation Results 
Despite the fact that significantly different reaction conditions were used for the 
transfer hydrogenation and hydrogenation reactions, a number of surprising similarities 
were observed. Of all the novel catalyst precursors tested, complex (ROx,RFc)-17 and, in 
a few cases, complex (ROx,RFc)-18 gave the best results. A similar dependence of the 
product enantiomeric excesses on the catalyst precursors and on the substrate 
substitution pattern was found (Tables 2 and 3, Figure 2).  
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 Table 3. Typical HY results obtained with complexes 16–21. 
entry substrate complex solvent base 
% 
conv. 
% 
e.e. 
abs. 
conf. 
1 ACP (RFc)-16 Tol/H2O K2CO3 99 95 S 
2 ACP (ROx,RFc)-17 Tol/H2O K2CO3 99 99 S 
3 ACP (ROx,RFc)-17 Tol/H2O NaOH 99 97 S 
4 ACP (ROx,RFc)-17 
i
PrOH KO
t
Bu 95 94 S 
5 ACP (SOx,RFc)-17 
i
PrOH KO
t
Bu 95 58 R 
6 ACP (ROx,RFc)-18 Tol/H2O K2CO3 99 98 S 
7 ACP (ROx,RFc)-18 Tol/H2O NaOH 99 96 S 
8 ACP (SOx,RFc)-18 
i
PrOH KO
t
Bu 95 62 R 
9 2-F-ACP (ROx,RFc)-17 Tol/H2O K2CO3 97 90 S 
10 2-F-ACP (ROx,RFc)-17 Tol/H2O NaOH 96 87 S 
11 2-F-ACP (ROx,RFc)-17 
i
PrOH KO
t
Bu 99 70 S 
12 2-Cl-ACP (ROx,RFc)-17 Tol/H2O K2CO3 95 91 S 
13 2-Cl-ACP (ROx,RFc)-17 Tol/H2O NaOH 98 90 S 
14 2-Cl-ACP (ROx,RFc)-17 
i
PrOH KO
t
Bu 80 82 S 
15 4-CF3-ACP (ROx,RFc)-17 Tol/H2O K2CO3 97 90 S 
16 4-CF3-ACP (ROx,RFc)-17 Tol/H2O NaOH 97 89 S 
17 4-Me-ACP (ROx,RFc)-17 Tol/H2O K2CO3 100 97 S 
18 4-Me-ACP (ROx,RFc)-17 Tol/H2O NaOH 99 95 S 
19 4-Me-ACP (ROx,RFc)-18 Tol/H2O K2CO3 100 97 S 
20 PBK (ROx,RFc)-17 
i
PrOH KO
t
Bu >99 99 S 
21 PBK (ROx,RFc)-18 
i
PrOH KO
t
Bu >99 93 S 
22 3,5-bTFA (ROx,RFc)-17 Tol/H2O K2CO3 95 40 S 
23 3,5-bTFA (ROx,RFc)-18 Tol/H2O NaOH 95 41 S 
 
For both transfer hydrogenations and hydrogenations an identical correlation 
between catalyst and product absolute configuration was found. All of the ligands and 
complexes with an (RFc) (2 and 5) or (ROx,RFc) absolute configuration (3, 4, 6, and 7) led 
to the transformation of all tested aryl-alkyl ketones into alcohols with the (S) absolute 
configuration. Only when the relative configuration of ligands 3 and 4 (complexes 17 
and 18) was changed from (ROx,RFc) to (SOx,RFc) did the product absolute configuration 
change from (S) to (R) (Table 3, entries 2/5 and 6/8). 
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 Table 4. Comparison of THY and HY results obtained with (ROx,RFc)-17. 
 THY
a
 HY 
substrate % conv. % e.e. % conv. % e.e. 
ACP 99 98 (S)
d
 99
 
99
b
 (S)
d
 
2-F-ACP 99 50 (S) 97
 
90
b
 (S) 
2-Cl-ACP >99 75 (S) 95
 
91
b
 (S) 
4-CF3-ACP >99 87 (S) 97
 
90
b
 (S) 
4-Me-ACP 97 98 (S) >99
 
97
b
 (S) 
PBK >99 97 (S) >99
 
99
c
 (S) 
a
 Solvent/base: 2-PrOH/KO
i
Pr; 
b
 solvent/base: Tol/H2O/K2CO3; 
c
 solvent/base: 2-PrOH/KO
t
Bu; 
d
 
product absolute configuration 
Furthermore, for all substrates tested, hydrogenation conditions could be 
identified that gave the desired product with comparable or higher enantiomeric excess 
than in transfer hydrogenations (Table 4). This was especially the case when the 
hydrogenations were carried out in the toluene/H2O/K2CO3 solvent/base system. Clearly 
these reaction conditions lead to much slower product racemization than in the 2-
PrOH/KOtBu system. 
 
Conclusion 
Ruthenium complexes of the type [RuCl2PPh3(L)] (16–21) of eight bidentate 
phosphine-oxazoline ligands (L = 2–7), all of which contain a ferrocenylethyl (16–19, L 
= 2–5) or a ferrocenylmethyl (20 and 21, L = 6 and 7) backbone, were synthesized, 
characterized and screened in transfer hydrogenations and hydrogenations against a 
total of one dialkyl and thirteen aryl-alkyl ketones. In addition, for comparative purposes, 
the transfer hydrogenations of all substrates were carried out with one analogous and 
well-established FOXAP ruthenium complex (15). The molecular structures of two 
catalyst precursors and of two corresponding acetonitrile complexes were studied by X-
ray diffraction. One catalyst precursor in particular (17) delivered products with an 
enantiomeric excess of up to 98%. A comparison of the transfer hydrogenation results 
obtained with the novel complex 17 and those of the analogous FOXAP-based catalyst 
15 showed surprising similarities. Although complexes 15 and 17 adopt totally different 
molecular structures, most substrates were transformed into products with nearly 
identical enantioselectivity. Except for the 2-substituted acetophenones and 1-tetralone, 
structural changes in the substrates were comparably reflected in changes in the 
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 product e.e. values. Based on structural and chemical evidence, a transition state 
model was proposed that allows qualitative rationalization of the absolute configuration 
of the product as well as the dependence of e.e. values on the substitution patterns of 
substrates and ligands. 
Complexes 16–21 were also used as catalyst precursors in hydrogenations of 
seven aryl-alkyl ketones and once again complex 17 delivered the best results, with 
product e.e. values of up to 99%. A comparison with the transfer hydrogenation results 
revealed that, for all substrates tested, hydrogenation conditions could be identified that 
gave product with comparable or higher enantiomeric excess. Furthermore, a similar 
dependence of the product enantiomeric excesses on the catalyst precursors and on 
the substrate substitution patterns was found. Also, for both transfer hydrogenations 
and hydrogenations an identical dependence of catalyst and product absolute 
configuration was seen. 
Based on these results, we expect that in most cases the use of catalyst 
precursors [RuCl2PPh3(P-oxazolines)] in the transfer hydrogenation and hydrogenation 
of aryl-alkyl ketones will deliver products of comparable enantiomeric excess. In these 
particular cases, the transfer hydrogenation results may be used to estimate achievable 
hydrogenation results. Based on the finding that complexes 15–21 gave highly 
comparable results in the hydrogenations as well as in the transfer hydrogenations of 
ketones, one might speculate whether this could be the result of comparable 
mechanistic features. Work is currently underway to clarify this possibility. 
 
Experimental Section  
General procedure for the asymmetric transfer hydrogenation of ketones 
To a solution of ruthenium complex (0.005 mmol, 0.5%) in anhydrous 2-PrOH 
(50 mL) were added a solution of ketone (1 mmol) in 2-PrOH (1 mL) and a solution of 2-
PrOK (0.02 mmol) in 2-PrOH (5% w/v). The reaction mixture was stirred at r.t. and the 
progress of the reaction was monitored by periodically analyzing 1 mL samples of the 
reaction mixture. The samples were quenched with aqueous H3PO4 (0.5 M, 0.5 mL), 
diethyl ether (1 mL) was added and the product was extracted. The organic phase was 
washed with brine and filtered through a short plug of MgSO4 (top) and aluminum oxide 
90 (bottom) using 2-PrOH as the eluent. The filtrate obtained was analyzed either by 
GC or HPLC (for details see Supporting Information).   
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 General procedure for the asymmetric hydrogenation of ketones 
For hydrogenations a customized Symyx high throughput screening system was 
used. All hydrogenations were carried out for 16 hours at r.t. under hydrogen gas at a 
pressure of 25 bar and a substrate to catalyst ratio of 25:1. Typically the following 
amounts of substrate, catalyst, and solvent were used: 41.67 µmol substrate and 1.67 
µmol catalyst precursor in a total of 500 µL solvent (for analysis data see Supporting 
Information). 
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General considerations 
All reactions required inert conditions and were carried out under an argon 
atmosphere using standard Schlenk techniques. All solvents were dried by standard 
procedures and distilled before use. Preparative chromatographic separations were 
performed under gravity on standardised aluminium oxide 90 (MERCK). Petroleum 
ether with a boiling range of 55–65 °C was used for chromatography. Abbreviations: 
PE: petroleum ether; DEE: diethyl ether; EA: ethyl acetate; DCM: dichloromethane; 
THF: tetrahydrofurane. The following substrates were purchased and were used without 
further purification: (S)-(4-isopropyloxazolin-2-yl)ferrocene (TCI), acetophenone 
(FLUKA), propiophenone (FLUKA), pinacolone (ABCR). All other substrates were 
purified by chromatography before use: 2'-fluoroacetophenone (FLUKA), 2'-chloro-
acetophenone (ALDRICH), 4'-chloroacetophenone (ALDRICH), 4'-(trifluoromethyl)-
acetophenone (ALDRICH), 1-(4-methoxyphenyl)ethanone (ALDRICH), 4'-methyl-
acetophenone (ALDRICH), 3′,5′-Bis(trifluoromethyl)acetophenone (ALDRICH), 1,2-
diphenylethanone (ALDRICH), 1,3-diphenyl-1-propanone (ABCR), acetylferrocene 
(ABCR) and 1-tetralone (ABCR). 
NMR spectra were recorded on a Bruker DPX-400 spectrometer in CDCl3 or 
CD2Cl2. Chemical shifts (δ) are given relative to CHCl3 (
1H: 7.26 ppm), CDCl3 (
13C: 77.0 
ppm), CH2Cl2 (
1H: 5.32 ppm), CD2Cl2 (
13C: 54.0 ppm) and 85% H3PO4 (
31P: 0 ppm). The 
coupling constants in 13C{1H} spectra are due to 13C-31P coupling. For signal assignment 
the following terms were used: s, bs, d, dd, t, q and m refer to singlet, broad singlet, 
doublet, doublet of doublets, triplet, quartet and multiplet, respectively. The terms PhA 
and PhB were used to distinguish phenyl groups of diphenylphosphino units. A general 
atom numbering scheme used for proton and carbon assignment is given below. 
Melting points were determined on a Kofler melting point apparatus and are 
uncorrected. Mass spectra were recorded on instruments Finnigan MAT 900 S, MAT 95 
S and Bruker ESI-Qq aoTOF. Optical rotations were measured on a Perkin-Elmer 241 
polarimeter. Conversion and e.e. values were measured with use of an Agilent 7890 A 
GC or an Agilent 1200 HPLC. Elemental analysis was carried out at the 
Mikroanalytisches Labor at the Faculty of Chemistry (University of Vienna).  
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Atom numbering scheme for NMR assignment of ferrocenes. 
(R,RFc)-2-(4,5-Dihydro-4,4-dimethyloxazol-2-yl)-1-[1-(diphenylphosphino)ethyl]-
ferrocene, (R,RFc)-5  
To a solution of (R,RFc)-12 (1.029 g, 2.01 mmol) in THF (5 mL) were added polymethyl-
hydrosiloxane (1.3 g) and titanium(IV) isopropoxide (2.29 g, 8.04 mmol) and the 
resulting mixture was reacted for 30 minutes at 80 °C. After cooling to r.t. and without 
further workup was the resulting dark solution chromatographed twice on aluminium 
oxide 90 under inert conditions and with use of deoxygenated solvents (eluent: 
PE/EA/TEA = 5/5/1). A third chromatography with use of PE/EA/TEA = 8/2/1 as the 
eluent gave the desired product as a yellow semisolid (669 mg, 1.35 mmol, 67 % yield). 
1H NMR (400 MHz, CDCl3): δ 1.17 (s, 3H, C(CH3)(CH3)), 1.18 (s, 3H, C(CH3)(CH3)), 
1.51 (dd, J = 7.2 Hz, J = 15.1 Hz, 3H, CHCH3), 3.58, 3.78 (AB, J = 7.6 Hz, 2H, CH2), 
4.14 (s, 5H, Cp'), 4.26–4.32 (m, 3H, H3/5 + H4 + CHCH3), 4.63 (dd, J = 2.6 Hz, J = 1.6 
Hz, 1H, H3/5), 6.84–6.88 (m, 2H, PhA-ortho), 7.05–7.09 (m, 2H, PhA-meta), 7.11–7.15 
(m, 1H, PhA-para), 7.40–7.44 (m, 3H, PhB-meta + PhB-para), 7.62–7.66 (m, 2H, PhB-
ortho). 13C{1H} NMR (100.6 MHz, CDCl3): δ 18.8 (d, J = 20.9 Hz, CHCH3), 27.9 
(C(CH3)(CH3)), 28.3 (C(CH3)(CH3)), 29.3 (d, J = 14.3 Hz, CHCH3), 66.5 (C(CH3)2), 68.4 
(C3/5), 68.7 (C4), 68.8 (C3/5), 69.8 (Cp'), 77.8 (CH2O), 93.8 (C1), 127.4 (d, J = 6.1 Hz, 
2C, PhA-meta), 127.7 (PhA-para), 128.3 (d, J = 7.8 Hz, 2C, PhB-meta), 129.2 (PhB-para), 
132.9 (d, J = 17.6 Hz, 2C, PhA-ortho ), 134.7 (d, J = 19.7 Hz, 2C, Ph
B-ortho), 135.9 (d, J 
= 16.4 Hz, PhB-ipso), 137.1 (d, J = 17.6 Hz, PhA-ipso), 164.1 (C=N), C2 not observed. 
31P NMR (162 MHz, CDCl3): δ 11.4 (PPh2). HR-MS (ESI, MeOH/MeCN): m/z = [M+Na]
+ 
calcd. 518.1312 for C29H30FeNOPNa; found: 518.1319. [α]
20
λ (nm): –273 (589), –307 
(578), –468 (546) (c 0.275, CHCl3).   
(SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-diphenylphosphino-
methyl]-ferrocene, (SOx,SFc)-6 
To a stirred solution of (SOx,RFc)-14 (1.5 g, 4.58 mmol) and sodium iodide (1.37 g, 9.14 
mmol) in acetonitrile (40 mL) was added chlorotrimethylsilane (1.08 g, 11.45 mmol) 
which led to a change of color from orange to red. After additional stirring for 10 min at 
r.t. diphenylphosphine (938 mg, 5.04 mmol) was added and this resulted in a change of 
Fe
1 2
3
4
5
Cp'
R
R
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color from red to orange. The reaction mixture was stirred for 24 h at r.t.; subsequently 
without previous workup the crude product was purified by chromatography under inert 
conditions with deoxygenated solvents on aluminium oxide 90. The solvent mixture 
PE/DEE = 20/1 removed excess of diphenylphosphine and PE/EA/TEA = 2/1/1 + 10% 
DCM eluted the title compound as a red oil (2.02 g, 4.08 mmol, 89 % yield). 
1H NMR 
(400 MHz, CDCl3): δ 0.96 (d, J = 6.7 Hz, 3H, CH(CH3)(CH3)), 1.04 (d, J = 6.7 Hz, 3H, 
CH(CH3)(CH3)), 1.74–1.84 (m, 1H, CH(CH3)2), 3.38 (dd, J = 2.5 Hz, J = 13.8 Hz, 1H, 
CHHP), 3.89–3.92 (m, 1H, H5), 3.92–4.00 (m, 3H, CHHO + CHHP + CHN), 4.07–4.10 
(m, 1H, H4), 4.09 (s, 5H, Cp'), 4.21–4.28 (m, 1H, CHHO), 4.61 (dd, J = 1.5 Hz, J = 2.5 
Hz, 1H, H3), 7.27–7.37 (m, 6H, Ph-meta + Ph-para), 7.39–7.45 (m, 2H, Ph-ortho), 
7.45–7.51 (m, 2H, Ph-ortho). 13C{1H} NMR (100.6 MHz, CDCl3): δ 18.5 (CH(CH3)(CH3)), 
18.9 (CH(CH3)(CH3)), 29.2 (d, J = 14.9 Hz, CH2P), 32.8 (CH(CH3)2), 68.3 (C4), 69.2 
(2C, CH2O + C3), 69.5 (C2), 70.3 (Cp'), 71.6 (d, J = 5.3 Hz, C5), 72.6 (CHN), 86.1 (d, J 
= 16.9 Hz, C1), 127.9 (Ph-para), 128.2 (d, J = 6.2 Hz, 2C, Ph-meta), 128.3 (d, J = 7.2 
Hz, 2C, Ph-meta), 128.8 (Ph-para), 132.2 (d, J = 17.5 Hz, 2C, Ph-ortho), 133.8 (d, J = 
19.7 Hz, 2C, Ph-ortho), 139.0 (d, J = 124.7 Hz, Ph-ipso), 141.6 (d, J = 115.8 Hz, Ph-
ipso), 165.6 (C=N). 31P NMR (162 MHz, CDCl3): δ –10.0 (PPh2). HR-MS (EI, 30 °C): 
m/z = [M + H]+ calcd. 496.1492 for C29H31FeNOP; found: 496.1491. [α]
20
λ (nm): –50.5 
(589), –59.9 (578), –112 (546) (c 0.192, CHCl3). 
(SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[bis(3,5-dimethylphenyl)-
phosphinomethyl]-ferrocene, (SOx,SFc)-7 
To a solution of (SOx,RFc)-14 (1.5 g, 4.58 mmol) and sodium iodide (1.37 g, 9.14 mmol) 
in acetonitrile (40 mL) was added chlorotrimethylsilane (1.08 g, 11.45 mmol) which 
resulted in a change of color from orange to red. After further stirring the solution at r.t. 
for 10 min bis(3,5-dimethylphenyl)phosphine (1.39 g, 5.04 mmol) was added and this 
led to a slow change of color from red to orange. The reaction mixture was stirred for 24 
h at r.t. and subsequently without previous workup the crude product was 
chromatographed under inert conditions with deoxygenated solvents on aluminium 
oxide 90. A mixture of PE/DEE = 20/1 removed excess of diphenylphosphine while with 
use of PE/EA/TEA = 2/1/1 + 10% DCM the title compound was obtained as a red oil 
(2.23 g, 4.04 mmol, 88 % yield). 
1H NMR (400 MHz, CDCl3): δ 1.00 (d, J = 6.8 Hz, 3H, 
CH(CH3)(CH3)), 1.08 (d, J = 6.7 Hz, 3H, CH(CH3)(CH3)), 1.74–1.85 (m, 1H, CH(CH3)2), 
2.29 (s, 6H, CH3
A), 2.31 (s, 6H, CH3
B), 3.39 (dd, J = 2.4 Hz, J = 14.0 Hz, 1H, CHHP), 
3.89 (d, J = 14.0 Hz, 1H, CHHP), 3.94–3.97 (m, 1H, H5), 3.98–4.02 (m, 2H, CHHO + 
CHN), 4.11 (t, J = 2.6 Hz, 1H, H4), 4.12 (s, 5H, Cp'), 4.22–4.30 (m, 1H, CHHO), 4.62 
(dd, J = 1.6 Hz, J = 2.6 Hz, 1H, H3), 6.92 (s, 1H, PhA-para), 6.98 (s, 1H, PhB-para), 7.07 
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(d, J = 7.3 Hz, 2H, PhA-ortho), 7.11 (d, J = 7.6 Hz, 2H, PhB-ortho). 13C{1H} NMR (100.6 
MHz, CDCl3): δ 18.6 (CH(CH3)(CH3)), 19.0 (CH(CH3)(CH3)), 21.2 (2C, CH3
A), 21.3 (2C, 
CH3
B), 28.9 (d, J = 14.6 Hz, CH2P), 32.9 (CH(CH3)2), 68.1 (C4), 69.0 (C3), 69.2 (CH2O), 
69.4 (d, J = 3.4 Hz, C2), 70.2 (Cp'), 71.7 (d, J = 6.2 Hz, C5), 72.6 (CHN), 86.5 (d, J = 
17.1 Hz, C1), 129.8 (PhA-para), 129.9 (d, J = 17.8 Hz, 2C, PhA-ortho), 130.5 (PhB-para), 
131.3 (d, J = 20.0 Hz, 2C, PhB-ortho), 137.4 (d, J = 6.1 Hz, 2C,  Ph-meta), 137.5 (d, J = 
6.8 Hz, 2C,  Ph-meta), 138.2 (d, J = 14.8 Hz, Ph-ipso), 139.3 (d, J = 15.5 Hz, Ph-ipso), 
165.5 (C=N). 31P NMR (162 MHz, CDCl3): δ –10.6 (PPh2). HR-MS (EI, 30 °C): m/z = [M 
+ H]+ calcd. 552.2119 for C33H39FeNOP; found: 552.2116. [α]
20
λ (nm): –56.8 (589), –
64.0 (578), –117.4 (546) (c 0.236, CHCl3).   
(R,SFc)-1-[1-(N,N-Dimethylamino)ethyl]-2-[(2-hydroxy-1,1-dimethylethyl)amino-
carbonyl]-ferrocene, (R,SFc)-10 
A solution of 2-amino-2-methyl-1-propanol (600 mg, 6.73 mmol) in toluene (10 mL) was 
cooled to 0 °C and treated with a solution of trimethylaluminium in toluene (2.0 M, 6.68 
mL, 13.36 mmol). After stirring for 5 min the solution was warmed to r.t. and stirring was 
continued for additional 45 min. Subsequently, a solution of (R,SFc)-9 (2.00 g, 6.07 
mmol) in toluene (10 mL) was added and the resulting mixture was stirred for 16 h at 
126 °C. After cooling to r.t., the reaction mixture was quenched carefully by addition of 
water and the phases were separated. The aqueous phase was extracted with EA (3 x 
50 mL), the organics were combined, washed with water and brine and dried over 
MgSO4. The solvents were removed under reduced pressure and the crude product 
was purified by chromatography on aluminium oxide 90 (eluent PE/EA/TEA = 1/1/1) to 
give the title compound as an orange solid (2.01 g, 5.40 mmol, 89 % yield). Mp: 117 °C. 
1H NMR (400 MHz, CDCl3): δ 1.27 (s, 3H, C(CH3)(CH3)), 1.34 (d, J = 6.9 Hz, 3H, 
CHCH3), 1.36 (s, 3H, C(CH3)(CH3)), 2.11 (s, 6H, N(CH3)2), 3.63 (bs, 2H, CH2O), 4.11 (q, 
J = 6.9 Hz, 1H, CHCH3), 4.13 (s, 5H, Cp'), 4.22–4.28 (m, 2H, H4 + H5), 4.90 (dd, J = 
2.5 Hz, J = 1.7 Hz, 1H, H3), 6.20 (bs, 1H, OH), 10.19 (bs, 1H, NH). 13C{1H} NMR (100.6 
MHz, CDCl3): δ 7.4 (CHCH3), 25.1 (2C, C(CH3)2), 38.7 (2C, N(CH3)2), 55.6 (C(CH3)2), 
57.9 (CHCH3), 68.0 (C4), 69.9 (C5), 70.6 (Cp'), 71.9 (CH2O), 73.8 (C3), 79.1 (C2), 86.0 
(C1), 171.5 (C=O). HR-MS (EI, 30 °C): m/z = [M]+ calcd. 372.1500 for C19H28FeN2O2; 
found: 372.1465. [α]20λ (nm): –8.8 (589), –4.8 (578), 28.0 (546) (c 0.25, CHCl3). 
(R,SFc)-2-(4,5-Dihydro-4,4-dimethyloxazol-2-yl)-1-[1-(N,N-dimethylamino)ethyl]-
ferrocene, (R,SFc)-11 
To a solution of (R,SFc)-10 (3 g, 8.06 mmol) in acetonitrile (50 mL) were added 
triphenylphosphine (3.17 g, 12.09 mmol), triethylamine (3.67 g, 36.27 mmol) and 
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carbon tetrachloride (11.16 g, 72.54mmol) and the resulting mixture was stirred for 16 h 
at r.t. The reaction was quenched by addition of water (10 mL) and the resulting mixture 
was acidified with an aqueous solution of citric acid. The aqueous phase was extracted 
with DCM (3 x 50 mL) and the organic phases were discarded. The aqueous phase was 
made basic by addition of an aqueous sodium hydroxide solution, followed by extraction 
with DCM (2 x 50 mL). The combined organics were washed with water and brine, dried 
over MgSO4 and the solvents were evaporated. The crude product was purified by 
chromatography on aluminium oxide 90 with use of PE/EA/TEA = 5/5/1 as the eluent to 
give the title compound as an orange-red solid (2.60 g, 7.34 mmol, 91 % yield). Mp: 105 
°C. 1H NMR (400 MHz, CDCl3): δ 1.27 (s, 6H, C(CH3)2), 1.52 (d, J = 7.0 Hz, 3H, 
CHCH3), 2.02 (s, 6H, N(CH3)2), 3.92, 4.04 (AB, J = 7.9 Hz, 2H, CH2O), 4.13 (s, 5H, Cp'), 
4.25–4.28 (m, 1H, H5), 4.30 (t, J = 2.5 Hz, 1H, H4), 4.38 (q, J = 7.0 Hz, 1H, CHCH3), 
4.3 (dd, J = 2.5 Hz, J = 1.5 Hz, 1H, H3). 13C{1H} NMR (100.6 MHz, CDCl3): δ 17.6 
(CHCH3), 28.2 (C(CH3)(CH3)), 28.4 (C(CH3)(CH3)), 40.5 (2C, N(CH3)2), 54.7 (CHCH3), 
66.9 (C(CH3)2), 68.5 (C4), 69.2 (C3), 69.5 (C5), 69.9 (C2), 70.2 (Cp'), 78.4 (CH2O), 88.4 
(C1), 164.9 (C=N). HR-MS (EI, 30 °C): m/z = [M]+ calcd. 354.1394 for C19H26FeN2O; 
found: 354.1365. [α]20λ (nm): –336.2 (589), –373.0 (578), –581.0 (546) (c 0.315, CHCl3). 
(R,RFc)-2-(4,5-Dihydro-4,4-dimethyloxazol-2-yl)-1-[1-(diphenylphosphinyl)ethyl]-
ferrocene, (R,RFc)-12 
To a stirred solution of (R,SFc)-11 (1.66 g, 4.69 mmol) in acetonitrile (10 mL) was added 
iodomethane (2.0 g, 14.07 mmol) at 0 °C and stirring was continued for 1 h at r.t. The 
solvent was removed under reduced pressure and the crude salt was dried in vacuo. In 
a separate flask, diphenylphosphine oxide (1.043 g, 5.16 mmol) was dissolved in THF 
(10 mL) and cooled to 0 °C. A solution of n-BuLi in hexane (1.6 M, 3.52 mL, 5.63 mmol) 
was added dropwise and the resulting mixture was stirred at r.t. for 1 h. The solvent 
was removed under reduced pressure and the crude diphenylphosphinyl lithium was 
dried in vacuo. The methiodide salt was then redissolved in THF (20 mL) and was 
transferred to the dried diphenylphosphinyl lithium. The resulting mixture was heated to 
85 °C for 1 h, cooled to r.t. and subsequently quenched by addition of water. The 
product was extracted with EA (3 x 50 mL), the combined organics were washed with 
water and brine and dried over MgSO4. After removing the solvent on a rotary 
evaporator, the crude product was chromatographed on aluminium oxide using 
EA/TEA/methanol = 100/10/1 as the eluent. The title compound was obtained as a 
yellow solid (1.59 g, 3.11 mmol, 66 % yield). Mp: 178 °C. 1H NMR (400 MHz, CDCl3): δ 
1.22 (s, 6H, C(CH3)2), 1.66 (dd, J = 7.4 Hz, J = 15.5 Hz, 3H, CHCH3), 3.68, 3.70 (AB, J 
= 7.8 Hz,  2H, CH2O), 4.14 (s, 5H, Cp'), 4.33 (t, J = 2.6 Hz, 1H, H4), 4.50 (dd, J = 2.6 
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Hz, J = 1.6 Hz, 1H, H3), 4.48–456 (m, J = 7.4 Hz, 1H, CHCH3), 4.59–4.62 (m, 1H, H5), 
7.07–7.13 (m, 2H, PhA-meta), 7.14–7.22 (m, 2H, PhA-ortho), 7.23–7.29 (m, 1H, PhA-
para), 7.51–7.59 (m, 3H, PhB-meta + PhB-para), 7.96–8.04 (m, 2H, PhB-ortho). 13C{1H} 
NMR (100.6 MHz, CDCl3): δ 15.0 (d, J = 2.2 Hz, CHCH3), 28.2 (C(CH3)(CH3)), 28.4 
(C(CH3)(CH3)), 32.4 (d, J = 65.2 Hz, CHCH3), 67.0 (C(CH3)2), 68.5 (C3), 69.1 (C4), 69.2 
(C2), 69.9 (Cp'), 70.2 (d, J = 2.3 Hz, C5), 77.7 (CH2O), 88.8 (d, J = 1.5 Hz, C1), 127.3 
(d, J = 11.7 Hz, 2C, PhA-meta), 128.5 (d, J = 10.8 Hz, 2C, PhB-meta), 130.9 (d, J = 3.2 
Hz, PhA-para), 131.5 (d, J = 9.2 Hz, PhA-ortho), 131.6 (d, J = 3.1 Hz, PhB-para), 131.7 
(d, J = 8.4 Hz, 2C, PhB-ortho), 132.2 (d, J = 62.0 Hz, PhA-ipso), 163.8 (C=N), PhB-ipso 
not observed. 31P NMR (162 MHz, CDCl3): δ 36.3 (P(O)PPh2). HR-MS (EI, 30 °C): m/z 
= [M]+ calcd. 511.1363 for C29H30FeNO2P; found: 511.1368. [α]
20
λ (nm): –100 (589),–
112 (578), –172 (546) (c 0.240, CHCl3).    
(SOx,RFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-hydroxymethyl-ferrocene, 
(SOx,RFc)-14 
To a solution of (S)-13 (1.0 g, 3.37 mmol) and tetramethylethylenediamine (431 mg, 
3.71 mmol) in anhydrous DEE (30 mL) cooled to –78 °C was added dropwise a solution 
of sec-BuLi in cyclohexane (1.4 M, 2.9 mL, 4.04 mmol). Stirring was continued for 2 h at 
–78 °C. Subsequently, dimethylformamide (259 mg, 3.54 mmol) was added to the 
reaction mixture. Stirring was continued for 30 min at –78 °C and for additional 45 min 
at r.t. The reaction mixture was quenched by addition of water, the phases were 
separated and the aqueous phase was extracted with DEE (3 x 50 mL). The combined 
organics were washed with water and brine, dried over MgSO4 and the solvent was 
removed under reduced pressure. In the next step the crude product (1.02 g, 3.14 
mmol) was dissolved in MeOH (20 mL), cooled to 0 °C and NaBH4 (356.4 mg, 9.42 
mmol) was added in portions. The reaction mixture was stirred for 2 h at r.t. 
Subsequently, the reaction mixture was quenched by addition of water at 0 °C, the 
phases were separated and the aqueous phase was extracted with DEE (3 x 50 mL). 
The combined organics were washed with water and brine, dried over MgSO4 and the 
solvents were removed under reduced pressure. The crude product was 
chromatographed on aluminum oxide 90 using PE/EA = 5/1 as the eluent. The desired 
compound was obtained as an orange solid (0.84 g, 2.57 mmol, 76 % yield). The 
spectroscopic data are in accordance with those reported in reference 20. 
Synthesis of neutral ruthenium complexes – General procedure 
A mixture of oxazoline ligand (1.00 mmol) and [RuCl2(PPh3)3] (0.95 mmol) dissolved in 
freshly distilled and degassed toluene (3 mL) was stirred for 16 h at r.t. Degassed 
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hexane was added to precipitate the product. The green solid was filtered off under 
inert conditions and was washed with freshly distilled and degassed hexane (2 × 2 mL). 
The crude product was redissolved in toluene, precipitated by addition of hexane and 
dried in vacuo to yield a green powder.  
Dichloro[(R,RFc)-2-[4,5-Dihydro-4,4-dimethyloxazol-κN)-1-[1-(diphenylphosphino)-
ethyl-κP]-ferrocene]triphenylphosphine ruthenium, [RuCl2(PPh3)((R,RFc)-5)], (RFc)-
19 
Starting from (R,RFc)-5 (250 mg, 0.505 mmol) and following the general procedure  
given above the desired product was obtained as a green powder (369.8 mg, 397.8 
mmol, 79  % yield). Single crystals suitable for X-ray crystallography were obtained from 
a solution of the product in Tol/PE by slow evaporation of the solvents.  Mp: > 230 °C 
(dec.). 1H NMR (400 MHz, CDCl3): δ 1.24 (s, 3H, C(CH3)(CH3)), 1.51 (dd, J = 7.1 Hz, J 
= 13.9 Hz, 3H, CHCH3), 1.69 (s, 3H, C(CH3)(CH3)), 3.87–3.89 (m, 1H, H5), 3.88  (t, J = 
2.7 Hz, 1H, H4), 4.01, 4.23 (AB, J = 7.7 Hz, 2H, CH2), 4.14 (s, 5H, Cp'), 4.29–4.39 (m, 
1H, CHCH3), 4.85 (dd, J = 2.5 Hz, J = 1.5 Hz, 1H, H3), 6.86–7.56 (m, 25H, Ph). 
13C{1H} 
NMR (100.6 MHz, CDCl3): δ 18.8 (d, J = 6.3 Hz, CHCH3), 23.5 (C(CH3)(CH3)), 28.6 
(C(CH3)(CH3)), 39.7 (d, J = 21.3 Hz, CHCH3), 69.0 (C4), 69.6 (bs, C5), 68.8 (C(CH3)2), 
70.2 (Cp'), 72.4 (C3), 79.8 (CH2), 125–138 (aromatic C, unresolved), C1, C2 and C=N 
not observed. 31P NMR (162 MHz, CDCl3): δ 48.3 (d, J = 43.6 Hz, PPh3), 95.1 (d, J = 
43.6 Hz, PN). HR-MS (ESI in MeOH/MeCN): m/z [M-Cl+ACN]+ calcd for 
C49H48FeN2OP2RuCl: 935.1323, found: 935.1344. [α]
20
λ (nm): +1159 (589), +1154 
(578), +1072 (546) (c 0.022, CHCl3).  
Dichloro[(SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl-κN)-1-[1-diphenyl-
phosphinomethyl-κP]-ferrocene]triphenylphosphine ruthenium, 
[RuCl2(PPh3)((SOx,SFc)-6)], (SOx,SFc)-20 
Starting from (SOx,SFc)-6 (0.80 g, 1.62 mmol) and following the general procedure  given 
above the desired product was obtained as a green powder (1.03 g, 1.11 mmol, 69 % 
yield). Mp: > 230 °C (dec.). 1H NMR (400 MHz, CD2Cl2): δ 0.88 (d, J = 7.1 Hz, 3H, 
CH(CH3)(CH3)), 1.06 (d, J = 6.7 Hz, 3H, CH(CH3)(CH3)), 2.99–3.11 (m, 1H, CH(CH3)2), 
3.37–3.48 (m, 1H, CHHP), 3.48–3.52 (m, 1H, H5), 3.89 (t, J = 2.6 Hz, 1H,  H4), 4.15–
4.21 (m, 1H, CHN), 4.18 (s, 5H, Cp'), 4.22–4.29 (m, 1H, CHHO), 4.52 (dd, J = 3.9 Hz, J 
= 8.3 Hz, 1H, CHHO), 4.66 (dd, J = 10.1 Hz, J = 12.8 Hz, 1H, CHHP), 4.71 (dd, J = 2.6 
Hz, J = 1.6 Hz, 1H, H3), 6.93–7.60 (m, 25H, Ph). 13C{1H} NMR (100.6 MHz, CD2Cl2): δ 
15.2 (CH(CH3)(CH3)), 19.5 (CH(CH3)(CH3)), 28.1 (CH(CH3)2), 39.6 (d, J = 26.1 Hz, 
CH2P), 67.6 (CH2O), 69.3 (C4), 70.8 (Cp'), 72.6 (C3), 72.9 (CHN), 73.6 (bs, C5), 82.3 
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(d, J = 1.9 Hz, C1), 125.5 (Ph-para), 127.0 (d, J = 10.4 Hz, 2C, Ph-meta), 127.5 (d, J = 
10.0 Hz, 2C, Ph-meta), 128.5 (Ph-para), 133.5 (d, J = 7.8 Hz, 2C, Ph-ortho),  135.3 (d, 
J = 10.4 Hz, 2C, Ph-ortho), 173.7 (C=N), C2 and Ph-ipso not observed, signals of PPh3 
are very broad and unresolved. 31P NMR (162 MHz, CD2Cl2): δ 48.3 (d, J = 43.7 Hz, 
PPh3), 84.6 (J = 43.8 Hz, PN). Anal. Calcd for C47H45Cl2FeNOP2Ru x toluene: C, 63.47; 
H, 5.23; N, 1.37. Found: C, 63.92; H, 5.14; N, 1.38. HR-MS (ESI in MeOH/MeCN): m/z 
[M-Cl]+ calcd for C47H45ClFeNOP2Ru: 894.1058, found: 894.1062. [α]
20
λ (nm): –766 
(589), –860 (578), –996 (546) (c 0.022, CH2Cl2). 
Dichloro[(SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl-κN)-1-[bis(3,5-
dimethylphenyl)phosphinomethyl-κP]-ferrocene]triphenylphosphine ruthenium, 
[RuCl2(PPh3)(( SOx,SFc)-7)], (SOx,SFc)-21 
Starting from (SOx,SFc)-7 (950 mg, 1.72 mmol) and following the general procedure  
given above the desired product was obtained as a green powder (1.05 g, 1.07 mmol, 
62 % yield). Mp: > 230 °C (dec.). 
1H NMR (400 MHz, CD2Cl2): δ 0.88 (d, J = 7.2 Hz, 3H, 
CH(CH3)(CH3)), 1.06 (d, J = 6.7 Hz, 3H, CH(CH3)(CH3)), 2.01 (s, 6H, CH3), 2.08 (s, 6H, 
CH3), 3.03–3.14 (m, 1H, CH(CH3)2), 3.35–3.45 (m, 1H, CHHP), 3.51–3.54 (m, 1H, H5), 
3.89 (t, J = 2.6 Hz, 1H, H4), 4.12–4.19 (m, 1H, CHN), 4.18 (s, 5H, Cp'), 4.21–4.27 (m, 
1H, CHHO), 4.50 (dd, J = 4.0 Hz, J = 8.3 Hz, 1H, CHHO), 4.60 (dd, J = 9.8 Hz, J = 12.8 
Hz, 1H, CHHP), 4.7 (dd, J = 2.6 Hz, J = 1.6 Hz, 1H, H3), 6.35–7.74 (m, 21H, Ph). 
13C{1H} NMR (100.6 MHz, CD2Cl2): δ 15.3 (CH(CH3)(CH3)), 19.5 (CH(CH3)(CH3)), 21.2 
(2C, CH3), 21.3 (2C, CH3), 28.1 (CH(CH3)2), 39.4 (d, J = 26.5 Hz, CH2P), 67.4 (C2), 
67.5 (d, J = 1.6 Hz, CH2O), 69.1 (C4), 70.7 (Cp'), 72.4 (C3), 72.9 (CHN), 73.7 (d, J = 1.5 
Hz, C5), 82.7 (d, J = 1.5 Hz, C1), 131.2 (d, J = 7.7 Hz, 2C, Ph-ortho), 131.3 (d, J = 3.0 
Hz, Ph-para), 131.4 (d, J = 2.4 Hz, Ph-para), 133.0 (d, J = 10.5 Hz, 2C, Ph-ortho), 
136.4 (d, J = 11.5 Hz, 2C, Ph-meta), 137.0 (d, J = 10.8 Hz, 2C, Ph-meta), 140.4, 
140.45, 140.9, 150.0 (2C, Ph-ipso), 173.8 (C=N), signals of PPh3: very broad and 
unresolved. 31P NMR (162 MHz, CD2Cl2): δ 48.9 (d, J = 44.2 Hz, PPh3), 83.4 (d, J = 
43.5 Hz, PN). Anal. Calcd for C51H53Cl2FeNOP2Ru x 0.25 toluene: C, 62.81; H, 5.49; N, 
1.39. Found: C, 62.38; H, 5.25; N, 1.38. HR-MS (ESI in MeOH/MeCN): m/z [M-Cl]+ 
calcd for C51H53ClFeNOP2Ru: 950.1684, found: 950.1692. [α]
20
λ (nm): –805 (589), –880 
(578), –1005 (546) (c 0.020, CH2Cl2).   
Synthesis of the saturated acetonitrile complexes – General procedure 
The ruthenium complex (0.05 mmol) was dissolved at r.t. in freshly distilled and 
degassed acetonitrile (2 mL) which resulted in an immediate change of color from green 
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to yellow. After 15 minutes stirring, the solvent was removed under reduced pressure. 
The complexes were characterized without further purification.  
Dichloro(acetonitrile)[(R,ROx,RFc))-2-[4,5-dihydro-4-(1-methylethyl)oxazol-2-yl-κN)-
1-[1-(diphenylphosphino)ethyl-κP]-ferrocene]triphenylphosphine ruthenium, 
[RuCl2(CH3CN)(PPh3)((R,ROx,RFc)-3)], (ROx,RFc)-22 
Starting from complex (ROX)-17 (50 mg, 0.053 mmol) and following the general 
procedure given above the desired product was obtained. Single crystals suitable for X-
ray crystallography were obtained from a DCM solution by slow evaporation of the 
solvent. Mp: > 230 °C (dec.). 1H NMR (400 MHz, CD2Cl2): δ 1.07 (d, J = 7.2 Hz, 3H, 
CH(CH3)(CH3)),  1.09 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.11 (s, 3H, CH3CN), 1.16 
(dd, J = 7.1 Hz, J = 10.8 Hz, 3H, CHCH3), 2.97–3.07 (m, 1H, CH(CH3)2), 3.29–3.39 (m, 
1H, CHCH3), 4.15 (s, 5H, Cp'), 4.26–4.29 (m, 1H, H4), 4.31–4.35 (m, 1H, H5), 4.43 (t, J 
= 8.4 Hz, 1H, CHHO), 4.67 (dd, J = 2.2 Hz, J = 8.4 Hz, 1H, CHHO), 4.75–4.79 (m, 1H, 
H3), 5.48–5.53 (m, 1H, NCH), 6.63 (t, J = 8.1 Hz, 2H, PhA-ortho), 6.86 –7.59 (m, 21H), 
7.81–7.95 (m, 2H, PhB-ortho). 13C{1H} NMR (100.6 MHz, CD2Cl2): δ 4.6 (CH3CN), 15.6 
(CH(CH3)(CH3)), 17.0 (d, J = 5.0 Hz, CHCH3), 19.1 (CH(CH3)(CH3)), 31.1 (CH(CH3)2), 
41.1 (d, J = 19.2 Hz, CHCH3), 68.9 (C4), 69.9 (CH2O), 70.3 (C3), 71.0 (C5), 71.2 (Cp'), 
73.1 (CHN), 126.8–136 (Ph), Signals from C1, C2, C=N, CN not observed. 31P NMR 
(162 MHz, CD2Cl2): δ 44.4 (d, J = 29.8 Hz, PPh3), 68.4 (d, J = 29.8 Hz, PN). HR-MS 
(ESI in MeOH/MeCN): m/z [M-Cl]+ calcd for C50H50ClFeN2OP2Ru: 949.1480, found: 
949.11486.  
Dichloro(acetonitrile)[( SOx,SFc)-2-[4,5-dihydro-4-(1-methylethyl)oxazol-2-yl-κN)-1-
[bis(3,5-dimethylphenyl)phosphinomethyl-κP]-ferrocene]triphenylphosphine 
ruthenium, [RuCl2 (CH3CN)(PPh3)(( SOx,SFc)-7)], (SOx,SFc)-23 
Starting from Complex (SOx,SFc)-7  (50 mg, 0.051 mmol)  and following the general 
procedure  given above the desired product was obtained. Single crystals suitable for 
X-ray crystallography were obtained from a Tol/PE solution by slow evaporation of the 
solvents. Mp: > 230 °C (dec.). 1H NMR (400MHz, CD2Cl2): δ 0.99 (d, J = 7.1 Hz, 3H, 
CH(CH3)(CH3)), 1.1 (d, J = 7.0 Hz, 3H, CH(CH3)(CH3)), 1.13 (s, 3H, CH3CN), 1.99 (s, 
6H, CH3
A), 2.35 (s, 6H, CH3
B), 2.96–3.07 (m, 1H, CH(CH3)2), 3.21–3.39 (m, 2H, CH2P), 
4.12 (s, 5H, Cp'), 4.21–4.24 (m, 1H, H4), 4.38–4.40 (m, 1H, H3/5), 4.41 (t, J = 8.5 Hz, 
1H, CHHO), 4.62–4.67 (m, 1H, CHHO), 4.70–4.74 (m, 1H, H3/5), 5.45–5.51(m, 1H, 
CHN), 6.29 (d, J = 9.1 Hz, 2H, PhA-ortho), 6.91–7.01 (m, 7H, PhA-para + PPh3-meta), 
7.07–7.17 (m, 7H, PhB-para + PPh3-para), 7.18 –7.91 (PPh3-ortho), 8.0 (d, J = 10.4 Hz, 
2H, PhB-ortho). 13C{1H} NMR (100.6 MHz, CD2Cl2): δ 5.2 (CH3CN), 16.3 
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(CH(CH3)(CH3)), 19.5 (CH(CH3)(CH3)), 21.8 (2C, CH3), 21.9 (2C, CH3), 31.5 
(CH(CH3)2), 43.4 (d, J = 22.5 Hz, CH2P), 69.2 (C4), 70.3 (C3/5), 70.8 (CH2O), 71.7 
(Cp'), 73.0 (CHN), 73.4 (C3/5), 127.6 (d, J = 9.3 Hz, 6C, PPh3-meta), 129.1 (6C, PPh3-
para), 130.9 (PhA-para), 131.7 (m, 3C, PhA-ortho+ PhB-para), 132.9 (d, J = 9.3 Hz, 2C, 
PhB-ortho), 135.0 –135.8 (bm, PPh3-ortho), 137.1 (d, J = 8.6 Hz, 2C, Ph
A-meta), 137.7 
(d, J = 9.9 Hz, 2C, PhB-meta). Signals of C1, C2, C=N, CN, all Ph-ipso not observed. 
31P {1H} NMR (100.6 MHz, CD2Cl2): δ 46.5 (d, J = 31.7 Hz, PPh3), 50.8 (J = 31.7 Hz, 
PN). HR-MS (ESI in MeOH/MeCN): m/z [M-Cl]+ calcd for C53H56ClFeN2OP2Ru: 
991.1949, found: 991.1945. 
Catalysis 
Asymmetric transfer hydrogenations 
Optimization of transfer hydrogenation reactions 
Test reactions were carried out with acetophenone in 2-propanol (19.6 mM), complex 
15 (0.5 %) as the catalyst precursor and the three different bases iPrONa, iPrOK, and 
tBuOK (2%). In all three cases product with nearly identical e.e. values (95–96%) was 
obtained, however the reaction rates differed significantly for the sodium and the 
potassium alkoxides. In order to reach 95% conversion 1 h was needed with iPrONa, 30 
min with tBuOK and 20 min with iPrOK (Table S1). Based on these results potassium 
isopropoxide was used as the base for all further reactions. When in the reaction with 
ACP and 15 the amount of base was increased from 2 to 6% the reaction rate was 
hardly influenced but a very small decrease in product e.e. was seen (95 versus 96%). 
Reducing the reaction temperature from 25 °C to 0 °C reduced only the reaction rate 
but did not significantly alter the enantioselectivity. An increase in substrate 
concentration from 19.6 mM to 0.1 M did neither result in a significant change of 
conversion nor in a change of enantiomeric excess. Only when a 0.2 M solution was 
used the product e.e. dropped to 89%. 
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Table S1. THY optimization results obtained with complexes 15 and 17 
entry complex  time % conv. % e.e. 
effect of type of base  base    
1 (SOx,SFc)-15 iPrONa 1 h 98 95 
2 (SOx,SFc)-15 tBuOK 30 m 97 95 
3 (SOx,SFc)-15 iPrOK 20 m 99 96 
effect of amount of base  % base    
4 (SOx,SFc)-15 2 20 m 99 96 
5 (SOx,SFc)-15 6 30 m 99 95 
effect of temperature  temp.    
6 (SOx,SFc)-15 25 °C 20 m 99 96 
7 (SOx,SFc)-15 10 °C 2 h 94 95 
8 (SOx,SFc)-15 0 °C 3 h 46 96 
effect of concentration  molarity    
9 (SOx,SFc)-15 19.6 mM 20 m 99 96 
10 (SOx,SFc)-15 0.1 M 5 m 94 95 
11 (SOx,SFc)-15 0.2 M 5 m 92 89 
12 (ROx,RFc)-17 19.6 mM 10 m 99 98 
13 (ROx,RFc)-17 0.1 M 10 m 90 96 
14 (ROx,RFc)-17 0.2 M 5 m 90 95 
effect of S/C ratio  S/C ratio    
15 (SOx,SFc)-17 200/1 10 m 99 98 
16 (SOx,SFc)-17 1000/1 1 h 13 81 
 
Table S2. Typical THY results obtained with complexes 15–21. 
entry substrate ligand complex time 
% 
conv. 
% 
e.e. 
abs. 
conf. 
1 ACP (SOx,SFc)-1 (SOx,SFc)-15 20 m 99 96 R 
2 ACP (R,RFc)-2 (RFc)-16 20 m 98 92 S 
3 ACP (R,ROx,RFc)-3 (ROx,RFc)-17 10 m 99 98 S 
4 ACP (R,SOx,RFc)-3 (SOx,RFc)-17 5 h 18 69 R 
5 ACP (R,ROx,RFc)-4 (ROx,RFc)-18 15 m >99 97 S 
6 ACP (R,SOx,RFc)-4 (SOx,RFc)-18 6 h 90 73 R 
7 ACP (R,RFc)-5 (RFc)-19 4 h 78 95 S 
8 ACP (SOx,SFc)-6 (SOx,SFc)-20 30 m 96 93 R 
9 ACP (SOx,SFc)-7 (SOx,SFc)-21 20 m 97 89 R 
 
10 2-F-ACP (SOx,SFc)-1 (SOx,SFc)-15 5 m 99 91 R 
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11 2-F-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 30 m 99 50 S 
 
12 2-Cl-ACP (SOx,SFc)-1 (SOx,SFc)-15 20 m >99 90 R 
13 2-Cl-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 5 m >99 75 S 
14 2-Cl-ACP (R,ROx,RFc)-4 (ROx,RFc)-18 30 m >99 67 S 
15 2-Cl-ACP (R,RFc)-5 (RFc)-19 6 h 89 10 S 
16 2-Cl-ACP (SOx,SFc)-6 (SOx,SFc)-20 30 m 64 27 R 
 
17 4-Cl-ACP (SOx,SFc)-1 (SOx,SFc)-15 10 m >99 93 R 
18 4-Cl-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 5 m 98 94 S 
19 4-Cl-ACP (R,ROx,RFc)-4 (ROx,RFc)-18 10 m >99 90 S 
20 4-Cl-ACP (R,RFc)-5 (RFc)-19 2 h 91 85 S 
21 4-Cl-ACP (SOx,SFc)-6 (SOx,SFc)-20 20 m 99 83 R 
 
22 4-CF3-ACP (SOx,SFc)-1 (SOx,SFc)-15 5 m 99 90 R 
23 4-CF3-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 20 m >99 87 S 
24 4-MeO-ACP (SOx,SFc)-1 (SOx,SFc)-15 20 m 80 90 R 
25 4-MeO-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 20 m 82 95 S 
26 4-MeO-ACP (R,ROx,RFc)-4 (ROx,RFc)-18 20 m 75 95 S 
27 4-MeO-ACP (R,RFc)-5 (RFc)-19 4 h 32 88 S 
28 4-MeO-ACP (SOx,SFc)-6 (SOx,SFc)-20 1 h 72 87 R 
 
29 4-Me-ACP (SOx,SFc)-1 (SOx,SFc)-15 10 m 97 96 R 
30 4-Me-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 10 m 97 98 S 
 
31 PEK (SOx,SFc)-1 (SOx,SFc)-15 10 m 99 97 R 
32 PEK (R,ROx,RFc)-3 (ROx,RFc)-17 20 m 99 96 S 
33 PEK (R,ROx,RFc)-4 (ROx,RFc)-18 15 m 94 96 S 
34 PEK (R,RFc)-5 (RFc)-19 3 h 89 91 S 
35 PEK (SOx,SFc)-6 (SOx,SFc)-20 1 h 97 88 R 
 
36 PBK (SOx,SFc)-1 (SOx,SFc)-15 10 m >99 95 R 
37 PBK (R,ROx,RFc)-3 (ROx,RFc)-17 20 m >98 97 S 
38 PBK (R,ROx,RFc)-4 (ROx,RFc)-18 2 h >99 95 S 
39 PBK (R,RFc)-5 (RFc)-19 3 h 77 93 S 
40 PBK (SOx,SFc)-6 (SOx,SFc)-20 4 h >99 91 R 
 
41 DPP (SOx,SFc)-1 (SOx,SFc)-15 10 m >99 94 R 
42 DPP (R,ROx,RFc)-3 (ROx,RFc)-17 15 m 99 96 S 
43 DPP (R,ROx,RFc)-4 (ROx,RFc)-18 20 m >99 94 S 
44 DPP (R,RFc)-5 (RFc)-19 3 h 77 93 S 
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45 DPP (SOx,SFc)-6 (SOx,SFc)-20 30 m 98 90 R 
 
46 TETN (SOx,SFc)-1 (SOx,SFc)-15 5 m 71 93 R 
47 TETN (R,ROx,RFc)-3 (ROx,RFc)-17 30 m 32 74 S 
48 TETN (R,ROx,RFc)-4 (ROx,RFc)-18 20 m 21 81 S 
49 TETN (SOx,SFc)-6 (SOx,SFc)-20 2 h 50 72 R 
 
50 AcFc (SOx,SFc)-1 (SOx,SFc)-15 30 m 24 80 R 
51 AcFc (R,ROx,RFc)-3 (ROx,RFc)-17 30 m 10 81 S 
52 AcFc (R,ROx,RFc)-4 (ROx,RFc)-18 30 m 16 93 S 
53 AcFc (SOx,SFc)-6 (SOx,SFc)-20 30 m 16 62 R 
 
54 
t
BMK (SOx,SFc)-1 (SOx,SFc)-15 24 h 85 >99 S 
55 
t
BMK (R,ROx,RFc)-3 (ROx,RFc)-17 24 h 42 9 R 
56 
t
BMK (R,ROx,RFc)-4 (ROx,RFc)-18 24 h 11 3 R 
57 
t
BMK (SOx,SFc)-6 (SOx,SFc)-20 24 h 36 21 R 
 
Asymmetric hydrogenations  
 
Table S3. Selected HY results obtained with complexes 15–21. 
entry substrate ligand complex Solvent Base 
% 
conv. 
% 
e.e. 
abs. 
conf. 
1 ACP (R,RFc)-2 (RFc)-16 Tol, H2O K2CO3 99 95 S 
2 ACP (R,RFc)-2 (RFc)-16 Tol, H2O NaOH 99 94 S 
3 ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O K2CO3 99 99 S 
4 ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O NaOH 99 97 S 
5 ACP (R,ROx,RFc)-3 (ROx,RFc)-17 
i
PrOH KO
t
Bu 95 94 S 
6 ACP (R,SOx,RFc)-3 (SOx,RFc)-17 
i
PrOH KO
t
Bu 95 58 R 
7 ACP (R,ROx,RFc)-4 (ROx,RFc)-18 Tol, H2O K2CO3 99 98 S 
8 ACP (R,ROx,RFc)-4 (ROx,RFc)-18 Tol, H2O NaOH 99 96 S 
9 ACP (R,SOx,RFc)-4 (SOx,RFc)-18 
i
PrOH KO
t
Bu 95 62 R 
 
10 2-F-ACP (ROx,RFc)-1 (ROx,RFc)-15 Tol, H2O K2CO3 94 93 S 
11 2-F-ACP (ROx,RFc)-1 (ROx,RFc)-15 Tol, H2O NaOH 96 91 S 
12 2-F-ACP (R,RFc)-2 (RFc)-16 Tol, H2O K2CO3 98 74 S 
13 2-F-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O K2CO3 97 90 S 
14 2-F-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol/H2O NaOH 96 87 S 
15 2-F-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 
i
PrOH KO
t
Bu 99 70 S 
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14 2-F-ACP (R,ROx,RFc)-4 (ROx,RFc)-18 Tol, H2O K2CO3 97 83 S 
16 2-F-ACP (SOx,SFc)-6 (SOx,SFc)-20 Tol, H2O NaOH 93 85 R 
17 2-F-ACP (SOx,SFc)-7 (SOx,SFc)-21 Tol, H2O NaOH 95 70 R 
 
18 2-Cl-ACP (R,RFc)-2 (RFc)-16 Tol, H2O K2CO3 97 71 S 
19 2-Cl-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O K2CO3 95 91 S 
20 2-Cl-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O NaOH 98 90 S 
21 2-Cl-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 
i
PrOH KO
t
Bu 80 82 S 
22 2-Cl-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 
i
PrOH KO
t
Bu 80 82 S 
23 2-Cl-ACP (R,SOx,RFc)-3 (SOx,RFc)-17 
i
PrOH KO
t
Bu 73 59 R 
24 2-Cl-ACP (R,ROx,RFc)-4 (ROx,RFc)-18 Tol, H2O K2CO3 96 87 S 
25 2-Cl-ACP (R,SOx,RFc)-4 (SOx,RFc)-18 
i
PrOH KO
t
Bu 76 75 R 
 
26 4-CF3-ACP (ROx,RFc)-1 (ROx,RFc)-15 Tol, H2O K2CO3 97 91 S 
27 4-CF3-ACP (R,RFc)-2 (RFc)-16 Tol, H2O K2CO3 98 64 S 
28 4-CF3-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O K2CO3 97 90 S 
29 4-CF3-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol/H2O NaOH 97 89 S 
30 4-CF3-ACP (R,ROx,RFc)-4 (ROx,RFc)-18 Tol, H2O K2CO3 98 80 S 
31 4-CF3-ACP (SOx,SFc)-6 (SOx,SFc)-20 Tol, H2O K2CO3 95 80 R 
32 4-CF3-ACP (SOx,SFc)-7 (SOx,SFc)-21 Tol, H2O NaOH 94 69 R 
  
33 4-Me-ACP (ROx,RFc)-1 (ROx,RFc)-15 Tol, H2O K2CO3 100 91 S 
34 4-Me-ACP (R,RFc)-2 (RFc)-16 Tol, H2O K2CO3 100 88 S 
35 4-Me-ACP (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O K2CO3 100 97 S 
36 4-Me-ACP (R,ROx,RFc)-4 (ROx,RFc)-18 
i
PrOH KO
t
Bu >99 93 S 
37 4-Me-ACP (R,ROx,RFc)-4 (ROx,RFc)-18 Tol, H2O K2CO3 100 97 S 
38 4-Me-ACP (SOx,SFc)-6 (SOx,SFc)-20 Tol, H2O K2CO3 99 92 R 
39 4-Me-ACP (SOx,SFc)-7 (SOx,SFc)-21 Tol, H2O K2CO3 98 86 R 
 
41 PBK (R,RFc)-2 (RFc)-16 
i
PrOH KO
t
Bu >99 74 S 
42 PBK (R,ROx,RFc)-3 (ROx,RFc)-17 
i
PrOH KO
t
Bu >99 99 S 
43 PBK (R,ROx,RFc)-4 (ROx,RFc)-18 
i
PrOH KO
t
Bu >99 93 S 
 
44 3,5-bTFA (ROx,RFc)-1 (ROx,RFc)-15 Tol, H2O K2CO3 99 94 S 
45 3,5-bTFA (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O K2CO3 95 40 S 
46 3,5-bTFA (R,ROx,RFc)-3 (ROx,RFc)-17 Tol, H2O K2CO3 95 40 S 
47 3,5-bTFA (R,ROx,RFc)-4 (ROx,RFc)-18 Tol, H2O NaOH 95 41 S 
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Analysis data: 
Conversions and e.e. values of substrates ACP, 2-F-ACP, 2-Cl-ACP, 4-Cl-ACP, 4-CF3-
ACP, 4-MeO-ACP, 4-Me-ACP, 3,5-bTFA, tBMK, PEK and TETN were determined by 
GC. Retention times are given for the reactants and both product enantiomers. 
Substrate tBMK: Column: Supelco, Beta DexTM 110 (30m); 62 °C isothermal, carrier gas 
He, 15.3 psi, split 100:1. 
tBMK = 4.6 min, (R) = 9.3 min, (S) = 9.7 min. 
Substrates ACP, PEK and 3,5-bTFA: column: Supelco, Beta DexTM 110 (30m); 110 °C 
isothermal, carrier gas He, 15.3 psi, split 30:1. 
ACP = 10.4 min, (R) = 15.6 min, (S) = 16.4 min. 
PEK = 16.5 min, (R) = 25.7 min, (S) = 26.9 min. 
3,5-bTFA = 3.8 min, (R) = 7.5 min, (S) = 8.0 min. 
Substrates 2-F-ACP, 4-Me-ACP: column: Supelco, Beta DexTM 110 (30m); 120 °C 
isothermal, carrier gas He, 15.3 psi, split 30:1. 
2-F-ACP = 4.2 min, (R) = 6.7 min, (S) = 6.9 min. 
4-Me-ACP = 9.4 min, (R) = 10.4 min, (S) = 11.0 min. 
Substrates 4-MeO-ACP, TETN: Column: Supelco, Beta DexTM 110 (30m); 125 °C 
isothermal, carrier gas He,17 psi, split 30:1. 
4-MeO-ACP = 28.3 min, (R) = 30.0 min, (S) = 31.2 min. 
TETN = 30.9 min, (S) =37.1 min, (R) = 37.7 min. 
Substrates 2-Cl-ACP, 4-Cl-ACP and 4-CF3-ACP: column: Supelco, Beta Dex
TM 110 
(30m); 130 °C isothermal, carrier gas He, 15.3 psi, split 30:1. 
2-Cl-ACP = 10.4 min, (R) = 19.2 min, (S) = 22.7 min. 
4-Cl-ACP = 13.5 min, (R) = 22.2 min, (S) = 23.8 min. 
4-CF3-ACP = 4.5 min, (R) = 7.7 min, (S) = 8.2 min. 
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Conversions and e.e. values of substrates PBK, DPP and AcFc were determined by 
HPLC. Retention times are given for the reactants and both product enantiomers. 
Substrate PBK: column: Daicel, Chiraldex OD-H, temperature: 25 ºC, eluent: 
hexane/iPrOH 96:4, flow rate: 0.6 mL/min, detector: DAD, Sig = 230 nm, 8, ref = 360 nm, 
100. 
PBK = 17.6 min, (R) = 20.4 min, (S) = 25.8 min. 
Substrate DPP: column: Daicel, Chiraldex OD-H, temperature: 25 ºC, solvent: 
hexane/iPrOH 9:1, Flow rate: 0.8 mL/min, detector: DAD, Sig = 215 nm, 8, ref = 360nm, 
100. 
DPP = 8.2 min, (R) = 12.4 min, (S) = 14.8 min. 
Substrate AcFc: column: Daicel, Chiraldex OJ, temperature: 25 ºC, solvent: 
hexane/iPrOH 97:3, flow rate: 0.8 mL/min, detector: DAD, Sig = 210 nm, 8, Ref = 650 
nm, 100. 
AcFc = 16.2 min, (R) = 19.0 min, (S) = 26.7 min. 
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X-ray structure determination of the complexes (ROx,RFc)-17, (RFc)-19, 
(ROx,RFc)-22, and (SOx,SFc)-23. 
Single crystals of the four complexes were obtained by layering toluene solutions 
((ROx,RFc)-17, (RFc)-19, (SOx,SFc)-23) or dichloromethane solutions ((ROx,RFc)-22) with 
diethyl ether or pentane as antisolvent. Except for (ROx,RFc)-17, which was unsolvated, 
all crystals represented either toluene ((RFc)-19, (SOx,SFc)-23) or dichloromethane 
solvates ((ROx,RFc)-22). The crystals of (ROx,RFc)-17 and (RFc)-19 were emerald-green, 
those of ((ROx,RFc)-22) and (SOx,SFc)-23) were orange. X-ray data were collected on a 
Bruker Kappa APEX-2 CCD diffractometer with a cryostream cooler (Oxford 
Cryosystems) using graphite-monochromatised Mo-Kα radiation (λ = 0.71073 Å) and 
0.5° - and ω-scan frames covering complete Ewald spheres with max = 30° or 25° 
((SOx,SFc)-23). The frames were integrated with program SAINT and corrections for 
absorption and λ/2 effects were applied with program SADABS. After structure solution 
with program SHELXS97 and direct methods, refinement on F2 was carried out with the 
program SHELXL97 (Sheldrick, 2008). Non-hydrogen atoms were refined anisotropically. 
All H atoms were placed in calculated positions and thereafter refined as riding. The 
absolute structures of all compounds could be unambiguously determined by anomalous 
dispersion effects and the Flack absolute structure parameter. Variata: The toluene 
solvent in (RFc)-19 resided in channels parallel to the a-axis of the orthorhombic unit cell 
(one toluene molecule per formula unit) and showed very large anisotropic displacement 
ellipsoids. Therefore its contribution to the structure factors was removed with procedure 
SQUEEZE of program PLATON (Spek, 2003) prior to the final refinement. 
Crystallographic data are compiled in Table S4 and atomic parameters are provided in 
CIF-format in the Supporting. Structural diagrams of the complexes (Fig. S1 – S4) and 
Tables (Tab. S5 – S8) with selected geometric parameters are given below. For 
molecular graphics the programs XP (Bruker) and MERCURY (Macrae et al., 2006) were 
used. 
Bruker programs: APEX2; SAINT, version 7.68A; SADABS, version 2008/1; SHELXTL, 
version 2008/4; XP, version 5 (Bruker AXS Inc., Madison, WI, 2009). 
SHELXS97 and SHELXL97: G. M. Sheldrick, Acta Cryst. 2008, A64, 112-122.  
PLATON: Spek, A. L. (2003). J. Appl. Cryst. 36, 7–13. 
MERCURY: Macrae, C. F., Edgington, P. R., McCabe, P., Pidcock, E., Shields, G. P., 
Taylor, R., Towler, M. & van de Streek, J. (2006). J. Appl. Cryst. 39, 453–457.
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Table S4. Crystal data and structure refinement for the four investigated complexes (ROx,RFc)-
17,  (RFc)-19, (ROx,RFc)-22, and  (SOx,SFc)-23. 
 (ROx,RFc)-17 (RFc)-19∙C7H8 
a)
 (ROx,RFc)-22∙CH2Cl2 (SOx,SFc)-23∙C7H8 
formula 
C48H47Cl2FeNOP
2Ru 
C47H45Cl2FeNOP2Ru∙
C7H8 
C50H50Cl2FeN2OP2Ru∙CH
2Cl2 
C53H56Cl2FeN2OP2Ru∙
C7H8 
fw 943.63 1021.73 1069.61 1118.89 
cryst.size, 
mm 
0.38 × 0.15 
× 0.13 
0.41 × 0.29 × 
0.25 
0.55 × 0.29 × 0.10 
0.22 × 0.15 × 
0.03 
crystal 
system 
monoclinic orthorhombic triclinic orthorhombic 
space group P21   (no. 4) 
P212121   (no. 
19) 
P1   (no. 1) P212121   (no. 19) 
a, Å 13.4450(4) 10.3672(4) 10.0952(6) 11.531(2) 
b, Å 11.3616(3) 15.3829(6) 11.0657(6) 21.358(4) 
c, Å 13.8849(4) 29.4389(12) 12.6518(12) 22.000(4) 
α, deg 90 90 105.215(4) 90 
β, deg 104.865(2) 90 96.050(4) 90 
γ, deg 90 90 115.719(2) 90 
V, Å
3 
2050.03(10) 4694.8(3) 1188.96(15) 5418.4(17) 
T, K 100 100 100 299 
Z 2 4 1 4 
ρcalc, g cm
-3
 1.529 1.446 1.494 1.372 
µ, mm
-1
 
(MoKα) 
0.970 0.853 0.955 0.746 
F(000) 968 2104 548 2320 
absorption 
corrections 
multi-scan, 
0.88-0.73 
multi-scan, 
0.82-0.66 
multi-scan, 0.92-
0.74 
multi-scan, 0.98-
0.83 
θ range, deg 2.3 - 30.0 1.9 – 30.0 2.2 - 30.0 1.9 - 25.0 
no. of rflns 
measd / Rint 
44495 / 
0.042 
129187 / 0.038 36346 / 0.051 59588 / 0.11 
no. of rflns 
unique 
11827 13664 13554 9550 
no. of rflns 
I>2σ(I) 
10932 13211 13243 7038 
no. of 
params / 
restraints 
508 / 1 499 / 0 563 / 3 617 / 271 
R1 (I > 
2σ(I)) 
0.0280 0.0226 0.0414 0.0476 
R1 (all data) 0.0338 0.0242 0.0424 0.0815 
wR2 (I > 
2σ(I)) 
0.0640 0.0535 0.1064 0.0805 
wR2 (all 
data) 
0.0672 0.0541 0.1075 0.0910 
Flack 
abs.str. 
param. 
-0.023(10) -0.005(8) -0.016(8) 0.00(2) 
Diff.Four.pe
aks 
min/max, eÅ
-3
 
-0.45 / 1.13 -0.64 / 0.47 -1.41 / 2.45 -0.39 / 0.56 
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Figure S1. Structural diagram of the asymmetric unit of (ROx,RFc)-17 showing 50% 
ellipsoids and the atom numbering. 
  
Table S5. Selected geometric data (Å, deg) of (ROx,RFc)-17. 
Ru(1)-N(1)         2.1588(18) 
Ru(1)-P(1)         2.1979(6) 
Ru(1)-P(2)         2.2834(6) 
Ru(1)-Cl(1)        2.3704(6) 
Ru(1)-Cl(2)        2.3943(6) 
 
Fe(1)-C(1)         2.061(2) 
Fe(1)-C(2)         2.049(2) 
Fe(1)-C(3)         2.047(2) 
Fe(1)-C(4)         2.066(2) 
Fe(1)-C(5)         2.054(2) 
Fe(1)-C(6)         2.045(2) 
Fe(1)-C(7)         2.049(2) 
Fe(1)-C(8)         2.067(2) 
Fe(1)-C(9)         2.062(2) 
Fe(1)-C(10)        2.051(2) 
 
P(1)-C(11)         1.888(2) 
P(1)-C(16)         1.836(2) 
P(1)-C(22)         1.829(2) 
 
P(2)-C(28)         1.831(2) 
P(2)-C(34)         1.843(2) 
P(2)-C(40)         1.833(2) 
 
N(1)-C(13)         1.284(3) 
N(1)-C(14)         1.494(3) 
O(1)-C(13)         1.346(3) 
O(1)-C(15)         1.468(3) 
C(14)-C(15)        1.528(3) 
C(14)-C(46)        1.541(3) 
C(46)-C(47)        1.519(3) 
C(46)-C(48)        1.524(3) 
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C(1)-C(2)          1.440(3) 
C(1)-C(5)          1.429(3) 
C(1)-C(11)         1.504(3) 
C(2)-C(3)          1.431(3) 
C(2)-C(13)         1.455(3) 
C(3)-C(4)          1.420(3) 
C(4)-C(5)          1.420(3) 
C(6)-C(7)          1.420(4) 
C(6)-C(10)         1.418(4) 
C(7)-C(8)          1.428(4) 
C(8)-C(9)          1.418(4) 
C(9)-C(10)         1.428(4) 
 
C(11)-C(12)        1.541(3) 
 
C(16)-C(17)        1.396(3) 
C(16)-C(21)        1.405(3) 
C(17)-C(18)        1.396(3) 
C(18)-C(19)        1.382(4) 
C(19)-C(20)        1.389(3) 
C(20)-C(21)        1.385(4) 
 
C(22)-C(27)        1.394(3) 
C(22)-C(23)        1.405(3) 
C(23)-C(24)        1.388(3) 
C(24)-C(25)        1.394(4) 
C(25)-C(26)        1.389(3) 
C(26)-C(27)        1.385(3) 
 
C(28)-C(33)        1.392(3) 
C(28)-C(29)        1.406(3) 
C(29)-C(30)        1.386(3) 
C(30)-C(31)        1.394(4) 
C(31)-C(32)        1.377(4) 
C(32)-C(33)        1.393(3) 
 
C(34)-C(35)        1.397(3) 
C(34)-C(39)        1.399(3) 
C(35)-C(36)        1.390(3) 
C(36)-C(37)        1.390(4) 
C(37)-C(38)        1.388(4) 
C(38)-C(39)        1.385(3) 
 
C(40)-C(41)        1.391(4) 
C(40)-C(45)        1.397(3) 
C(41)-C(42)        1.393(4) 
C(42)-C(43)        1.377(4) 
C(43)-C(44)        1.389(4) 
C(44)-C(45)        1.391(4) 
N(1)-Ru(1)-P(1)        99.20(5) 
N(1)-Ru(1)-P(2)       163.61(5) 
P(1)-Ru(1)-P(2)        96.74(2) 
N(1)-Ru(1)-Cl(1)       81.80(5) 
P(1)-Ru(1)-Cl(1)      108.79(2) 
P(2)-Ru(1)-Cl(1)       89.48(2) 
N(1)-Ru(1)-Cl(2)       86.22(5) 
P(1)-Ru(1)-Cl(2)       94.82(2) 
P(2)-Ru(1)-Cl(2)       96.26(2) 
Cl(1)-Ru(1)-Cl(2)     154.89(2) 
 
C(22)-P(1)-C(16)      102.57(10) 
C(22)-P(1)-C(11)      106.08(10) 
C(16)-P(1)-C(11)      100.76(10) 
C(22)-P(1)-Ru(1)      115.08(7) 
C(16)-P(1)-Ru(1)      122.95(7) 
C(11)-P(1)-Ru(1)      107.49(7) 
 
C(28)-P(2)-C(40)      101.63(10) 
C(28)-P(2)-C(34)      104.41(10) 
C(40)-P(2)-C(34)       97.85(10) 
C(28)-P(2)-Ru(1)      115.24(8) 
C(40)-P(2)-Ru(1)      108.34(8) 
C(34)-P(2)-Ru(1)      125.59(7) 
 
C(13)-N(1)-C(14)      106.53(18) 
C(13)-N(1)-Ru(1)      125.83(16) 
C(14)-N(1)-Ru(1)      117.94(14) 
C(13)-O(1)-C(15)      104.70(17) 
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Figure S2. Structural diagram of the asymmetric unit of (RFc)-19∙C7H8 showing 50% 
ellipsoids and the atom numbering. The toluene solvent molecule was squeezed with 
program PLATON and is not shown therefore. 
 
Table S6. Selected geometric data (Å, deg) of (RFc)-19∙C7H8. 
Ru(1)-N(1)         2.1623(13) 
Ru(1)-P(2)         2.2858(4) 
Ru(1)-P(1)         2.1993(4) 
Ru(1)-Cl(1)        2.3987(4) 
Ru(1)-Cl(2)        2.3767(4) 
 
Fe(1)-C(1)         2.0446(16) 
Fe(1)-C(2)         2.0378(16) 
Fe(1)-C(3)         2.0485(17) 
Fe(1)-C(4)         2.0626(18) 
Fe(1)-C(5)         2.0503(17) 
Fe(1)-C(6)         2.0443(18) 
Fe(1)-C(7)         2.0563(19) 
Fe(1)-C(8)         2.0629(18) 
Fe(1)-C(9)         2.0488(17) 
Fe(1)-C(10)        2.0405(17) 
 
P(1)-C(11)         1.8876(17) 
P(1)-C(16)         1.8325(17) 
P(1)-C(22)         1.8292(16) 
 
P(2)-C(28)         1.8270(18) 
P(2)-C(34)         1.8368(17) 
P(2)-C(40)         1.8326(17) 
 
O(1)-C(13)         1.3586(19) 
O(1)-C(15)         1.452(2) 
N(1)-C(13)         1.281(2) 
N(1)-C(14)         1.518(2) 
C(14)-C(15)        1.531(3) 
C(14)-C(46)        1.526(3) 
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C(14)-C(47)        1.514(2) 
 
C(1)-C(2)          1.437(2) 
 
C(1)-C(5)          1.425(2) 
C(1)-C(11)         1.507(2) 
C(2)-C(3)          1.432(2) 
C(2)-C(13)         1.454(2) 
 
C(3)-C(4)          1.415(2) 
C(4)-C(5)          1.419(2) 
C(6)-C(7)          1.425(3) 
C(6)-C(10)         1.420(3) 
C(7)-C(8)          1.418(3) 
C(8)-C(9)          1.417(3) 
C(9)-C(10)         1.416(3) 
 
C(11)-C(12)        1.540(2) 
 
C(16)-C(17)        1.397(2) 
C(16)-C(21)        1.403(2) 
C(17)-C(18)        1.389(2) 
C(18)-C(19)        1.394(2) 
C(19)-C(20)        1.384(2) 
C(20)-C(21)        1.397(2) 
 
C(22)-C(23)        1.400(2) 
C(22)-C(27)        1.403(2) 
C(23)-C(24)        1.391(2) 
C(24)-C(25)        1.388(3) 
C(25)-C(26)        1.376(3) 
C(26)-C(27)        1.392(2) 
 
C(28)-C(33)        1.390(3) 
C(28)-C(29)        1.398(2) 
C(29)-C(30)        1.386(3) 
C(30)-C(31)        1.390(3) 
C(31)-C(32)        1.387(3) 
C(32)-C(33)        1.394(2) 
 
C(34)-C(35)        1.396(2) 
C(34)-C(39)        1.401(2) 
C(35)-C(36)        1.394(2) 
C(36)-C(37)        1.388(3) 
C(37)-C(38)        1.393(3) 
C(38)-C(39)        1.391(2) 
 
C(40)-C(41)        1.392(3) 
C(40)-C(45)        1.393(2) 
C(41)-C(42)        1.395(3) 
C(42)-C(43)        1.378(3) 
C(43)-C(44)        1.374(3) 
C(44)-C(45)        1.381(3) 
N(1)-Ru(1)-P(1)       100.61(4) 
N(1)-Ru(1)-P(2)       161.15(4) 
P(1)-Ru(1)-P(2)        98.234(16) 
N(1)-Ru(1)-Cl(2)       86.31(4) 
P(1)-Ru(1)-Cl(2)       89.641(16) 
P(2)-Ru(1)-Cl(2)       94.279(15) 
N(1)-Ru(1)-Cl(1)       82.88(4) 
P(1)-Ru(1)-Cl(1)      108.069(16) 
P(2)-Ru(1)-Cl(1)       90.897(15) 
Cl(2)-Ru(1)-Cl(1)     160.650(15) 
 
C(22)-P(1)-C(16)      102.41(7) 
C(22)-P(1)-C(11)      105.23(7) 
C(16)-P(1)-C(11)       99.31(7) 
C(22)-P(1)-Ru(1)      116.10(6) 
C(16)-P(1)-Ru(1)      122.68(5) 
C(11)-P(1)-Ru(1)      108.73(5) 
 
C(28)-P(2)-C(40)      102.65(8) 
C(28)-P(2)-C(34)      101.51(7) 
C(40)-P(2)-C(34)      102.80(8) 
C(28)-P(2)-Ru(1)      118.24(6) 
C(40)-P(2)-Ru(1)      100.90(5) 
C(34)-P(2)-Ru(1)      127.14(5) 
 
C(13)-O(1)-C(15)      105.13(13) 
C(13)-N(1)-C(14)      106.33(13) 
C(13)-N(1)-Ru(1)      129.00(12) 
C(14)-N(1)-Ru(1)      120.14(10) 
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Figure S3. Structural diagram of the asymmetric unit of (ROx,RFc)-22∙CH2Cl2  showing 
50% ellipsoids (except for the CH2Cl2 solvent molecule) and the atom numbering.  
 
Table S7. Selected geometric data (Å, deg) of (ROx,RFc)-22∙CH2Cl2
Ru(1)-N(1)         2.190(2) 
Ru(1)-N(2)         2.007(3) 
Ru(1)-P(1)         2.2908(7) 
Ru(1)-P(2)         2.3076(7) 
Ru(1)-Cl(1)        2.4793(7) 
Ru(1)-Cl(2)        2.4191(7) 
 
Fe(1)-C(1)         2.062(3) 
Fe(1)-C(2)         2.046(3) 
Fe(1)-C(3)         2.041(3) 
Fe(1)-C(4)         2.058(3) 
Fe(1)-C(5)         2.044(3) 
Fe(1)-C(6)         2.040(3) 
Fe(1)-C(7)         2.051(4) 
Fe(1)-C(8)         2.065(3) 
Fe(1)-C(9)         2.060(3) 
Fe(1)-C(10)        2.038(3) 
 
P(1)-C(11)         1.900(3) 
P(1)-C(16)         1.834(3) 
P(1)-C(22)         1.845(3) 
P(2)-C(28)         1.828(3) 
P(2)-C(34)         1.839(3) 
P(2)-C(40)         1.851(3) 
 
O(1)-C(13)         1.352(3) 
O(1)-C(15)         1.452(4) 
N(1)-C(13)         1.288(4) 
N(1)-C(14)         1.495(4) 
C(14)-C(15)        1.533(4) 
C(14)-C(46)        1.544(4) 
C(46)-C(48)        1.531(4) 
C(46)-C(47)        1.532(4) 
 
N(2)-C(49)         1.134(4) 
C(49)-C(50)        1.471(5) 
C(1)-C(2)          1.431(4) 
C(1)-C(5)          1.438(4) 
C(1)-C(11)         1.517(4) 
C(2)-C(3)          1.438(4) 
C(2)-C(13)         1.444(4) 
C(3)-C(4)          1.431(4) 
C(4)-C(5)          1.426(4) 
 
C(6)-C(7)          1.414(6) 
C(6)-C(10)         1.432(7) 
C(7)-C(8)          1.423(5) 
C(8)-C(9)          1.425(5) 
C(9)-C(10)         1.424(6) 
 
C(11)-C(12)        1.531(4) 
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C(16)-C(17)        1.398(5) 
C(16)-C(21)        1.406(4) 
C(17)-C(18)        1.392(5) 
C(18)-C(19)        1.389(6) 
C(19)-C(20)        1.367(7) 
C(20)-C(21)        1.393(5) 
 
C(22)-C(27)        1.392(4) 
C(22)-C(23)        1.405(4) 
C(23)-C(24)        1.391(5) 
C(24)-C(25)        1.381(6) 
C(25)-C(26)        1.389(5) 
C(26)-C(27)        1.399(4) 
 
C(28)-C(33)        1.389(5) 
C(28)-C(29)        1.404(4) 
C(29)-C(30)        1.404(5) 
C(30)-C(31)        1.384(6) 
C(31)-C(32)        1.400(6) 
C(32)-C(33)        1.396(5) 
 
C(34)-C(35)        1.393(4) 
C(34)-C(39)        1.402(4) 
C(35)-C(36)        1.390(4) 
C(36)-C(37)        1.393(5) 
C(37)-C(38)        1.393(5) 
C(38)-C(39)        1.383(4) 
 
C(40)-C(41)        1.399(4) 
C(40)-C(45)        1.404(4) 
C(41)-C(42)        1.398(4) 
C(42)-C(43)        1.386(5) 
C(43)-C(44)        1.392(5) 
C(44)-C(45)        1.381(5) 
 
C(51)-Cl(3)        1.730(8) 
C(51)-Cl(4)        1.759(7) 
N(2)-Ru(1)-N(1)        92.94(10) 
N(2)-Ru(1)-P(1)        86.99(8) 
N(1)-Ru(1)-P(1)        92.02(7) 
N(2)-Ru(1)-P(2)        93.67(8) 
N(1)-Ru(1)-P(2)       167.30(6) 
P(1)-Ru(1)-P(2)        99.14(3) 
N(2)-Ru(1)-Cl(2)      171.99(7) 
N(1)-Ru(1)-Cl(2)       87.43(7) 
P(1)-Ru(1)-Cl(2)      101.00(2) 
P(2)-Ru(1)-Cl(2)       84.52(2) 
N(2)-Ru(1)-Cl(1)       79.16(8) 
N(1)-Ru(1)-Cl(1)       80.89(6) 
P(1)-Ru(1)-Cl(1)      164.03(2) 
P(2)-Ru(1)-Cl(1)       89.72(3) 
Cl(2)-Ru(1)-Cl(1)      93.01(2) 
 
C(16)-P(1)-C(22)      106.56(14) 
C(16)-P(1)-C(11)      102.89(13) 
C(22)-P(1)-C(11)       96.17(12) 
C(16)-P(1)-Ru(1)      114.85(10) 
C(22)-P(1)-Ru(1)      121.97(10) 
C(11)-P(1)-Ru(1)      111.34(9) 
 
C(28)-P(2)-C(34)      104.80(14) 
C(28)-P(2)-C(40)      100.38(13) 
C(34)-P(2)-C(40)       99.09(13) 
C(28)-P(2)-Ru(1)      113.60(10) 
C(34)-P(2)-Ru(1)      118.31(9) 
C(40)-P(2)-Ru(1)      118.06(10) 
 
C(13)-O(1)-C(15)      105.2(2) 
C(13)-N(1)-C(14)      106.1(2) 
C(13)-N(1)-Ru(1)      127.0(2) 
C(14)-N(1)-Ru(1)      118.98(17) 
C(49)-N(2)-Ru(1)      173.0(3) 
 
N(2)-C(49)-C(50)      178.6(4) 
 
Cl(3)-C(51)-Cl(4)     112.4(4) 
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Figure S4. Structural diagram of the asymmetric unit of (SOx,SFc)-23∙C7H8 showing 20% 
ellipsoids (except for the toluene solvent molecule) and the atom numbering. 
 
Table S8. Selected geometric data (Å, deg) of (SOx,SFc)-23∙C7H8. 
Ru(1)-N(1)         2.215(4) 
Ru(1)-N(2)         1.988(4) 
Ru(1)-P(1)         2.3014(15) 
Ru(1)-P(2)         2.2968(15) 
Ru(1)-Cl(1)        2.4773(14) 
Ru(1)-Cl(2)        2.4162(14) 
 
Fe(1)-C(1)         2.062(6) 
Fe(1)-C(2)         2.045(6) 
Fe(1)-C(3)         2.016(6) 
Fe(1)-C(4)         2.034(6) 
Fe(1)-C(5)         2.023(6) 
Fe(1)-C(6)         2.023(8) 
Fe(1)-C(7)         2.041(8) 
Fe(1)-C(8)         2.043(7) 
Fe(1)-C(9)         2.031(7) 
Fe(1)-C(10)        2.026(7) 
 
P(1)-C(16)         1.839(5) 
P(1)-C(22)         1.849(5) 
P(1)-C(11)         1.877(5) 
P(2)-C(28)         1.826(5) 
P(2)-C(40)         1.837(5) 
P(2)-C(34)         1.843(6) 
 
O(1)-C(13)         1.357(6) 
O(1)-C(15)         1.452(7) 
N(1)-C(13)         1.276(7) 
N(1)-C(14)         1.511(6) 
C(14)-C(15)        1.525(8) 
C(14)-C(46)        1.551(8) 
C(46)-C(47)        1.528(8) 
C(46)-C(48)        1.513(8) 
 
N(2)-C(49)         1.118(6) 
C(49)-C(50)        1.462(8) 
 
C(1)-C(2)          1.437(7) 
C(1)-C(5)          1.415(8) 
C(1)-C(11)         1.483(7) 
C(2)-C(3)          1.436(7) 
C(2)-C(13)         1.460(8) 
C(3)-C(4)          1.409(8) 
C(4)-C(5)          1.398(8) 
C(6)-C(7)          1.389(11) 
C(6)-C(10)         1.374(10) 
C(7)-C(8)          1.413(11) 
C(8)-C(9)          1.386(11) 
C(9)-C(10)         1.425(11) 
 
C(16)-C(21)        1.391(7) 
C(16)-C(17)        1.393(7) 
C(17)-C(18)        1.384(7) 
C(18)-C(19)        1.358(8) 
C(18)-C(51)        1.539(8) 
C(19)-C(20)        1.407(8) 
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C(20)-C(21)        1.397(7) 
C(20)-C(52)        1.496(8) 
 
C(22)-C(27)        1.396(7) 
C(22)-C(23)        1.398(7) 
C(23)-C(24)        1.392(7) 
C(24)-C(25)        1.381(8) 
C(24)-C(53)        1.489(8) 
C(25)-C(26)        1.385(8) 
C(26)-C(27)        1.383(8) 
C(26)-C(54)        1.491(8) 
 
C(28)-C(33)        1.381(7) 
C(28)-C(29)        1.399(7) 
C(29)-C(30)        1.390(8) 
C(30)-C(31)        1.373(8) 
C(31)-C(32)        1.374(9) 
C(32)-C(33)        1.394(8) 
 
C(34)-C(39)        1.366(7) 
C(34)-C(35)        1.407(8) 
C(35)-C(36)        1.388(8) 
C(36)-C(37)        1.366(9) 
C(37)-C(38)        1.353(9) 
C(38)-C(39)        1.386(7) 
 
C(40)-C(41)        1.375(7) 
C(40)-C(45)        1.394(7) 
C(41)-C(42)        1.400(8) 
C(42)-C(43)        1.351(8) 
C(43)-C(44)        1.352(9) 
C(44)-C(45)        1.388(8) 
 
N(2)-Ru(1)-N(1)        89.88(17) 
N(2)-Ru(1)-P(2)        91.28(13) 
N(1)-Ru(1)-P(2)       170.36(12) 
N(2)-Ru(1)-P(1)        87.70(13) 
N(1)-Ru(1)-P(1)        92.09(12) 
P(2)-Ru(1)-P(1)        97.52(5) 
N(2)-Ru(1)-Cl(2)      172.29(13) 
N(1)-Ru(1)-Cl(2)       88.32(12) 
P(2)-Ru(1)-Cl(2)       89.26(5) 
P(1)-Ru(1)-Cl(2)       99.85(5) 
N(2)-Ru(1)-Cl(1)       82.78(13) 
N(1)-Ru(1)-Cl(1)       82.58(12) 
P(2)-Ru(1)-Cl(1)       88.08(5) 
P(1)-Ru(1)-Cl(1)      169.07(5) 
Cl(2)-Ru(1)-Cl(1)      89.56(5) 
 
C(16)-P(1)-C(22)      104.4(2) 
C(16)-P(1)-C(11)      102.5(2) 
C(22)-P(1)-C(11)       95.1(2) 
C(16)-P(1)-Ru(1)      117.71(17) 
C(22)-P(1)-Ru(1)      123.35(17) 
C(11)-P(1)-Ru(1)      109.71(18) 
 
C(28)-P(2)-C(40)      100.3(2) 
C(28)-P(2)-C(34)      106.4(3) 
C(40)-P(2)-C(34)       97.0(2) 
C(28)-P(2)-Ru(1)      111.11(17) 
C(40)-P(2)-Ru(1)      120.31(19) 
C(34)-P(2)-Ru(1)      119.11(18) 
 
C(13)-O(1)-C(15)      104.4(4) 
C(13)-N(1)-C(14)      106.3(4) 
C(13)-N(1)-Ru(1)      129.0(4) 
C(14)-N(1)-Ru(1)      118.7(3) 
C(49)-N(2)-Ru(1)      174.5(5) 
 
N(2)-C(49)-C(50)      178.5(7) 
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Figure S5. Molecular structure of (SOx,SFc)-15 (retrieved from the Cambridge Structural 
Database, refcode MAPLUK)[6c] 
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Abstract 
Two complementary and highly modular routes were developed for the synthesis of 
ferrocenyl-based phosphino-oxazolines all having the phosphino unit attached to a 
ferrocenylmethyl or a ferrocenylethyl side-chain. Both routes started from (S)-4-iso-
propyl- (5) or (S)-4-phenyl-2-ferrocenyloxazoline (8) and in both cases was the 
phosphino-substituted side chain built up diastereoselectively. In the first synthesis 
sequence, 2-oxazolinyl substituted ferrocene aldehydes were prepared from 5 and 8 and 
subsequently arylated or alkylated through an auto-activated phenyl or alkyl transfer 
either from diphenyl zinc or from dialkyl zinc reagents and provided the product alcohols 
in form of single diastereomers. Furthermore, these alcohols were transformed into the 
desired phosphino-oxazolines all having the matching (S,SOx,SFc) relative and absolute 
configuration. In the second sequence, starting from 5 and 8, 2-phosphinylmethyl 
substituted ferrocenyl-oxazolines were prepared. These phosphine oxides were 
subjected to a diastereoselective -deprotonation with tert-BuLi in THF at –78 °C. 
Quenching with MeI and subsequent reduction resulted in phosphino-oxazoline ligands 
with (R,SOx,SFc) absolute configuration. These side chain epimers could be isomerized 
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 with tert-butyl lithium and water to the desired (S,SOx,SFc) configured ligands. All newly 
synthesized ligands were transformed into [RuCl2(PPh3)(L)] complexes and were used 
as catalyst precursors for transfer hydrogenations of ketones. From a comparison of 
these catalysis results with our previously reported data it is concluded that for this type 
of ligand the (S,SOx,SFc) relative configuration constitutes the matching configuration 
while a change of either the side-chain or the oxazoline configuration leads to less 
efficient transfer hydrogenation catalysts. With the matching ligands and complexes 
products were obtained with quantitative conversion and in up to 98% enantiomeric 
excess. 
 
Introduction 
Since more than fifteen years have oxazoline based ferrocene derivatives been 
employed as ligands of asymmetric catalysts.1 Especially FOXAP type ligands such as 
derivative (SOx,SFc)-1 (Chart 1) were successfully used in asymmetric transformations.
2 
For example, ruthenium complexes of FOXAP ligands ([RuCl2(PPh3)(FOXAP)]) 
performed very efficiently as catalyst precursors in the transfer hydrogenation of 
ketones when isopropanol was used as the hydrogen source.3 In addition, the same 
type of complexes gave excellent results in hydrogenations in the presence of hydrogen 
gas4 and with these conditions up-scaling even to the large industrial scale became 
possible.5  
Fe
PPh2
O
N R
(R,SOx,RFc)-3
(R,ROx,RFc)-3
R =
(R,SOx,RFc)-4
(R,ROx,RFc)-4
CHMe2
CHMe2
Ph
Ph
Fe
PPh2
N
O
(SOx,SFc)-1 (SOx,SFc)-2
Fe
N
O
PPh2
 
Chart 1. 
Very recently, in a search for novel asymmetric hydrogenation catalysts, we 
have modified FOXAP type ligands by extending their ferrocene backbone to a 
ferrocenylmethyl or a ferrocenylethyl unit.6 Examples of these ligands, that we called 
'Raffa-FOX' ligands, are shown in Chart 1 (2–4). Ruthenium complexes 
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 [RuCl2(PPh3)(L)] of a number of such ligands were extensively tested as catalysts in 
transfer hydrogenations and hydrogenations of alkyl-aryl ketones (see Chapter 3.1). In 
both types of reaction several substrates were transformed into product with 
quantitative conversion and with an enantiomeric excess of up to 99%. From all ligands 
tested, derivative (R,ROx,RFc)-3 performed best. In certain cases also ligand (R,ROx,RFc)-
4 gave comparable results while with (SOx,SFc)-2 always slightly lower product e.e. 
values were obtained. It was also found that the results of both hydrogenation and 
transfer hydrogenation reactions were strongly depending on the relative configuration 
of the ligands applied. For example, when the transfer hydrogenation of acetophenone 
was carried out with use of ligand (R,ROx,RFc)-3, product 1-phenylethanol with (S) 
absolute configuration and 98% e.e. was obtained while when the configuration at the 
oxazoline carbon C4 was changed from (ROx) to (SOx) and the resulting ligand 
(R,SOx,RFc)-3 was used, product with (R) absolute configuration and 69% e.e. was 
formed. Also for ligands 4 the (ROx,RFc) relative configuration constitutes the matching 
and the (SOx,RFc) configuration the mismatching combination of stereogenic units. 
Our reported synthesis of ligands of type (SOx,SFc)-2 required only three 
straightforward steps from easily accessible and commercially available ferrocenyl 
oxazoline (SOx)-5 (see Chapter 3.1). In the first step a diastereoselective ortho-
deprotonation followed by reaction with dimethylformamide resulted in aldehyde 
(SOx,SFc)-6 which after reduction to alcohol (SOx,SFc)-7 was transformed into the final 
product. It is obvious that the ortho-deprotonation step already determined the relative 
configuration of the final product. 
The original synthesis of diastereomeric ligands 3 and their analogs was 
designed to allow for a variation of the oxazoline substituent and the relative 
configuration at the oxazoline carbon to which this substituent is bound (C4). These 
variations could be achieved by choosing a proper aminoalcohol in the second step of 
the reaction sequence (Scheme 2) but this advantage was limited by the fact that for 
the synthesis of each ligand two enantiopure reagents were needed. For example, for 
the synthesis of (R,ROx,RFc)-3 enantiopure starting material (R)-12 as well as (R)-valinol, 
(R)-14, were required. 
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Scheme 1. Synthesis of ligands (SOx,SFc)-2 and (SOx,SFc)-11. 
 
 
Scheme 2. Synthesis route for ligand 3 (R = iPr) and analogs. 
Since for 3 and analogs the (ROx,RFc) relative configuration was identified as the 
matching configuration, we questioned whether the synthesis of such ligands with either 
(ROx,RFc) or (SOx,SFc) configuration could be simplified. As mentioned above, the ortho 
deprotonation of (S)-5 and further transformations led to ligand 2 having the desired 
(SOx,SFc) relative configuration. It seemed therefore promising to start an alternative 
synthesis route for 3 and related derivatives from ferrocenyl oxazolines such as 5 and 8 
(Scheme 1) and to build up the side chain diastereoselectively instead of starting from 
enantiopure 12 that has the side chain already in place (Scheme 2). 
For introducing the side chains and side chain substituents diastereoselectively, 
two different methodologies were taken into account. The first one is related to work of 
Brocard who has shown that ferrocenyl amino-aldehydes can be directly alkylated with 
dialkylzinc reagents.7 The second methodology makes use of an -deprotonation 
reaction. As originally reported by Marr, ferrocenylmethyl substituted phosphineoxides 
can be deprotonated and alkylated at the ferrocene -position.8 Later on Stepnicka 
applied this methodology to cyanomethyl substituted ferrocenes.9  
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 In this contribution we describe two complementary approaches for the synthesis of 
ligands 3 and analogs all having (SOx,SFc) configuration and either (R) or (S) 
configuration at the side chain -carbon. In addition, we report on a few transfer 
hydrogenations that show the influence of different side chain substituents as well as of 
different side chain configurations on the product enantiomeric excess. 
 
Results 
Synthesis of ligands (SOx,SFc)-3 and analogs. In order to modify and simplify the original 
synthesis sequence we explored two novel routes that both start from ferrocenyl 
oxazolines (SOx)-5 and (SOx)-8. It was our intention to build up the phosphino-substituted 
side chain of 3 and analogs in such a way that the use of a second enantiopure reagent 
could be avoided. Furthermore, we aimed for synthesis routes that allow for a variation 
of the configuration at the side chain -carbon. For this purpose, diastereoselective 
alkylations of aldehydes 6 and 9 (Scheme 3) were employed. As an alternative route, 
the diastereoselective -deprotonation of phosphine oxides 26 and 27 was investigated 
(Scheme 4). 
 
Scheme 3.  
Alkyl and phenyl transfer with use of R2Zn reagents. Several groups have already 
investigated the diastereoselectivity of alkyl and aryl transfers to 2-substituted 
ferrocenylaldehydes.7,10 Mainly the reactivity of lithium, magnesium and zinc reagents 
was studied. It was found that in many cases the transfer of rather small alkyl groups 
such as methyl or ethyl substituents work best with use of dialkyl zinc reagents. Usually, 
the alkyl transfer from dialkyl zinc reagents to aldehydes proceeds rather slowly, but its 
reaction rate increases significantly when a catalyst such as an amino alcohol is added. 
However, according to Brocard7 and Fukuzawa,10d the reaction of amino substituted 
ferrocenyl carbaldehydes 2-(N,N-dimethylaminomethyl)-ferrocenylcarbaldehyde and 2-
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 (1-N,N-dimethylaminoethyl)-ferrocenylcarbaldehyde with dialkyl zinc reagents went on 
smoothly without a catalyst and this fact was rationalized by invoking an autocatalytic or 
auto-activation mechanism that involves the participation of the dimethylamino nitrogen 
and the carbonyl oxygen. Since such an effect has also been reported for a pyrimidyl 
substituted ferrocenylaldehyde11 we reasoned whether oxazoline units could also 
promote autocatalytic alkyl transfers.  
When aldehyde (SOx,SFc)-6 was reacted in toluene with dimethyl zinc or diethyl 
zinc (Scheme 3), indeed, the desired product alcohols (S,SOx,RFc)-18 and (S,SOx,RFc)-23 
were obtained in nearly quantitative yield and in each case with a diastereomer ratio of 
97:3. Surprisingly, when diphenyl zinc was used as the reagent also a phenyl transfer 
was possible resulting in alcohol (S,SOx,RFc)-20. With oxazoline (SOx,SFc)-9, which was 
easily accessible form (SOx)-8, and dimethyl zinc alcohol (S,SOx,RFc)-24 was formed 
again with a diastereomer ratio of 97:3 (for details on the synthesis of (SOx)-8 see 
Supporting). In all cases had the main product the desired (S) side chain configuration. 
From alcohol (S,SOx,RFc)-18 suitable single crystals could be grown and its 
molecular structure in the solid state was studied by X-ray diffraction confirming both its 
relative and absolute configuration (Figure 1). Details of this X-ray crystallography study 
are given in Table 1 of the Supporting Information.  
 
Figure 1. Molecular structure of (S,SOx,RFc)-18. 
After chromatographic separation of the respective diastereomers, alcohols 
(S,SOx,RFc)-18, 20, and 24 were transformed into the acetates 19, 21, and 25. A further 
reaction with diphenylphosphine led to the desired phosphino-oxazolines (S,SOx,SFc)-3 
and (S,SOx,SFc)-4 as well as to the novel ligand (S,SOx,SFc)-22 having a phenyl 
substituent attached to the side chain -carbon. As expected, the acetate/phosphine 
exchange proceeded with retention of configuration at the ferrocenyl -carbon.12 It 
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 should be mentioned that ligands 3 and 4 were obtained with the same relative 
configuration, (S,SOx,SFc), than those that preformed best in transfer hydrogenation and 
hydrogenation reactions.  
Diastereoselective -deprotonation of phosphine oxides 
 In 1975 Marr reported that – like benzyldiphenylphosphine oxide – also 
ferrocenylmethyldiphenylphosphine oxide can be deprotonated with butyl lithium at the α-
position and the resulting anion can be reacted with electrophiles.8 Recently this 
methodology has been used by Stepnicka to derivatize a cyanomethyl substituted 
ferrocene diastereoselectively.9 Therefore we questioned whether phosphine oxide 26 
(Scheme 4) could also be deprotonated and alkylated at the side chain methylene group 
and whether this reaction could be run diastereoselectively.  
 
Scheme 4. 
For this purpose phosphine oxide (SOx,SFc)-26 was prepared from phosphine 
(SOx,SFc)-2 (98%) by reaction with H2O2 in acetone.
12 As mentioned above, this 
precursor, (SOx,SFc)-2, is accessible in three steps from oxazoline (SOx)-5 (Scheme 1). 
In order to optimize the reaction conditions, phosphine oxide 26 was treated in THF or 
Et2O at different temperatures with bases n-BuLi, tert-BuLi or Li-TMP and the 
intermediate anions were quenched with MeI (Table 1).  In all cases was the product 
diastereomer ratio strongly depending on the reaction temperature and the solvent 
used. 
The best diastereoselectivity could be obtained when (SOx,SFc)-26 was reacted 
in THF with 1.2 equivalents of tert-BuLi at –78 °C (Table 1, entry 6). Quenching with 
MeI resulted in a 97/3 mixture of diastereomers (R,SOx,SFc)-17 and 
 (S,SOx,SFc)-17 (93% 
overall isolated yield). We suspect that this high diastereoselectivity could at least in 
part be caused by a corroborative action of the oxazoline unit and the base. The 
oxazoline unit is expected to co-ordinate to lithium and thereby directing the base to the 
pro-(R) methylene hydrogen of the side chain. Quenching with MeI under retention of 
configuration would result in the observed main diastereomer (R,SOx,SFc)-17. A further 
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 reduction of this diastereomer gave ligand (R,SOx,SFc)-3 which represents the side chain 
epimer of (S,SOx,SFc)-3. As already mentioned, its enantiomer (R,ROx,RFc)-3 had 
performed the best in the hydrogenation and transfer hydrogenation of ketones. 
 
Table 1. -Alkylation of (SOx,SFc)-26 with different bases and MeI. 
entry base/solvent 
equiv. 
base 
T, °C (R)-17
a
/(S)-17
b
/30
c
 
1 n-BuLi / THF 1.1 r.t. 65/15/20
d
 
2 tert-BuLi / THF 1.1 r.t. 80/17/3 
3 tert-BuLi / Et2O 1.1 r.t. 57/43/0 
4 Li-TMP / THF 1.1 0 79/16/5 
5 tert-BuLi / THF 1.1 –78 94/6/0 
6 tert-BuLi / THF 1.2 –78 97/3/0 
7 n-BuLi / THF 1.2 –78 91/4/5 
8 Li-TMP / THF 1.2 –78 92/3/5 
a 
(R,SOx,SFc)-17, 
b 
(S,SOx,SFc)-17, 
c 
unreacted starting material, 
d
 ratios determined by 
1
H-NMR 
Since the alkylation of (SOx,SFc)-26 to (R,SOx,SFc)-17 could be carried out with full 
conversion of substrate and with high diastereoselectivity, we questioned whether 17 
could be alkylated a second time at the ferrocenyl -position. Indeed, when (R,SOx,SFc)-
17 was reacted in THF with 1.2 equivalents of tert-BuLi at –78 °C, after quenching with 
MeI, the doubly -substituted ferrocene derivative (SOx,SFc)-27 was obtained 93% 
isolated yield.  
Furthermore, we investigated whether the epimers (R,SOx,SFc)-17 and 
(S,SOx,SFc)-17 can be converted into each other. For this purpose (R,SOx,SFc)-17 was 
reacted with tert-BuLi and the lithiated intermediate was quenched with water (Scheme 
5). Under optimized conditions (THF, 2 equivalents of base, –78 °C) 95% of the epimer 
(S,SOx,SFc)-17 was formed. In a control experiment (S,SOx,SFc)-17 was subjected to the 
same reaction conditions, but in this case no epimerization took place. This result 
indicates that phosphine oxide (S,SOx,SFc)-17 is thermodynamically more stable than its 
epimer (R,SOx,SFc)-17 and consequently, in the alkylation of (SOx,SFc)-26 with tert-BuLi 
and MeI the thermodynamically less stable diastereomer (R,SOx,SFc)-17 was formed.  
In summary, the reaction of the oxazoline substituted ferrocenyl aldehydes 
(SOx,SFc)-6 and (SOx,SFc)-9 with dimethyl- and diphenyl zinc gave alcohols 18, 20, and 
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 24 with very high diastereoselectivity (94% d.e.) which could be further transformed into 
the desired ligands 3, 4, and 22. In this case, all ligands were obtained with (S,SOx,SFc) 
absolute configuration. Complementary, -deprotonation and alkylation of phosphine 
oxide (SOx,SFc)-26 gave intermediate 17 which after reduction of the phosphine oxide 
resulted in the side chain epimer  (R,SOx,SFc)-3. 
 
Scheme 5. -Alkylation and isomerization of (R,SOx,SFc)-17. 
Transfer hydrogenation of ketones 
Since with use of ruthenium complex [RuCl2(PPh3)((R,ROx,RFc)-3)] excellent 
results had been obtained in the transfer hydrogenation and hydrogenation of a variety 
of aryl-alkyl ketones,6 it was of interest to compare the performance of this ligand with 
that of its side-chain epimer (S,ROx,RFc)-3 and its side-chain substituted analog 
(R,ROx,RFc)-22 that bears a phenyl instead of a methyl group at the ferrocenyl -
position. Because of synthetic availability, for the transfer hydrogenations of ketones the 
enantiomers (R,SOx,SFc)-3 and (S,SOx,SFc)-22 were used. For this purpose complexes 
(R,SOx,SFc)-29 and (S,SOx,SFc)-30 were prepared by reaction of ligands (R,SOx,SFc)-3 
and (S,SOx,SFc)-22 with [RuCl2(PPh3)3] (Scheme 6). 
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 + L [RuCl2(PPh3)(L)][RuCl2(PPh3)3] toluene
(R,SOx,SFc)-3
(R,ROx,RFc)-3
L = complex =
(R,SOx,SFc)-29
(R,ROx,RFc)-29
(S,SOx,SFc)-22 (S,SOx,SFc)-30
(SOx,SFc)-1 (SOx,SFc)-28
 
Scheme 6. 
All transfer hydrogenations were carried out at r.t. with 2-propanol as the 
hydrogen source and potassium isopropoxide as the base (for reaction details see 
Experimental). The transfer hydrogenation results obtained with ketones acetophenone 
(ACP), 4-methyl-acetophenone (4-Me-ACP) and phenyl-benzylketone (PBK) and 
complexes (R,ROx,RFc)-29, (R,SOx,SFc)-29 and (S,SOx,SFc)-30 are summarized in Table 
2. In all cases only isolated ruthenium complexes were used as the catalyst precursors. 
For assuring comparable reaction conditions, FOXAP complex (SOx,SFc)-28 (Scheme 6) 
of ligand 1 (Chart 1) was used as the reference. 
A comparison of all data of Table 2 shows that complex (R,ROx,RFc)-29 [ligand 
(R,ROx,RFc)-3] performed best with all three substrates (entries 2,6,10). When complex 
(S,SOx,SFc)-30 with the side-chain phenyl substituted ligand (S,SOx,SFc)-22 was used all 
product e.e.s dropped by about 10% and also the reaction rate decreased (entries 
4,8,12). With complex (R,SOx,SFc)-29 [ligand (R,SOx,SFc)-3] the most significant changes 
were observed. Not only decreased the reaction rates further, but also the product e.e.s 
became very low (entries 3, 7 and11).  
With respect to product absolute configuration a consistent picture is seen. With 
all complexes of (ROx,RFc) absolute configuration always products of (S) configuration 
were obtained. From these and our previously reported transfer hydrogenation results 
some conclusions can be drawn. When the performance of the diastereomeric 
complexes and ligands (R,ROx,RFc)-29 [ligand (R,ROx,RFc)-3], (R,SOx,RFc)-29 [ligand 
(R,SOx,RFc)-3], and (S,ROx,RFc)-29 [ligand (S,ROx,RFc)-3] – all normalized to the same 
(RFc) ferrocene configuration – are compared to each other some general features are 
seen. With all investigated substrates ligand (R,ROx,RFc)-3 performed best with respect 
to product e.e. and therefore we consider the (R,ROx,RFc) relative configuration to be the 
matching configuration. Changes either of the side-chain [ligand (S,ROx,RFc)-3] or the 
oxazoline configuration [ligand (R,SOx,RFc)-3] led to lower product e.e.s. Furthermore, a 
change of the side-chain substituent of ligand (R,ROx,RFc)-3 from methyl to phenyl 
[ligand (R,ROx,RFc)-22] resulted in a drop of product enantiomeric excess.  
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 Table 2. Transfer hydrogenation results obtained for three ketones.a 
entry substrate complex time
e 
% conv. % e.e. 
abs. 
conf. 
1 ACP
b 
(SOx,SFc)-28 20 min 99 96 R 
2 ACP (R,ROx,RFc)-29 10 min 99 98 S 
3 ACP (R,SOx,SFc)-29 1 h 80 41 R 
4 ACP (S,SOx,SFc)-30 30 min 97 90 R 
5 4-Me-ACP
c 
(SOx,SFc)-28 10 min 97 96 R 
6 4-Me-ACP (R,ROx,RFc)-29 10 min 97 98 S 
7 4-Me-ACP (R,SOx,SFc)-29 2 h 95 28 R 
8 4-Me-ACP (S,SOx,SFc)-30 30 min 95 88 R 
9 PBK
d 
(SOx,SFc)-28 10 min >99 95 R 
10 PBK (R,ROx,RFc)-29 20 min >98 97 S 
11 PBK (R,SOx,SFc)-29 4 h 35 57 R 
12 PBK (S,SOx,SFc)-30 4 h 57 87 R 
a
 Reaction conditions: 1 mmol of substrate in 51 mL of 2-propanol (19.6 mM), 0.5% catalyst and 
2% base (S/C/base = 200/1/4), 
b
 ACP: acetophenone, 
c
 4-Me-ACP: 4-methyl-acetophenone, 
d
 
PBK: phenylbenzyl ketone, 
e
 reaction time optimised with respect to conversion and product e.e. 
 
Conclusions 
In order to simplify the synthesis of ferrocenyl-based phosphino-oxazolines that 
have the phosphino unit attached to a ferrocenylmethyl or a ferrocenylethyl side-chain 
two complementary synthesis routes were explored. Both routes started from easily 
accessible ferrocenyl-oxazolines and in both cases the phosphino-substituted side 
chain was build up diastereoselectively. The first route made use of an auto-activated 
alkyl transfer either from diphenyl zinc or from dialkyl zinc reagents to 2-oxazolinyl 
substituted ferrocene aldehydes. The resulting alcohols were obtained in form of single 
diastereomers and could be further transformed into the desired phosphino-oxazolines. 
Via this route differently substituted ligands all suitable for use in transfer 
hydrogenations of ketones and all having the matching (S,SOx,SFc) relative configuration 
could be obtained in enantiomerically pure form.  
The second route made use of the fact that phosphine oxides can be 
deprotonated and alkylated at their -positions. In this case 2-phosphinylmethyl 
substituted ferrocenyloxazolines were deprotonated and alkylated at the side-chain 
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 methylene group. However in this case product with (R,SOx,SFc) configuration was 
obtained in very high diastereoselectivity. Furthermore, it was shown that with use of 
this methodology not only one but two alkyl (methyl) groups can be attached 
consecutively to the ferrocene side-chain -position. In addition, the epimerization of 
phosphine oxazoline (R,SOx,SFc)-3 into (S,SOx,SFc)-3 was studied. It was found that 
(R,SOx,SFc)-3 can be transformed almost quantitatively into its thermodynamically more 
stable epimer (S,SOx,SFc)-3. Therefore both epimers of 3 are accessible via this route. 
Transfer hydrogenations with 2-propanol as the hydrogen source and potassium 
alkoxide as the base were carried out with use of [RuCl2(PPh3)(L)] complexes of two 
ligands and three aryl-alkyl ketones. The results obtained were compared with our 
previously reported data. It was concluded that for this type of ligand the (S,SOx,SFc) 
relative configuration constitutes the matching configuration while both changes of the 
side-chain or of the oxazoline configuration leads to less efficient transfer hydrogenation 
catalysts. 
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 S2 
General considerations 
 
All reactions required inert conditions and were carried out under an argon atmosphere 
using standard Schlenk techniques. All solvents were dried by standard procedures and 
distilled before use. Preparative chromatographic separations were performed under 
gravity on standardised aluminium oxide 90 (MERCK). Petroleum ether with a boiling 
range of 55–65 °C was used for chromatography. Abbreviations: PE: petroleum ether; 
DEE: diethyl ether; EA: ethyl acetate; DCM: dichloromethane; THF: tetrahydrofurane, 
DMAP: 4-N,N-dimethylaminopyridine. The following substrates were purchased and 
were used without further purification: (S)-(4-isopropyloxazolin-2-yl)ferrocene (TCI), 
diethylzinc solution in toluene (Aldrich). NMR spectra were recorded on a Bruker DPX-
400 spectrometer in CDCl3 or CD2Cl2. Chemical shifts (δ) are given relative to CHCl3 (
1H: 
7.26 ppm, 13C: 77.0 ppm), CH2Cl2 (
1H: 5.32 ppm, 13C: 54.0 ppm) and 85% H3PO4 (
31P: 0 
ppm). The coupling constants in 13C{1H} spectra are due to 13C-31P coupling. For signal 
assignment the following terms were used: s, bs, d, dd, t, q and m refer to singlet, broad 
singlet, doublet, doublet of doublets, triplet, quartet and multiplet, respectively. The terms 
PhA and PhB were used to distinguish phenyl groups of diphenylphosphino units and 
PhOx and PhP were used to distinguish phenyl groups of oxazoline and 
diphenylphosphino units. A general atom numbering scheme used for proton and carbon 
assignment is given below. Melting points were determined on a Kofler melting point 
apparatus and are uncorrected. Mass spectra were recorded on instruments Finnigan 
MAT 900 S, MAT 95 S and Bruker ESI-Qq aoTOF. Optical rotations were measured on a 
Perkin-Elmer 241 polarimeter. Conversion and e.e. values were measured with use of an 
Agilent 7890 A GC or an Agilent 1200 HPLC. 
 
 
 
 
 
 
Atom numbering scheme for NMR assignment of ferrocenes. 
Fe
1 2
3
4
5
Cp'
R
R
104
 S3 
(R,SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-(diphenylphosphino)-
ethyl]-ferrocene, (R,SOx,SFc)-3 
To a solution of (R,SOx,SFc)-17 (1.0 g, 1.90 mmol) in THF (5 mL) were added 
polymethylhydrosiloxane (1.23 g) and titanium(IV) isopropoxide (2.16 g, 7.6 mmol) and 
the resulting mixture was heated at 80 °C for 30 minutes. After cooling to r.t, the dark 
solution was chromatographed on aluminium oxide 90 without previous workup under 
inert conditions with deoxygenated solvents. The crude product was chromatographed 
twice using PE/EA/TEA = 5/5/1 as the eluent. A third chromatography using PE/EA/TEA 
= 8/2/1 provided the pure product as an orange semisolid (873 mg, 1.71 mmol, 90% 
yield). 1H NMR (400MHz, CDCl3): δ 1.03 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.06 (dd, J = 
7.4 Hz, J = 8.3 Hz, 3H, CHCH3), 1.01 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.83–1.94 (m, 
1H, CH(CH3)2), 3.99–4.8 (m, 7H, Cp' + CHHO + CHN), 4.23 (t, J = 2.5 Hz, 1H, H4), 
4.24–4.28 (m, 1H, CHHO), 4.64 (m, 1H, H5), 4.41–4.497 (m, 1H, CHCH3), 4.62–4.67 
(dd, J = 1.5 Hz, J = 2.5 Hz, 1H, H3), 7.29–7.40 (m, 6H, Ph-meta + Ph-para), 7.55–7.62 
(m, 2H, Ph-ortho), 7.66–7.73 (m, 2H, Ph-ortho). 13C{1H} NMR (100.6 MHz, CDCl3): δ 
18.4 (CH(CH3)(CH3)), 19.0 (CH(CH3)(CH3)), 21.3 (d, J = 4.8 Hz, CHCH3), 28.7 (d, J = 
13.6 Hz, CHCH3), 32.8 (CH(CH3)2), 68.4 (C4), 68.8 (CH2O), 69.0 (d, J = 2.2 Hz, C3), 
70.3 (Cp'), 70.7 (d, J = 10.8 Hz, C5), 72.7 (CHN), 95.1 (C1), 128.0, 128.1, 128.2 (3C, Ph-
meta + Ph-para), 128.4 (d, J = 6.1 Hz, 2C, Ph-meta), 128.9 (Ph-para), 132.9 (d, J = 17.6 
Hz, 2C, Ph-ortho), 135.3 (d, J = 21.6 Hz, 2C, Ph-ortho), 165.7 (C=N). C2 and Ph-ipso not 
observed. 31P{1H} NMR (100.6 MHz, CDCl3): δ 0.6 (PPh2), HR-MS (ESI in MeOH/MeCN): 
m/z [M+H]+ calcd. for C30H33FeNOP: 510.1649, found: 510.1652. [α]
20
λ (nm): –80 (589), –
90 (578), –131 (546) (c 0.740, CHCl3).  
(SOx,RFc)-2-[4,5-Dihydro-4-(phenyl)oxazol-2-yl)-1-hydroxymethyl-ferrocene, 
(SOx,RFc)-10 
To a solution of (SOx,SFc)-9 (1.5 g, 4.18 mmol) in methanol (50 mL) was added NaBH4 
(474 mg, 12.53 mmol) in portions at 0 °C. The mixture was warmed to r.t. and stirred for 
90 minutes. After cooling again to 0 °C, the reaction mixture was quenched by dropwise 
addition of water, and then the phases were separated. The aqueous phase was 
extracted with DEE (3 × 25 mL), and the organic phase was washed with water and dried 
over MgSO4 and then the solvents were removed under reduced pressure. The crude 
product was chromatographed on aluminium oxide 90 using PE/EA = 5/1 as eluent 
giving the pure compound as an orange oil (1.49 g, 4.12 mmol, 99% yield). 1H NMR 
(400MHz, CDCl3): δ 4.26 (s, 5H, Cp'), 4.27–4.31 (m, 2H, CHHO + H5), 4.38–4.47 (m, 
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2H, CHHOH + H3/4), 4.65–4.75 (m, 3H, CHHO + CHHOH + H3/4), 5.21–5.31 (m, 1H, 
CHN), 6.11 (bs, 1H, OH), 7.29–7.36 (m, 3H, Ph-ortho + Ph-para), 7.38–7.44 (m, 2H, Ph-
meta). 13C{1H} NMR (100.6 MHz, CDCl3): δ 59.6 (CH2OH), 68.4 (C5), 68.4 (C2), 69.1 
(CHN), 70.1 (Cp'), 70.5 (C3/4), 72.3 (C3/4), 74.8 (CH2O), 89.8 (C1), 126.2 (2C, Ph-
ortho), 127.7 (Ph-para), 128.3 (2C, Ph-meta), 142.4 (Ph-ipso), 169.1 (C=N). HR-MS (ESI 
in MeOH/MeCN): m/z [M+H]+ calcd. for C20H20FeNO2: 362.0843, found: 362.0836. [α]
20
λ 
(nm): –410 (589), –468 (578), –750 (546) (c 0.285, CHCl3).   
(SOx,SFc)-2-[4,5-Dihydro-4-(phenyl)oxazol-2-yl)-1-(diphenylphosphino)methyl-
ferrocene, (SOx,SFc)-11 
To a stirred solution of (SOx,RFc)-10 (1.3 g, 3.60 mmol) and sodium iodide (1.08 g, 7.21 
mmol) in acetonitrile (35 mL) was added chlorotrimethylsilane (978 mg, 9.0 mmol). which 
led to a change of color from orange to red. After additional stirring for 10 minutes at r.t. 
diphenylphosphine (804 mg, 4.32 mmol) was added. The reaction mixture was stirred for 
24 h at r.t.; subsequently without previous workup the crude product was purified by 
chromatography under inert conditions with deoxygenated solvents on aluminium oxide 
90. The solvent mixture PE/DEE = 20/1 removed excess of diphenylphosphine and 
PE/EA/TEA = 2/1/1 + 10% DCM eluted the title compound as an orange semisolid (1.65 
g, 3.12 mmol, 86% yield). 1H NMR (400MHz, CDCl3): δ 3.39 (dd, J = 1.9 Hz, J = 13.8 Hz, 
1H, CHHP), 3.96–4.01 (m, 2H, CHHP + H5), 4.09 (t, J = 8.2 Hz, 1H, CHHO), 4.14 (s, 5H, 
Cp'), 4.14–4.17(m, 1H, H4), 4.63 (dd, J = 8.2 Hz, J = 9.9 Hz, 1H, CHHO), 4.68–4.72 (m, 
1H, H3), 5.24 (dd, J = 8.2 Hz, J = 9.9 Hz, 1H, CHN), 7.20–7.52 (18H, Ph). 13C{1H} NMR 
(100.6 MHz, CDCl3): δ 29.4 (d, J = 15.3 Hz, CH2P), 68.6 (C4), 68.9 (C2), 69.3 (C3), 69.9 
(CHN), 70.3 (Cp'), 71.9 (d, J = 5.4 Hz, C5), 79.9 (CH2O), 86.4 (d, J = 17.3 Hz, C1), 126.7 
(2C, PhOx-ortho), 127.3 (Ph-para), 128.0 (Ph-para), 128.1 (d, J = 6.9 Hz, 2C, PhP-meta), 
128.3 (d, J = 6.9 Hz, 2C, PhP-meta), 128.6 (PhOx-meta), 128.8 (Ph-para), 132.2 (d, J = 
17.6 Hz, 2C, PhP-ortho), 133.7 (d, J = 19.9 Hz, 2C, PhP-ortho), 138.3 (d, J = 15.7 Hz, 
PhP-ipso), 139.4 (d, J = 16.5 Hz, PhP-ipso), 143.2 (PhOx-ipso), 167.3 (C=N). 31P{1H} NMR 
(100.6 MHz, CDCl3): δ –9.1 (PPh2). HR-MS (ESI in MeOH/MeCN): m/z [M+CH3OH+H]
+ 
calcd. for C33H33FeNO2P: 562.1598, found: 562.1050. [α]
20
λ (nm): +2 (589), +0.4 (578), –
12 (546) (c 0.280, CHCl3).  
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(R,SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-(diphenylphosphinyl)-
ethyl]-ferrocene, (R,SOx,SFc)-17 
To a solution of (SOx,SFc)-26 (1.5 g, 2.93 mmol) in THF (20 mL) was added 
tBuLi (2.2 mL, 
1.6 M, 3.52 mmol) at –78 °C which immediately led to a change of color from orange to 
dark red. After stirring at –78 °C for 30 minutes, methyl iodide (1.32 g, 8.79 mmol) was 
added. The reaction mixture was stirred for 30 minutes at –78 ºC, and for additional 3 h 
at r.t. Subsequently, the reaction mixture was quenched by addition of water and the 
phases were separated. The aqueous phase was extracted with DEE (3 x 25 mL). The 
organics were combined, washed with water and brine, dried over MgSO4 and the 
solvents were removed under reduced pressure. The crude product was purified by 
chromatography on aluminium oxide 90 (eluent PE/EA/TEA = 1/1/1) to provide the title 
compound as an orange semisolid (1.43 g, 2.72 mmol, 93% yield). 1H NMR (400MHz, 
CDCl3): δ 1.06 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.13 (d, J = 6.8 Hz, 3H, 
CH(CH3)(CH3)), 1.15 (dd, J = 7.3 Hz, J = 16.2 Hz, 3H, CHCH3), 1.89–1.99 (m, 1H, 
CH(CH3)2), 3.67 (s, 5H, Cp'), 3.99–4.08 (m, 2H, CHHO + CHN), 4.18–4.29 (m, 1H, 
CHHO), 4.31 (t, J = 2.5 Hz, 1H, H4), 4.64–4.68 (m, 1H, H3), 4.74–4.82 (m, 1H, CHCH3), 
4.82–4.86 (m, 1H, H5), 7.42–7.48 (m, 3H, PhA-meta + PhA-para), 7.49–7.57 (m, 3H, PhB-
meta + PhB-para), 7.79–7.89 (m, 2H, PhA-ortho), 8.17–8.26 (m, 2H, PhB-ortho). 13C{1H} 
NMR (100.6 MHz, CDCl3): δ 18.3 (CH(CH3)(CH3)), 18.9 (CH(CH3)(CH3)), 20.8 (bs, 
CHCH3), 29.9 (d, J = 73.6 Hz, CHCH3), 32.7 (CH(CH3)2), 68.52 (C3), 68.54 (CH2O), 69.0 
(C4), 70.3 (Cp'), 71.6 (C2), 71.8 (bs, C5), 72.6 (CHN), 89.4 (bs, C1), 128.5 (d, J = 11.0 
Hz, 2C, PhA-meta), 128.7 (d, J = 11.1 Hz, 2C, PhB-meta), 130.7 (d, J = 8.4 Hz, 2C, PhA-
ortho), 130.9 (d, J = 2.3 Hz, PhA-para), 131.4 (d, J = 8.7 Hz, 2C, PhB-ortho), 131.5 (d, J = 
2.4 Hz,  PhB-para), 165.8 (C=N), Ph-ipso not observed. 31P{1H} NMR (100.6 MHz, 
CDCl3): δ 34.9 (P(O)Ph2), HR-MS (ESI in MeOH/MeCN): m/z [M+H]
+ calcd. for 
C30H32FeNO2P: 526.1598, found: 526.1593. [α]
20
λ (nm): –168 (589), –189 (578), –272 
(546) (c 0.263, CHCl3).  
(S,SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-(hydroxy)ethyl]-
ferrocene, (S,SOx,SFc)-18 
To a solution of (SOx,SFc)-6 (1.0 g, 3.08 mmol) in THF (30 mL) was added a solution of 
dimethylzinc in toluene (5.64 mL, 1.2 M, 6.77 mmol) at 0 °C. After warming up to r.t and 
stirring overnight, the reaction mixture was quenched by addition of water and the 
phases were separated. The aqueous phase was extracted with DEE (3 x 25 mL); the 
organics were combined, washed with water and brine and dried over MgSO4. The 
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solvent was removed under reduced pressure and the crude product was purified by 
chromatography on aluminium oxide 90 (eluent PE/EA = 5/1) to give the title compound 
as an orange solid (1.02 g, 2.99 mmol, 97% yield). Single crystals suitable for X-ray 
crystallography were obtained from EA solution by slow evaporation of the solvent. M.p.: 
112 °C. 1H NMR (400MHz, CDCl3): δ 1.01 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.04 (d, J 
= 6.8 Hz, 3H, CH(CH3)(CH3)), 1.53 (d, J = 6.7 Hz, 3H, CHCH3), 1.77–1.87 (m, 1H, 
CH(CH3)2), 3.96–4.05 (m, 1H, CHN), 4.12–4.19 (m, 1H, CHHO), 4.15 (s, 5H, Cp'), 4.24 
(t, J = 2.5 Hz, 1H, H4), 4.28–4.35 (m, 1H, CHHO), 4.40 (dd, J = 1.5 Hz, J = 2.5 Hz, 1H, 
H5), 4.60 (dd, J = 1.5 Hz, J = 2.5 Hz, 1H, H3), 4.99 (q, J = 6.7 Hz, 1H, CHCH3), 6.82 (bs, 
1H, OH). 13C{1H} NMR (100.6 MHz, CDCl3): δ 18.4 (CH(CH3)(CH3)), 18.5 
(CH(CH3)(CH3)), 20.9 (CHCH3), 32.6 (CH(CH3)2), 64.8 (CHCH3), 68.1 (C4), 69.1 (C2), 
69.4 (C5), 70.1 (Cp'), 70.2 (CH2O), 70.6 (C3), 71.6 (CHN), 93.3 (C1), 167.6 (C=N). HR-
MS (ESI in MeOH/MeCN): m/z [M+Na]+ calcd. for C18H23FeNO2Na: 364.0976, found: 
364.0968. [α]20λ (nm): –322 (589), –372 (578), –629 (546) (c 0.260, CHCl3).    
(S,SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-(acetoxy)ethyl]--
ferrocene, (S,SOx,SFc)-19 
A solution of a catalytic amount of DMAP in Ac2O (1.17 mL, 12.35 mmol) was added to a 
stirred solution of (S,SOx,SFc)-18 (836 mg, 2.45 mmol) in freshly distilled triethylamine 
(4.5 mL). After stirring for 17 h at r.t, the reaction mixture was quenched by addition of 
water and the phases were separated. The aqueous phase was extracted with EA (3 x 
25 mL); the organics were combined, washed with water and brine and dried over 
MgSO4. The solvents were removed under reduced pressure and the crude product was 
used without any further purification (854 mg, 2.23 mmol). 1H NMR (400MHz, CDCl3): δ 
0.89 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 0.96 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.67 (d, 
J = 6.5 Hz, 3H, CHCH3), 1.72–1.84 (m, 1H, CH(CH3)2), 1.92 (s, 3H, COCH3), 3.90–4.03 
(m, 2H, CHN + CHHO), 4.16 (s, 5H, Cp'), 4.24–4.31 (m, 1H, CHHO), 4.34 (t, J = 2.5 Hz, 
1H, H4), 4.44–4.48 (m, 1H, H5), 4.79 (dd, J = 1.5 Hz, J = 2.5 Hz, 1H, H3), 6.29 (q, J = 
6.5 Hz, 1H, CHCH3). 
13C{1H} NMR (100.6 MHz, CDCl3): δ 17.9 (CH(CH3)(CH3)), 18.5 
(CH(CH3)(CH3)), 18.6 (CHCH3), 21.2 (COCH3), 32.4 (CH(CH3)2), 68.5 (CHCH3), 68.9 
(C5), 69.1 (C4), 69.5 (CH2O), 70.3 (Cp'), 70.9 (C3), 72.0 (CHN), 87.4 (C1), 165.2 (C=N), 
170.5 (C=O). C2 not observed. HR-MS (ESI in MeOH/MeCN): m/z [M–CH3COO]
+ calcd. 
for C18H22FeNO: 324.1051, found: 324.1046.  
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(S,SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-hydroxy-1-(phenyl)-
methyl]-ferrocene, (S,SOx,SFc)-20 
A solution of diphenylzinc (446 mg, 2.03 mmol) in THF (5 mL) was added to a stirred 
solution of (SOx,SFc)-6 (300 mg, 0.923 mmol) in THF (10 mL) at 0 °C. After warming up to 
r.t and stirring for 24 h, the reaction mixture was quenched by addition of water and the 
phases were separated. The aqueous phase was extracted with DEE (3 x 25 mL); the 
organics were combined, washed with water and brine and dried over MgSO4. The 
solvent was removed under reduced pressure and the crude product was purified by 
chromatography on aluminium oxide 90 (eluent PE/EA = 5/1) to give the title compound 
as an orange oil (361 mg, 0.895 mmol, 97% yield). 1H NMR (400MHz, CDCl3): δ 1.04 (d, 
J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.09 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.79–1.91 (m, 
1H, CH(CH3)2), 3.95–4.04 (m, 2H, H5 + CHN), 4.14–4.19 (m, 1H, CHHO), 4.21 (t, J = 2.6 
Hz, 1H, H4), 4.24 (s, 5H, Cp'), 4.29–4.37 (m, 1H, CHHO), 4.65 (dd, J = 1.5 Hz, J = 2.6 
Hz, 1H, H3), 5.84 (bs, 1H, CHPh), 7.23–7.28 (m, 1H, Ph-para), 7.29–7.37 (m, 2H, Ph-
meta), 7.45–7.51 (m, 2H, Ph-ortho), 7.91 (bs, 1H, OH). 13C{1H} NMR (100.6 MHz, 
CDCl3): δ 18.5 (CH(CH3)(CH3)), 18.6 (CH(CH3)(CH3)), 32.6 (CH(CH3)2), 67.8 (C2), 68.4 
(C4), 70.4 (6C, Cp' + CH2O), 70.7 (C3), 71.5 (CHN), 71.9 (CHPh/C5), 72.0 (CHPh/C5), 
93.5 (C1), 126.8 (2C, Ph-ortho), 127.0 (Ph-para), 128.0 (2C, Ph-meta), 143.5 (Ph-ipso), 
167.4 (C=N). HR-MS (ESI in MeOH/MeCN): m/z [M-OH]+ calcd. for C23H24FeNO: 
386.1207, found: 386.1213. [α]20λ (nm): –297 (589), –339 (578), –554 (546) (c 0.300, 
CHCl3).    
(S,SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-(acetoxy)-1-(phenyl)-
methyl]-ferrocene, (S,SOx,SFc)-21 
A solution of a catalytic amount of DMAP in Ac2O (0.805 mL, 8.57 mmol) was added to a 
stirred solution of (S,SOx,SFc)-20 (685 mg, 1.70 mmol) in freshly distilled triethylamine 
(3.2 mL). After stirring for 17 h at r.t, the reaction mixture was quenched by addition of 
water and the phases were separated. The aqueous phase was extracted with EA (3 x 
25 mL); the organics were combined, washed with water and brine and dried over 
MgSO4. The solvents were removed under reduced pressure and the crude product was 
used without any further purification (695 mg, 1.56 mmol). 1H NMR (400MHz, CDCl3): δ 
0.96 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.03 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.77–
1.89 (m, 1H, CH(CH3)2), 1.94 (s, 3H, COCH3), 3.92–4.07 (m, 8H, CHN + CHHO + Cp' + 
H5), 4.26  (t, J = 2.5 Hz, 1H, H4), 4.30–4.37 (m, 1H, CHHO), 4.79–4.82 (m, 1H, H3), 
7.18 (s, 1H, CHPh), 7.31–7.39 (m, 1H,Ph-para), 7.39–7.48 (m, 2H, Ph-meta), 7.55–7.63 
(m, 2H, Ph-ortho). 13C{1H} NMR (100.6 MHz, CDCl3): δ 18.1 (CH(CH3)(CH3)), 18.7 
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(CH(CH3)(CH3)), 21.1 (COCH3), 32.4 (CH(CH3)2), 69.2 (C4), 69.5 (CH2O), 70.2 (C2), 
70.4 (Cp'), 70.8 (C3), 71.3 (C5), 72.4 (CHN), 74.1 (CHPh), 87.4 (C1), 127.6 (2C, Ph-
ortho), 127.9 (Ph-para), 128.1 (2C, Ph-meta), 140.0 (Ph-ipso), 164.5 (C=N), 169.2 
(C=O). HR-MS (ESI in MeOH/MeCN): m/z [M-CH3COO]
+ calcd. for C23H24FeNO: 
386.1207, found: 386.1214. [α]20λ (nm): +53 (589), +62 (578), +120 (546) (c 0.320, 
CHCl3).    
(S,SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)]-1-[1-phenyl-1-(diphenyl-
phosphino)methyl]-ferrocene, (S,SOx,SFc)-22 
To a stirred solution of (S,SOx,SFc)-21 (830 mg, 1.86 mmol) in methanol (50 mL) was 
added diphenylphosphine (3.46 g, 18.6 mmol). The reaction mixture was refluxed for 7 h. 
After cooling to r.t, subsequently was the crude product chromatographed without 
previous workup under inert conditions with deoxygenated solvents on aluminium oxide 
90. A mixture of PE/DEE = 20/1 removed excess of diphenylphosphine while with use of 
PE/EA/TEA = 9/1/ the title compound was obtained as a yellow solid (895 mg, 1.57 
mmol, 84% yield). M.p.: 149 °C. 1H NMR (400MHz, CDCl3): δ 1.02 (d, J = 6.8 Hz, 3H, 
CH(CH3)(CH3)), 1.12 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.71–1.83 (m, 1H, CH(CH3)2), 
3.62 (s, 5H, Cp'), 3.76–3.87 (m, 2H, CHHO + CHN), 4.03–4.10 (m, 1H, CHHO), 4.23 (t, J 
= 2.6 Hz, 1H, H4), 4.39 (dd, J = 1.5 Hz, J = 2.6 Hz, 1H, H3), 4.59 (dd, J = 1.5 Hz, J = 2.6 
Hz, 1H, H5), 6.02 (d, J = 7.5 Hz, 1H, CHPh), 6.99–7.06 (m, 2H, PhA-meta), 7.07–7.15 
(m, 3H, PhA-ortho + PhA-para), 7.16–7.27 (m, 4H, PhB-meta + PhB-para + PhC-para), 
7.28–7.35 (m, 2H, PhC-meta), 7.46–7.54 (m, 2H, PhB-ortho), 7.61–7.68 (m, 2H, PhC-
ortho). 13C{1H} NMR (100.6 MHz, CDCl3): δ 18.9 (CH(CH3)(CH3)), 18.98 (CH(CH3)(CH3)), 
32.9 (CH(CH3)2), 41.3 (d, J = 11.9 Hz, CHPh), 67.8 (C3), 67.7 (CH2O), 67.8 (C4), 69.2 
(C2), 69.9 (Cp'), 41.3 (d, J = 11.9 Hz, C5), 72.6 (CHN), 93.0 (d, J = 17.6 Hz, C1), 126.2 
(d, J = 1.5 Hz, PhC-para), 127.0 (d, J = 6.9 Hz, 2C, PhA-meta), 127.8–128.0 (4C, PhC-
meta + PhB-meta), 128.1 (PhA-para), 128.5 (PhB-para), 130 (d, J = 9.9 Hz, 2C, PhC-
ortho), 133.8 (d, J =19.6 Hz, 2C, PhB-ortho), 134.1 (d, J = 19.5 Hz, 2C, PhA-ortho), 136.8 
(d, J = 16.0 Hz, PhA-ipso), 137.2 (d, J = 15.3 Hz, PhB-ipso), 144.3 (d, J = 14.2 Hz, PhC-
ipso), 165.1 (C=N). 31P{1H} NMR (100.6 MHz, CDCl3): δ 10.3 (PPh2), HRMS (ESI in 
MeOH/MeCN): m/z [M+H]+ calcd. for C35H35FeNOP: 572.1806, found: 572.1810. [α]
20
λ 
(nm): –15 (589), –17 (578), –27 (546) (c 0.230, CHCl3).    
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(S,SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-(hydroxy)propyl]-
ferrocene, (S,SOx,SFc)-23 
To a solution of (SOx,SFc)-6 (500 mg, 1.54 mmol) in THF (15 mL) was added a solution of 
diethylzinc in toluene (3.38 mL, 1.0 M, 3.38 mmol) at 0 °C. After warming up to r.t. and 
stirring overnight, the reaction mixture was quenched by addition of water and the 
phases were separated. The aqueous phase was extracted with DEE (3 x 25 mL); the 
organics were combined, washed with water and brine and dried over MgSO4. The 
solvent was removed under reduced pressure and the crude product was purified by 
chromatography on aluminium oxide 90 (eluent PE/EA = 5/1) to provide the title 
compound as an orange solid (525 mg, 1.48 mmol, 96% yield). M.p.: 81 °C. 1H NMR 
(400MHz, CDCl3): δ 1.00 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.03 (t, J = 7.5 Hz, 3H, 
CH2CH3), 1.04 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.73–1.89 (m, 3H, CH2CH3 + 
CH(CH3)2), 3.93–4.01 (m, 1H, CHN), 4.13 (dd, J = 7.5 Hz, J = 8.3 Hz, 1H, CHHO), 4.19 
(s, 5H, Cp'), 4.23 (t, J = 2.5 Hz, 1H, H4), 4.31 (dd, J = 8.3 Hz, J =9.6 Hz, 1H, CHHO), 
4.34 (dd, J = 1.5 Hz, J = 2.5 Hz, 1H, H5), 4.5 (q, J = 6.6 Hz, 1H, CHEt), 4.60 (dd, J = 1.5 
Hz, J = 2.5 Hz, 1H, H3), 6.98 (d, J = 6.5 Hz, 1H, OH). 13C{1H} NMR (100.6 MHz, CDCl3): 
δ 11.1 (CH2CH3), 18.6 (2C, CH(CH3)2), 29.7 (CH2CH3), 32.6 (CH(CH3)2), 66.7 (C2), 
68.21 (C4), 70.18 (CH2O), 70.21 (Cp'), 70.3 (C3), 70.6 (C5), 70.9 (CHEt), 71.7 (CHN), 
93.8 (C1), 167.8 (C=N). HR-MS (ESI in MeOH/MeCN): m/z [M+H]+ calcd. for 
C19H26FeNO2: 356.1313, found: 356.1317. [α]
20
λ (nm): –301(589), –347 (578), –575 (546) 
(c 0.365, CHCl3).    
(S,SOx,SFc)-2-[4,5-Dihydro-4-(phenyl)oxazol-2-yl)-1-[1-(hydroxy)ethyl]-ferrocene, 
(S,SOx,SFc)-24 
To a solution of (SOx,SFc)-9 (1.0 g, 2.78 mmol) in THF (30 mL) was added dimethylzinc 
(5.1 mL, 1.2 M, 6.12 mmol) at 0 ºC. After warming up to r.t and stirring for 24 h, the 
reaction mixture was quenched by addition of water and the phases were separated. The 
aqueous phase was extracted with DEE (3 x 25 mL); the organics were combined, 
washed with water and brine and dried over MgSO4. The solvent was removed under 
reduced pressure and the crude product was purified by chromatography on aluminium 
oxide 90 (eluent PE/EA = 5/1) to provide the title compound as an orange oil (1.0 g, 2.66 
mmol, 96% yield). 1H NMR (400MHz, CDCl3): δ 1.54 (d, J = 6.7 Hz, 3H, CHCH3), 4.22 (s, 
5H, Cp'), 4.69 (dd, J = 7.2 Hz, J = 9.9 Hz, 1H, CHHO), 4.70 (t, J = 2.6 Hz, 1H, H4), 4.48 
(dd, J = 1.5 Hz, J = 2.6 Hz, 1H, H5), 4.64–4.74 (m, 2H, H3 + CHHO), 5.01–5.11 (q, J = 
6.7 Hz, 1H, CHCH3), 5.28 (dd, J = 7.2 Hz, J = 9.9 Hz, 1H, CHN), 6.55 (bs, 1H, OH), 
7.29–7.36 (m, 3H, Ph-para + Ph-ortho), 7.38–7.45 (m, 2H, Ph-meta). 13C{1H} NMR 
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(100.6 MHz, CDCl3): δ 21.1 (CHCH3), 64.8 (CHCH3), 68.3 (C2), 68.5 (C4), 69.1 (CHN), 
69.8 (C5), 70.2 (Cp'), 70.9 (C3), 74.8 (CH2O), 93.3 (C1), 126.3 (2C, Ph-ortho), 127.7 
(Ph-para), 128.6 (2C, Ph-meta), 142.5 (Ph-ipso), 169.1 (C=N). HR-MS (ESI in 
MeOH/MeCN): m/z [M-OH]+ calcd. for C21H20FeNO: 358.0894, found: 358.0888; m/z 
[M+H]+ calcd. for C21H22FeNO2: 376.1000, found: 376.0994. [α]
20
λ (nm): –460 (589), –524 
(578), –833 (546) (c 0.220, CHCl3).    
(S,SOx,SFc)-2-[4,5-Dihydro-4-(phenyl)oxazol-2-yl)-1-[1-(acetoxy)ethyl]-ferrocene, 
(S,SOx,SFc)-25 
A solution of a catalytic amount of DMAP in Ac2O (0.620 mL, 6.60 mmol) was added to a 
stirred solution of (S,SOx,SFc)-24 (492 mg, 1.31 mmol) in freshly distilled triethylamine 
(2.4 mL). After stirring for 17 h at r.t, the reaction mixture was quenched by addition of 
water and the aqueous phase was extracted with EA (3 x 25 mL); the organics were 
combined, washed with water and brine and dried over MgSO4. The solvents were 
removed under reduced pressure and the crude product (red oil) was used without any 
further purification (498 mg, 1.19 mmol). 1H NMR (400MHz, CDCl3): δ 1.71 (d, J = 6.5 
Hz, 3H, CHCH3), 1.93 (s, 3H, COCH3), 4.10 (t, J = 8.3 Hz, 1H, CHHO), 4.21 (s, 5H, Cp'), 
4.40 (t, J = 2.6 Hz, 1H, H4), 4.52 (dd, J = 1.5 Hz, J = 2.6 Hz, 1H, H5), 4.70 (dd, J = 8.3 
Hz, J = 9.9 Hz, 1H, CHHO), 4.89 (dd, J = 1.5 Hz, J = 2.6 Hz, 1H, H3), 5.23  (dd, J = 8.3 
Hz, J = 9.9 Hz, 1H, CHN), 6.40 (d, J = 6.5 Hz,  1H, CHCH3), 7.23–7.29 (m, 3H, Ph-para 
+ Ph-ortho), 7.31–7.37 (m, 2H, Ph-meta). 13C{1H} NMR (100.6 MHz, CDCl3): δ 18.8 
(CHCH3), 21.2 (COCH3), 68.6 (CHCH3), 69.1 (C5), 69.4 (C4), 69.7 (CHN), 69.9 (C2), 
70.4 (Cp'), 71.0 (C3), 74.4 (CH2O), 87.5 (C1), 126.5 (2C, Ph-ortho), 127.4 (Ph-para), 
128.6 (2C, Ph-meta), 142.6 (Ph-ipso), 166.8 (C=N), 170.1 (C=O). HR-MS (ESI in 
MeOH/MeCN): m/z [M-CH3COO]
+ calcd. for C21H20FeNO: 358.0894, found: 358.0887; 
m/z [M+H]+ calcd. for C23H24FeNO3: 418.1105, found: 418.1090. 
(SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-(diphenylphosphinyl)-
methyl]-ferrocene, (SOx,SFc)-26 
To a solution of (SOx,SFc)-2 (2 g, 4.04 mmol) in acetone (80 mL) was added an aqueous 
solution of hydrogen peroxide (5 mL, 30%). After stirring for 1 h at r.t., the reaction 
mixture was quenched with Na2S2O3, and acetone was removed under reduced 
pressure. The residue was dissolved in DCM and washed with water and brine and dried 
over MgSO4. The solvents were removed under reduced pressure. The title compound 
was obtained as a yellow powder (2.02 g, 3.95 mmol, 98% yield). M.p.: 151 °C. 1H NMR 
(400MHz, CDCl3): δ 0.96 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 1.06 (d, J = 6.8 Hz, 3H, 
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CH(CH3)(CH3)), 1.63–1.79 (m, 1H, CH(CH3)2), 3.49 (dd, J = 15.0 Hz, J = 18.4 Hz, 1H, 
CHHP), 3.78–3.88 (m, 2H, CHHO + CHN), 4.08 (s, 5H, Cp'), 4.11–4.18 (m, 1H, CHHO), 
4.23 (t, J = 2.5 Hz, 1H, H4), 4.48–4.52 (m, 1H, H3), 4.62–4.67 (m, 1H, H5), 4.79 (dd, J = 
8.2 Hz, J = 15.0 Hz, 1H, CHHP), 7.20–7.27 (m, 2H, PhA-meta), 7.31–7.38 (m, 1H, PhA-
para), 7.44–7.62 (m, 5H, PhA-ortho + PhB-meta + PhB-para), 7.84–7.93 (m, 2H, PhB-
ortho). 13C{1H} NMR (100.6 MHz, CDCl3): δ 18.7 (CH(CH3)(CH3)), 19.0 (CH(CH3)(CH3)), 
31.4 (d, J = 66.6 Hz, CH2P), 32.8 (CH(CH3)2), 69.0 (C3), 69.1 (CH2O), 69.2 (C4), 70.5 
(Cp'), 72.3 (d, J = 1.8 Hz, C5), 72.6 (CHN), 79.9 (d, J = 3.2 Hz, C1), 127.7 (d, J = 12.1 
Hz, 2C, PhA-meta), 128.4 (d, J = 11.3 Hz, 2C, PhB-meta), 131.1–131.6 (m, 6C, Ph-ortho 
+ Ph-para), 131.7 (d, J = 17.5 Hz, PhA-ipso). C2, PhB-ipso and C=N not observed. 
31P{1H} NMR (100.6 MHz, CDCl3): δ 30.9 (P(O)Ph2), HR-MS (ESI in MeOH/MeCN): m/z 
[M+H]+ calcd. for C29H31FeNO2P: 512.1442, found: 512.1462. [α]
20
λ (nm): –35 (589), –41 
(578), –82 (546) (c 0.230, CHCl3).    
(SOx,SFc)-2-[4,5-Dihydro-4-(1-methylethyl)oxazol-2-yl)-1-[1-methyl-1-(diphenyl-
phosphinyl)ethyl]-ferrocene, (SOx,SFc)-27 
To a solution of (R,SOx,SFc)-17 (1.5 g, 2.85 mmol) in THF (20 mL) was added 
tBuLi (2.2 
mL, 1.6 M, 3.52 mmol) at –78 °C. which immediately led to a change of color from 
orange to dark red. After stirring at -78 °C for 30 minutes, methyl iodide (1.28 g, 8.55 
mmol) was added. The reaction mixture was stirred for 30 minutes at –78 ºC, and for 
additional 3 h at r.t. Subsequently, the reaction mixture was quenched by addition of 
water. After phase separation, the aqueous phase was extracted with DEE (2 x 25 mL). 
The organics were combined, washed with water and brine, dried over MgSO4 and the 
solvents were removed under reduced pressure. The crude product was purified by 
chromatography on aluminium oxide 90 (eluent PE/EA/TEA = 1/1/1) to provide the title 
compound as an orange semisolid (1.43 g, 2.65 mmol, 93% yield). Mp: 110 °C. 1H NMR 
(400MHz, CDCl3): δ 0.78 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 0.88 (d, J = 6.8 Hz, 3H, 
CH(CH3)(CH3)), 1.48–1.58 (m, 1H, CH(CH3)2), 1.66 (d, J = 14.4 Hz, 3H, C(CH3)(CH3)), 
1.96 (d, J = 15.4 Hz, 3H, C(CH3)(CH3)), 3.44–3.53 (m, 1H, CHN), 3.62 (t, J = 8.3 Hz, 1H, 
CHHO), 3.97 (dd, J = 8.3 Hz, J = 9.7 Hz, 1H, CHHO), 4.00–4.04 (m, 1H, H5), 4.20 (s, 
5H, Cp'), 4.26 (t, J = 2.6 Hz, 1H, H4), 4.63 (dd, J = 1.6 Hz, J = 2.6 Hz, 1H, H3), 7.27–
7.37 (m, 4H, Ph-meta), 7.38–7.44 (m, 2H, Ph-para), 7.57–7.65 (m, 2H, Ph-ortho), 7.65–
7.72 (m, 2H, Ph-ortho). 13C{1H} NMR (100.6 MHz, CDCl3): δ 18.5 (CH(CH3)(CH3)), 19.0 
(CH(CH3)(CH3)), 23.9 (C(CH3)(CH3)), 26.8 (C(CH3)(CH3)), 32.6 (CH(CH3)2), 39.8 (J = 
64.8 Hz, C(CH3)(CH3)), 67.8 (C4), 69.1 (CH2O), 70.1 (Cp'), 72.0 (C3), 72.6 (d, J = 1.9 
Hz, C5), 72.7 (d, J = 1.7 Hz, C2), 73.2 (CHN), 92.4 (d, J = 4.6 Hz, C1), 127.5 (d, J = 10.7 
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Hz, 2C, Ph-meta), 127.7 (d, J = 11.4 Hz, 2C, Ph-meta), 130.39, 130.4, 131.29, 131.3 
(Ph-ipso), 130.9 (d, J = 2.7 Hz, 2C, Ph-para), 131.1 (d, J = 2.6 Hz, Ph-para), 132.8 (d, J 
= 4.6 Hz, Ph-ortho), 132.9 (d, J = 4.7 Hz, 2C, Ph-ortho), 164.0 (C=N). 31P{1H} NMR 
(100.6 MHz, CDCl3): δ 36.9 (P(O)Ph2), HR-MS (ESI in MeOH/MeCN): m/z [M+H]
+ calcd. 
for C31H35FeNO2P: 540.1755, found: 540.1761. [α]
20
λ (nm): +129 (589), +162 (578), +229 
(546) (c 0.337, CHCl3).    
(SOx)-{N-[2-hydroxy-1-(phenyl)eth-1-yl]aminocarbonyl}-ferrocene,  
A solution of (+)-(S)-2-amino-2-phenylethanol (2.30 g, 16.8 mmol) in toluene (50 mL) 
was cooled to 0 °C and treated with a solution of trimethylaluminium in toluene (16.7 mL, 
2.0 M, 33.4 mmol). After stirring for 5 minutes the solution was warmed to r.t. and stirring 
was continued for additional 45 minutes. Subsequently, a solution of (methoxycarbonyl)- 
Ferrocene (3.70 g, 15.2 mmol) in toluene (20 mL) was added and the resulting mixture 
was stirred for 16 h at 126 °C. After cooling to r.t, the reaction mixture was quenched 
carefully by addition of water and the phases were separated. The aqueous phase was 
extracted with EA (3 x 25 mL), the organics were combined, washed with water and 
brine and dried over MgSO4. The solvents were removed under reduced pressure and 
the crude product was purified by crysallisation (DCM and PE) and afforded the title 
compound as yellow crystals (5.12 g, 14.66 mmol, 97% yield). M.p.: 158 °C. 1HNMR 
(400 MHz, CDCl3): δ 2.82 (bs, 1H, OH), 3.91–3.04 (m, 2H, CH2), 4.10 (s, 5H, Cp'), 4.33–
4.39 (m, 2H, H3 + H4), 4.67–4.70 (m, 1H, H2/H5), 4.70–4.75 (m, 1H, H2/H5), 5.18–5.26 
(m, 1H, CHPh), 6.37 (d, J = 6.9 Hz, 1H, NH), 7.29–7.45 (m, 5H, Ph). 13C{1H} NMR (100.6 
MHz, CDCl3): δ  55.9 (CHPh), 66.8 (CH2O), 68.0 (C2/C5), 68.5 (C2/C5), 69.8 (Cp'), 70.6 
(C3/C4), 70.7 (C3/C4), 75.5 (C1), 126.7 (2C, Ph), 127.9 (Ph-para), 128.9 (2C, Ph), 139.4 
(Ph-ipso), 171.0 (C=O). HR-MS (ESI in MeOH/MeCN): m/z [M+Na]+ calcd. for 
C19H19FeNNaO2: 372.0663, found: 372.0664. [α]
20
λ (nm): +29 (589), +31 (578), +42 (546) 
(c 0.344, CHCl3).    
Synthesis of neutral ruthenium complexes – General procedure 
A mixture of oxazoline ligand (1.0 mmol) and [RuCl2(PPh3)3] (0.95 mmol) dissolved in 
freshly distilled and degassed toluene (3 mL) was stirred for 16 h at r.t. Degassed 
hexane was added to precipitate the product. The green solid was filtered off under inert 
conditions and was washed with freshly distilled and degassed hexane (2 × 2 mL). The 
crude product was redissolved in toluene, precipitated by addition of hexane and dried in 
vacuo to yield a green powder.  
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Dichloro[(R,SOx,SFc)-2-[4,5-dihydro-4-(1-methylethyl)oxazol-2-yl-κN)-1-[1-(diphenyl-
phosphino)ethyl-κP]-ferrocene]triphenylphosphine ruthenium, 
[RuCl2(PPh3)((R,SOx,SFc)-3)], (R,SOx,SFc)-29 
Starting from (R,SOx,SFc)-3 (195 mg, 0.383 mmol) and following the general procedure 
stated above the desired product was obtained as a green powder (292 mg, 0.310 mmol, 
81% yield). Mp: > 230 °C (dec.). 1H NMR (400 MHz, CD2Cl2): δ 0.90 (d, J = 7.2 Hz, 3H, 
CH(CH3)(CH3)), 1.08 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 2.16 (dd, J = 7.0 Hz, J = 15.2 
Hz, 3H, CHCH3), 2.15–3.29 (m, 2H, CH(CH3)2 + CHCH3), 3.51–3.54 (m, 1H, H5), 3.97 (d, 
J = 2.6 Hz, 1H, H4), 3.99–4.05 (m, 1H, CHN), 4.22–4.28 (m, 6H, Cp' + CHHO), 4.55 (dd, 
J = 3.3 Hz, J = 8.5 Hz, 1H, CHHO),  4.79 (dd, J = 1.5 Hz, J = 2.6 Hz, 1H, H3), 6.90 –7.31 
(m, 25H, Ph). 13C{1H} NMR (100.6 MHz, CD2Cl2): δ 15.1 (CH(CH3)(CH3)), 20.0 
(CH(CH3)(CH3)), 22.3 (d, J = 4.1 Hz, CHCH3), 28.5 (CH(CH3)2), 42.0 (d, J = 25.1 Hz, 
CHCH3), 67.7 (d, J = 3.8 Hz, C2), 68.27 (C4), 68.28 (CH2O), 70.2 (Cp'), 73.1 (2C, C3 + 
CHN), 74.4 (d, J = 3.0 Hz, C5), 93.1 (d, J = 4.6 Hz, C1), 126.2–139.5 (Ph), 176.1 (C=N). 
31P{1H} NMR (162 MHz, CD2Cl2): δ 45.6 (d, J = 39.8 Hz, PPh3), 103.9 (d, J = 39.8 Hz, 
PN). HR-MS (ESI in MeOH/MeCN): m/z [M-Cl]+ calcd. for C48H47ClFeNOP2Ru: 908.1214, 
found: 908.1192. [α]20λ (nm): –908 (589), –950 (578), –1013 (546) (c 0.0240, CH2Cl2).   
Dichloro[(S,SOx,SFc)-2-[4,5-dihydro-4-(1-methylethyl)oxazol-2-yl-κN)-1-[1-phenyl-1-
(diphenylphosphino)methyl-κP]-ferrocene]triphenylphosphine ruthenium, 
[RuCl2(PPh3)((S,SOx,SFc)-22], (S,SOx,SFc)-30 
Starting from (S,SOx,SFc)-22 (300 mg, 0.525 mmol) and following the general procedure 
stated above the desired product was obtained as a green powder (456 mg, 0.453 mmol, 
86% yield). Mp: > 230 °C (dec.). 1H NMR (400MHz, CDCl3): δ 0.97 (d, J = 7.1 Hz, 3H, 
CH(CH3)(CH3)), 1.19 (d, J = 6.8 Hz, 3H, CH(CH3)(CH3)), 3.21–3.33 (m, 1H, CH(CH3)2), 
3.50–3.56(m, 1H, H5), 3.86 (s, 5H, Cp'), 3.97 (t, J = 2.6 Hz, 1H, H4), 4.13–4.22 (m, 1H, 
CHN), 4.34 (t, J = 8.7 Hz, 1H, CHHO), 4.61 (dd, J = 4.1 Hz, J = 8.7 Hz, 1H, CHHO), 
4.86–4.89 (m, 1H, H3), 6.17 (d, J = 13.5 Hz, 1H, CHPh), 6.46–7.88 (Ph). 13C{1H} NMR 
(100.6 MHz, CDCl3): δ 15.3 (CH(CH3)(CH3)), 19.5 (CH(CH3)(CH3)), 28.2 (CH(CH3)2), 
53.3 (d, J = 16.1 Hz, CHPh), 67.9 (d, J = 1.7 Hz, CH2O), 70.5 (C4), 70.6 (Cp'), 71.2 (bs, 
C5), 72.6 (C3), 73.0 (CHN), 88.2 (d, J = 4.6 Hz, C1), 125.4–141.0 (Ph), 175.4 (C=N). C2 
not obsereved. 31P{1H} NMR (100.6 MHz, CD2Cl2): δ 48.6 (d, J = 39.5 Hz, PPh3), 95.1 (J 
= 39.6 Hz, PN). HR-MS (ESI in MeOH/MeCN): m/z [M-Cl]+ calcd. for C53H49ClFeNOP2Ru: 
970.1371, found: 970.1381. [α]20λ (nm): –688 (589), –722 (578), –803 (546) (c 0.025, 
CH2Cl2).   
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Asymmetric transfer hydrogenations 
To a solution of ruthenium complex (0.005 mmol, 0.5%) in anhydrous 2-PrOH (50 mL) 
were added a solution of ketone (1 mmol) in 2-PrOH (1 mL) and a solution of 2-PrOK 
(0.02 mmol) in 2-PrOH (5% w/v). The reaction mixture was stirred at r.t. and the progress 
of the reaction was monitored by periodically analyzing 1 mL samples of the reaction 
mixture. The samples were quenched with aqueous H3PO4 (0.5 M, 0.5 mL), diethyl ether 
(1 mL) was added and the product was extracted. The organic phase was washed with 
brine and filtered through a short plug of MgSO4 (top) and aluminum oxide 90 (bottom) 
using 2-PrOH as the eluent. The filtrate obtained was analyzed either by GC or HPLC. 
Analysis data: 
Conversions and e.e. values of substrates ACP and 4-Me-ACP were determined by GC. 
Retention times are given for the reactants and both product enantiomers. 
Substrate ACP: column: Supelco, Beta DexTM 110 (30m); 110 °C isothermal, carrier gas 
He, 15.3 psi, split 30:1. 
ACP = 10.4 min, (R) = 15.6 min, (S) = 16.4 min. 
Substrate 4-Me-ACP: column: Supelco, Beta DexTM 110 (30m); 120 °C isothermal, 
carrier gas He, 15.3 psi, split 30:1. 
4-Me-ACP = 9.4 min, (R) = 10.4 min, (S) = 11.0 min. 
 
Conversions and e.e. values of substrate PBK as determined by HPLC. Retention times 
are given for the reactant and both product enantiomers. 
Substrate PBK: column: Daicel, Chiraldex OD-H, temperature: 25 ºC, eluent: 
hexane/iPrOH 96:4, flow rate: 0.6 mL/min, detector: DAD, Sig = 230 nm, 8, ref = 360 nm, 
100. 
PBK = 17.6 min, (R) = 20.4 min, (S) = 25.8 min. 
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X-ray structure determination of (S,SOx,SFc)-18 
Orange single crystals of the (S,SOx,SFc)-18 were obtained from EA solution by slow 
evaporation of the solvent. X-ray data were collected on a Bruker Kappa APEX-2 CCD 
diffractometer with a cryostream cooler (Oxford Cryosystems) using graphite-
monochromatised Mo-Kα radiation (λ = 0.71073 Å) and 0.5° - and ω-scan frames 
covering complete Ewald spheres with max = 30° or 25° ((SOx,SFc)-23). The frames were 
integrated with program SAINT and corrections for absorption and λ/2 effects were 
applied with program SADABS. After structure solution with program SHELXS97 and 
direct methods, refinement on F2 was carried out with the program SHELXL97 
(Sheldrick, 2008). Non-hydrogen atoms were refined anisotropically. All H atoms were 
placed in calculated positions and thereafter refined as riding. The absolute structures of 
all compounds could be unambiguously determined by anomalous dispersion effects and 
the Flack absolute structure parameter. Crystallographic data are compiled in Table S1. 
A structural diagram of complex 18 is shown in Figure S1. Atomic coordinates and 
anisotropic displacement parameters are given in Tables S2–S4. For molecular graphics 
the programs XP (Bruker) and MERCURY (Macrae et al., 2006) were used. 
 
Bruker programs: APEX2; SAINT, version 7.68A; SADABS, version 2008/1; SHELXTL, 
version 2008/4; XP, version 5 (Bruker AXS Inc., Madison, WI, 2009). 
SHELXS97 and SHELXL97: G. M. Sheldrick, Acta Cryst. 2008, A64, 112-122.  
PLATON: Spek, A. L. (2003). J. Appl. Cryst. 36, 7–13. 
MERCURY: Macrae, C. F., Edgington, P. R., McCabe, P., Pidcock, E., Shields, G. P., 
Taylor, R., Towler, M. & van de Streek, J. (2006). J. Appl. Cryst. 39, 453–457. 
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Table S1. Crystal data and structure refinement for (S,SOx,SFc)-18. 
 (S,SOx,SFc)-18 
formula C18H23FeNO2 
fw 341.22 
cryst.size, mm 0.45 x 0.25 x 0.04  
crystal system Orthorhombic 
space group P21…(no. 3) 
a, Å 9.8793(3) 
b, Å 12.7041(4) 
c, Å 12.8138(4) 
α, deg 90 
β, deg 90 
γ, deg 90 
V, Å
3 
1608.23(9) 
T, K 100 
Z 4 
ρcalc, g cm
-3
 1.409 
µ, mm
-1
 (MoKα) 0.944 
F(000) 720 
absorption corrections multi-scan, 0.96–0.60 
θ range, deg 2.2–30.0 
no. of rflns measd / Rint 55009 / 0.069 
no. of rflns unique 4490 
no. of rflns I>2σ(I) 4490 
no. of params / restraints 203 
R1 (I > 2σ(I))  0.0266 
R1 (all data) 0.0311 
wR2 (I > 2σ(I)) 0.0655 
wR2 (all data) 0.0675 
Flack abs.str. param. -0.012(11) 
Diff.Four.peaks, min/max, eÅ
-
3
  
-0.43 / 0.59 
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Figure S1. Structural diagram of the asymmetric unit of (S,SOx,SFc)-18 showing 50% 
ellipsoids and the atom numbering. 
 
Table 2.  Bond lengths [Å] and angles [deg] for (S,SOx,SFc)-18. 
 
Bond distances 
 
Fe(1)-C(2)         2.0339(14) 
Fe(1)-C(1)         2.0438(16) 
Fe(1)-C(7)         2.0456(16) 
Fe(1)-C(8)         2.0458(17) 
Fe(1)-C(3)         2.0464(15) 
Fe(1)-C(9)         2.0509(16) 
Fe(1)-C(6)         2.0512(16) 
Fe(1)-C(10)        2.0517(16) 
Fe(1)-C(5)         2.0564(16) 
Fe(1)-C(4)         2.0571(16) 
O(1)-C(11)         1.4377(18) 
O(1)-H(1)          0.84 
O(2)-C(13)         1.3611(16) 
O(2)-C(15)         1.4581(16) 
N(1)-C(13)         1.2711(18) 
N(1)-C(14)         1.4802(17) 
C(1)-C(5)          1.4315(19) 
C(1)-C(2)          1.4395(19) 
C(1)-C(11)         1.517(2) 
C(2)-C(3)          1.4325(19) 
C(2)-C(13)         1.4590(17) 
C(3)-C(4)          1.424(2) 
C(3)-H(3)          0.95 
C(4)-C(5)          1.417(2) 
C(4)-H(4)          0.95 
C(5)-H(5)          0.95 
C(6)-C(7)          1.422(2) 
C(6)-C(10)         1.430(2) 
C(6)-H(6)          0.95 
C(7)-C(8)          1.416(2) 
C(7)-H(7)          0.95 
C(8)-C(9)          1.423(2) 
C(8)-H(8)          0.95 
C(9)-C(10)         1.423(2) 
C(9)-H(9)          0.95 
C(10)-H(10)        0.95 
C(11)-C(12)        1.511(2) 
C(11)-H(11)        1.00 
C(12)-H(12A)       0.98 
C(12)-H(12B)       0.98 
C(12)-H(12C)       0.98 
C(14)-C(16)        1.532(2) 
C(14)-C(15)        1.538(2) 
C(14)-H(14)        1.00 
C(15)-H(15A)       0.99 
C(15)-H(15B)       0.99 
C(16)-C(18)        1.526(2) 
C(16)-C(17)        1.527(2) 
C(16)-H(16)        1.00 
C(17)-H(17A)       0.98 
C(17)-H(17B)       0.98 
C(17)-H(17C)       0.98 
C(18)-H(18A)       0.98 
C(18)-H(18B)       0.98 
C(18)-H(18C)       0.98 
 
 
Bond  angles 
 
C(1)-Fe(1)-C(5)        40.87(5) 
C(2)-Fe(1)-C(1)        41.34(6) 
C(2)-Fe(1)-C(3)        41.10(5) 
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C(3)-Fe(1)-C(4)        40.60(6) 
C(5)-Fe(1)-C(4)        40.30(7) 
C(7)-Fe(1)-C(8)        40.50(6) 
C(8)-Fe(1)-C(9)        40.66(6) 
C(7)-Fe(1)-C(6)        40.61(6) 
C(9)-Fe(1)-C(10)       40.60(7) 
C(6)-Fe(1)-C(10)       40.80(6) 
C(11)-O(1)-H(1)       109.5 
C(13)-O(2)-C(15)      105.46(11) 
C(13)-N(1)-C(14)      107.33(11) 
C(5)-C(1)-C(2)        106.50(12) 
C(5)-C(1)-C(11)       127.33(12) 
C(2)-C(1)-C(11)       126.17(12) 
C(5)-C(1)-Fe(1)        70.04(9) 
C(2)-C(1)-Fe(1)        68.96(8) 
C(11)-C(1)-Fe(1)      126.05(11) 
C(3)-C(2)-C(1)        108.51(12) 
C(3)-C(2)-C(13)       125.87(12) 
C(1)-C(2)-C(13)       125.62(12) 
C(3)-C(2)-Fe(1)        69.92(8) 
C(1)-C(2)-Fe(1)        69.70(8) 
C(13)-C(2)-Fe(1)      127.01(11) 
C(4)-C(3)-C(2)        107.66(13) 
C(4)-C(3)-Fe(1)        70.10(9) 
C(2)-C(3)-Fe(1)        68.98(8) 
C(4)-C(3)-H(3)        126.2 
C(2)-C(3)-H(3)        126.2 
Fe(1)-C(3)-H(3)       126.3 
C(5)-C(4)-C(3)        108.18(13) 
C(5)-C(4)-Fe(1)        69.82(9) 
C(3)-C(4)-Fe(1)        69.30(9) 
C(5)-C(4)-H(4)        125.9 
C(3)-C(4)-H(4)        125.9 
Fe(1)-C(4)-H(4)       126.5 
C(4)-C(5)-C(1)        109.15(13) 
C(4)-C(5)-Fe(1)        69.88(10) 
C(1)-C(5)-Fe(1)        69.10(9) 
C(4)-C(5)-H(5)        125.4 
C(1)-C(5)-H(5)        125.4 
Fe(1)-C(5)-H(5)       127.2 
C(7)-C(6)-C(10)       107.58(14) 
C(7)-C(6)-Fe(1)        69.48(9) 
C(10)-C(6)-Fe(1)       69.62(9) 
C(7)-C(6)-H(6)        126.2 
C(10)-C(6)-H(6)       126.2 
Fe(1)-C(6)-H(6)       126.3 
C(8)-C(7)-C(6)        108.61(13) 
C(8)-C(7)-Fe(1)        69.76(9) 
C(6)-C(7)-Fe(1)        69.90(9) 
C(8)-C(7)-H(7)        125.7 
C(6)-C(7)-H(7)        125.7 
Fe(1)-C(7)-H(7)       126.2 
C(7)-C(8)-C(9)        107.82(14) 
C(7)-C(8)-Fe(1)        69.74(9) 
C(9)-C(8)-Fe(1)        69.86(9) 
C(7)-C(8)-H(8)        126.1 
C(9)-C(8)-H(8)        126.1 
Fe(1)-C(8)-H(8)       125.9 
C(8)-C(9)-C(10)       108.19(13) 
C(8)-C(9)-Fe(1)        69.48(9) 
C(10)-C(9)-Fe(1)       69.73(9) 
C(8)-C(9)-H(9)        125.9 
C(10)-C(9)-H(9)       125.9 
Fe(1)-C(9)-H(9)       126.5 
C(9)-C(10)-C(6)       107.80(14) 
C(9)-C(10)-Fe(1)       69.67(9) 
C(6)-C(10)-Fe(1)       69.58(9) 
C(9)-C(10)-H(10)      126.1 
C(6)-C(10)-H(10)      126.1 
Fe(1)-C(10)-H(10)     126.2 
O(1)-C(11)-C(12)      107.71(13) 
O(1)-C(11)-C(1)       110.51(12) 
C(12)-C(11)-C(1)      111.82(11) 
O(1)-C(11)-H(11)      108.9 
C(12)-C(11)-H(11)     108.9 
C(1)-C(11)-H(11)      108.9 
C(11)-C(12)-H(12A)    109.5 
C(11)-C(12)-H(12B)    109.5 
H(12A)-C(12)-H(12B)   109.5 
C(11)-C(12)-H(12C)    109.5 
H(12A)-C(12)-H(12C)   109.5 
H(12B)-C(12)-H(12C)   109.5 
N(1)-C(13)-O(2)       118.54(12) 
N(1)-C(13)-C(2)       125.55(13) 
O(2)-C(13)-C(2)       115.87(12) 
N(1)-C(14)-C(16)      111.28(11) 
N(1)-C(14)-C(15)      103.77(11) 
C(16)-C(14)-C(15)     114.82(13) 
N(1)-C(14)-H(14)      108.9 
C(16)-C(14)-H(14)     108.9 
C(15)-C(14)-H(14)     108.9 
O(2)-C(15)-C(14)      104.75(11) 
O(2)-C(15)-H(15A)     110.8 
C(14)-C(15)-H(15A)    110.8 
O(2)-C(15)-H(15B)     110.8 
C(14)-C(15)-H(15B)    110.8 
H(15A)-C(15)-H(15B)   108.9 
C(18)-C(16)-C(17)     110.77(13) 
C(18)-C(16)-C(14)     112.71(12) 
C(17)-C(16)-C(14)     110.20(14) 
C(18)-C(16)-H(16)     107.7 
C(17)-C(16)-H(16)     107.7 
C(14)-C(16)-H(16)     107.7 
C(16)-C(17)-H(17A)    109.5 
C(16)-C(17)-H(17B)    109.5 
H(17A)-C(17)-H(17B)   109.5 
C(16)-C(17)-H(17C)    109.5 
H(17A)-C(17)-H(17C)   109.5 
H(17B)-C(17)-H(17C)   109.5 
C(16)-C(18)-H(18A)    109.5 
C(16)-C(18)-H(18B)    109.5 
H(18A)-C(18)-H(18B)   109.5 
C(16)-C(18)-H(18C)    109.5 
H(18A)-C(18)-H(18C)   109.5 
H(18B)-C(18)-H(18C)   109.5 
 
 
Torsion angles 
 
C5-C1-C2-C3         -0.96(17) 
C11-C1-C2-C3       179.33(14) 
Fe1-C1-C2-C3        59.34(11) 
C5-C1-C2-C13       178.06(14) 
C11-C1-C2-C13       -1.6(2) 
Fe1-C1-C2-C13     -121.64(15) 
C5-C1-C2-Fe1       -60.30(11) 
C11-C1-C2-Fe1      119.99(15) 
C1-C2-C3-C4          0.47(18) 
C13-C2-C3-C4      -178.55(15) 
Fe1-C2-C3-C4        59.67(11) 
C1-C2-C3-Fe1       -59.20(10) 
C13-C2-C3-Fe1      121.78(15) 
C2-C3-C4-C5          0.23(18) 
Fe1-C3-C4-C5        59.19(12) 
C2-C3-C4-Fe1       -58.96(11) 
C3-C4-C5-C1         -0.84(19) 
Fe1-C4-C5-C1        58.03(11) 
C3-C4-C5-Fe1       -58.87(12) 
120
 S19 
C2-C1-C5-C4          1.11(18) 
C11-C1-C5-C4      -179.19(15) 
Fe1-C1-C5-C4       -58.50(12) 
C2-C1-C5-Fe1        59.61(10) 
C11-C1-C5-Fe1     -120.69(16) 
C10-C6-C7-C8         0.23(19) 
Fe1-C6-C7-C8       -59.20(11) 
C10-C6-C7-Fe1       59.43(11) 
C6-C7-C8-C9         -0.43(19) 
Fe1-C7-C8-C9       -59.73(12) 
C6-C7-C8-Fe1        59.29(11) 
C7-C8-C9-C10         0.47(19) 
Fe1-C8-C9-C10      -59.18(12) 
C7-C8-C9-Fe1        59.65(12) 
C8-C9-C10-C6        -0.33(19) 
Fe1-C9-C10-C6      -59.35(11) 
C8-C9-C10-Fe1       59.02(11) 
C7-C6-C10-C9         0.07(19) 
Fe1-C6-C10-C9       59.41(12) 
C7-C6-C10-Fe1      -59.34(11) 
C5-C1-C11-O1      -116.02(16) 
C2-C1-C11-O1        63.63(19) 
Fe1-C1-C11-O1      152.60(10) 
C5-C1-C11-C12        4.0(2) 
C2-C1-C11-C12     -176.39(15) 
Fe1-C1-C11-C12     -87.42(15) 
C14-N1-C13-O2       -2.75(19) 
C14-N1-C13-C2      179.58(14) 
C15-O2-C13-N1        0.34(18) 
C15-O2-C13-C2      178.23(13) 
C3-C2-C13-N1       166.58(16) 
C1-C2-C13-N1       -12.3(2) 
Fe1-C2-C13-N1     -102.59(17) 
C3-C2-C13-O2       -11.1(2) 
C1-C2-C13-O2       170.00(14) 
Fe1-C2-C13-O2       79.68(15) 
C13-N1-C14-C16    -120.25(14) 
C13-N1-C14-C15       3.75(17) 
C13-O2-C15-C14       2.11(16) 
N1-C14-C15-O2       -3.49(16) 
C16-C14-C15-O2     118.18(13) 
N1-C14-C16-C18      56.67(17) 
C15-C14-C16-C18    -60.82(16) 
N1-C14-C16-C17     -67.64(16) 
C15-C14-C16-C17    174.88(12) 
 
Hydrogen-bond 
  
 D-H...A                      d(D-H)      d(H...A)    d(D...A)    <(DHA) 
 O(1)-H(1)...N(1)             0.84        2.06        2.7912(16)  145.1 
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Synthesis of chiral, nonracemic ferrocene derivatives by ortho-
metallation and partial reductive removal of ortho-directing 
amino groups. 
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Abstract: Chiral, nonracemic 1,2-disubstituted ferrocenes have been prepared from 
monosubstituted ferrocene derivatives by amine-mediated ortho-directed reactions and 
subsequent partial reductive removal of the stereogenic ortho-directing group. It was 
found that the ortho-directing amino group of 2-substituted derivatives of N,N-
dimethylaminoethyl-ferrocene and similar compounds can – after quaternisation with 
methyl iodide – be reductively removed with sodium borohydride to give 2-substituted 
methyl- or ethylferrocenes. In most cases the substituents I, Br, COOEt, P(O)Ph2 and CN 
tolerate the reaction conditions used. In addition, a few examples are reported that show 
how the use of LiTMP allows 2-bromo- and especially 2-cyano-substituted derivatives to 
be further ortho-lithiated and reacted to give 1,2,3-trisubstituted ferrocenes.  
 
Keywords: ferrocenes, stereoselective synthesis, ortho-metallation, reduction, sodium 
borohydride 
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1. Introduction 
Chiral, nonracemic ferrocene derivatives have found widespread applications in 
a variety of different fields, including homogeneous enantioselective catalysis, 
bioorganometallic chemistry, polymers and dendrimers, electrooptical materials and 
thermotropic liquid crystals.1 In catalytic applications 1,2-disubstituted ferrocenes, as 
well as more highly substituted analogues, were found to give excellent results as 
catalyst ligands in enantioselectively catalysed reactions.1–4 Almost all synthetic 
approaches to ferrocene derivatives with such substitution patterns involve directed 
metallation, mainly directed ortho-lithiation steps.5 For example, 1,2-disubstituted 
enantiopure or highly enantiomerically enriched ferrocenes have been prepared by 
ortho-lithiation of a monosubstituted ferrocene Fc-R1, where R1 is either a stereogenic 
or, less frequently, a nonstereogenic ortho-directing substituent.6 In the latter case, 
chiral lithiation reagents such as an alkyllithium in the presence of (–)-sparteine have 
been used.7–9  
The ortho-metallation strategy has been extended further to the synthesis of 
chiral, nonracemic 1,2,3-trisubstituted ferrocene derivatives. Depending on the ortho-
directing properties of substituents R1 and R2 of the 1,2-disubstituted ferrocenes, a third 
substituent R3 can be introduced either next to R2 or next to R1 [Scheme 1, reactions (b) 
and (c)].10–15 
Fe
R1 R2
Fe
R1 R2
R3
Fe
R1
Fe
R1 R2
R3
(a) (b)
(c)
R1 =
Me
N
S
Me
O
N
O O
OMe
Me
 
Scheme 1. Synthesis routes to 1,2-di- and 1,2,3-trisubstituted ferrocenes. 
In 1970 Nozaki,16 as well as Ugi17 and co-workers, reported the first 
diastereoselective ortho-lithiation of a monosubstituted ferrocene derivative [lithiation of 
(S)-N-ferrocenylmethyl-2-methylpiperidine (Scheme 1) with butyllithium] and since that 
time a variety of stereogenic ortho-directing groups have been developed. The N,N-
dimethylaminoethyl group (Scheme 1), again introduced by Ugi,18 and the p-tolylsulfinyl- 
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and 4-methoxymethyl-1,3-dioxan-2-yl groups developed by Kagan19–23 have been the 
most frequently applied.  
Within the group of stereogenic ortho-directing substituents the p-tolylsulfinyl 
group holds a unique position since, to the best of our knowledge, it is the only ortho-
directing stereogenic ferrocene substituent that can be fully replaced by other 
electrophiles. This feature has been extensively used for the preparation of 1,2-
disubstituted ferrocene derivatives.24 For example, starting from p-tolylsulfinylferrocene, 
Kagan and co-workers synthesised purely ferrocene-stereogenic 1,2-disubstituted 
diphosphino-ferrocenes25 (Scheme 2, sequence 1, A), compounds that are difficult to 
prepare otherwise. These and other derivatives prepared from p-tolylsulfinyl-ferrocene 
have been very successfully applied as catalyst ligands in enantioselectively catalysed 
reactions.1,5,24 
Interestingly, replacement of the sulfinyl group by other electrophiles (Scheme 2, 
sequence 1, second step) works nicely on the small to medium laboratory scale, but 
unfortunately the process on the larger industrial scale proved to be difficult. In order to 
circumvent this problem, workaround strategies have been developed. For example, the 
synthesis of purely ferrocene-stereogenic diphosphines could be achieved by using a 
novel directing group that allows the introduction of different phosphino groups into the 
ortho-position and in a subsequent step the directing group can be transformed into a 
second set of phosphino units (Scheme 2, sequence 2).26,27 
An alternative approach has been used to achieve the same aim (Scheme 2, 
sequence 3). In a first ortho-directed reaction 2-bromo-N,N-dimethylaminoethyl-
ferrocene was prepared from N,N-dimethylaminoethylferrocene and in a subsequent 
two-step sequence the dimethylamino group was removed, thus transforming the ortho-
directing group into a noncoordinating ethyl group. Further ortho-lithiation adjacent to 
the bromide allowed the introduction of various phosphino units and subsequent 
bromide/lithium exchange enabled a second set of phosphino groups to be 
attached.28,29 Both approaches allowed the synthesis of a variety of diphosphines of 
types A and B (Scheme 2) in a very flexible way.  
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Scheme 2. 
In this context we envisaged that simplifying and extending the latter strategy to 
additional ortho-directing groups and substituents other than bromide could lead to a 
much broader applicability of this methodology.  
In this contribution we report a simple method for the partial removal of ortho-
directing amines in the presence of various substituents, which themselves are able to 
ortho-direct further metallation reactions. Several examples of such ortho-metallation 
reactions that led to chiral, nonracemic 1,2,3-trisubstituted ferrocenes as the final 
products are given. 
 
2. Results and discussion 
A three-step sequence for the preparation of chiral, nonracemic ferrocene derivatives 
was explored (Scheme 3). In the first step 1,2-disubstituted derivatives were synthesised 
by diastereoselective ortho-directed reactions (ODR). For this purpose the well-
established ferrocenyl amines (R)-2,18 (1R,2S)-3,30,31 and (R)-432 were used as the 
starting materials. In the second step, suitable reaction conditions for the reductive 
removal of the amino substituents were investigated and in a few cases possibilities for 
the synthesis of 1,2,3-trisubstituted ferrocenes through further ortho-directed reactions 
were explored. 
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O
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Scheme 3. 
 
2.1. Reductive removal of quaternised amino substituents 
The reduction of ferrocenylmethyl ammonium iodides to methylferrocenes with 
the use of sodium amalgam,33 sodium in liquid ammonia34 or sodium borohydride35 has 
been reported previously. Since a number of functional groups tolerate sodium 
borohydride as the reducing agent, its use for the removal of the amino substituents 
from derivatives of 2–4 seemed to be the most promising approach.  
In order to identify suitable reaction conditions, amines 1–4 were reacted with 
methyl iodide and the resulting ammonium salts were subjected to the reduction with 
sodium borohydride in different solvents (acetonitrile, dimethylsulfoxide, 
dimethylformamide) and at different reaction temperatures (80 °C, 100 °C). As shown in 
Table 1, the ammonium salts of all amines tested could be reduced in good (1) to 
excellent (2–4) yields to either methylferrocene (5) or ethylferrocene (6).  
Based on these promising results, the selective reduction of 2-substituted 
derivatives of 2–4 bearing various substituents [I, Br, COOEt, P(O)Ph2, CN] was 
investigated. Starting from enantiomerically pure amines (R)-2, (1R,2S)-3 and (R)-4 
(e.e. >99%), the 2-substituted derivatives (R,Sp)-7a–7e, (1R,2S,Rp)-8a–8e and (R,Rp)-
9a, 9c, 9e [a: I, b: Br, c: COOEt, d: P(O)Ph2, e: CN] were prepared by ortho-lithiation 
with tBuLi (236 and 330) or sBuLi (432) and an appropriate electrophile [Scheme 4; E: I2, 
BrCl2CCCl2Br, CO(OEt)2, ClPPh2 followed by H2O2, 4-CH3C6H4SO2CN]. It should be 
mentioned that the use of tosylcyanide as the electrophile gave the 2-cyano-substituted 
derivatives 7e, 8e and 9e in good to excellent yields (7e: 88%; 8e: 77%; 9e: 90%).37  
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Table 1: Isolated yields obtained in the reduction of the ammonium iodide salts of 1–4 
with NaBH4 
a 
amine product
b 
CH3CN 
80 °C 
DMSO 
100 °C 
DMF 
100 °C 
1
 
5 38 89 87 
2
 
6 98 89 94 
3
 
5 97 98 96 
4
 
5 99 94 96 
 a reaction time: 4 h; b 5: methylferrocene, 6: ethylferrocene  
All amines 7a–7e, 8a–8e and 9a, 9c, 9e were transformed with methyl iodide 
into their corresponding ammonium iodide salts, which were subjected to reductions 
with sodium borohydride. In most cases suitable reaction conditions could be found. 
The reaction conditions, products and yields are summarised in Table 2. All derivatives 
of amine 2 [(R,Sp)-7a–7e] were nicely reduced in acetonitrile at 80 °C to give products 
(Sp)-10a–10e in 79–96% isolated yield. The O-methylephedrine derivatives (1R,2S,Rp)-
8a–8d could be reduced in dimethylsulfoxide at 100 °C to give products (Rp)-11a–11d 
in 72–93% yield. Interestingly, in the reduction of the iodo- and bromo-derivatives 8a 
and 8b a rather small amount (<5%) of dehalogenated product (methylferrocene, 5) 
was obtained in addition to the expected products 11a and 11b. However, in the case of 
iodide 9a not only did the overall yield drop significantly but the dehalogenation side 
reaction became very pronounced. In this particular case, both facts severely restrict 
the synthetic applicability of this transformation. In addition, in contrast to the cyano 
derivative 7e, which could be reduced without difficulties to 10e, synthetically suitable 
reaction conditions have not yet been identified for the reduction of the analogous 
derivatives 8e and 9e. 
When the ammonium salt of ester 9c was reacted with NaBH4 in DMSO at 100 
°C the overall conversion was low and 11c was isolated in only 42% yield. However, an 
increase in the reaction temperature to 120 °C led to full conversion and the product 
was isolated in 80% yield. Interestingly, although the ammonium iodide salt of 
pyrrolidine derivative 4 can be reduced at 80 °C (Table 1), the reduction of its 2-
substituted derivatives requires significantly higher reaction temperatures. This effect is 
likely to be steric in nature but is much less pronounced for the corresponding O-
methylephedrine derivatives 8a–8d.  
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Scheme 4. Preparation of derivatives 7–11. 
  
2.2. Synthesis of 1,2,3-trisubstituted derivatives by ortho-directed reactions 
The substituents Br,11,38–40 COOEt,6,41–43 P(O)Ph2
41,44–46 and CN41 are well 
recognised ortho-directing groups. Therefore, the derivatives 10b–10e and 11b–11d 
should all be suitable starting materials for the preparation of chiral, nonracemic 1,2,3-
trisubstituted ferrocenes – including exclusively ferrocene-stereogenic (planar chiral) 
derivatives. In order to prove and extend this concept, a few examples of further ortho-
directed reactions have been explored without extensive optimisation of reaction 
conditions.  
According to our previously reported protocol,39 bromo derivatives (Sp)-10b and 
(Rp)-11b were ortho-deprotonated with 2 equivalents of lithium 2,2,6,6-
tetramethylpiperidide (LiTMP) and quenched with CO2 as the electrophile. These 
reactions gave the ferrocenecarbonic acids (Rp)-12 and (Sp)-14 in 77% and 73% yield, 
respectively (Scheme 5). Since acid 12 was accompanied by a small amount of by-
product (about 5%), it was transformed with diazomethane into the corresponding 
methyl ester (Rp)-13, which could be purified easily. Whereas ortho-lithiation of 
ferrocenylbromides has been applied several times for the synthesis of catalyst 
ligands28,29,38 – as well as for the preparation of pincer-type 1,3-disubstituted 
ferrocenes39,47 – to the best of our knowledge the ortho-metallation of ferrocenyl 
cyanides has been reported only once.41  
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Table 2: Reduction of the ammonium iodide salts of 7–9 with NaBH4
a 
amine solvent 
reaction 
temp. (°C) 
product 
Isolated yield 
(%) 
7a
 
CH3CN 80 10a 86 
7b
 
CH3CN 80 10b 96 
7c
 
CH3CN 80 10c 90 
7d
 
CH3CN 80 10d 79 
7e CH3CN 80 10e 91 
8a DMSO 100 11a 93 
8b DMSO 100 11b 92 
8c DMSO 100 11c 72 
8d DMSO 100 11d 78 
9a CH3CN 80 11a/5 36
b
 (64/36)
c 
9a DMSO 100 11a/5 68
b
 (61/39)
c
 
9a DMF 100 11a/5 50
b
 (0/100)
c
 
9c DMSO 100 11c 42 
9c DMSO 120 11c 80 
 
a reaction time: 4 h; b conversion; c ratio of 11a/5 as determined by 1H-NMR 
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Scheme 5. Synthesis of 1,2,3-substituted ferrocenes 12–15. 
It has been shown that ferrocenyl cyanides can be ortho-magnesiated with TMP-
MgCl.LiCl and further reacted with electrophiles to give 2-substituted 
cyanoferrocenes.
41
 Interestingly, the application of our ortho-lithiation protocol for 
bromides to cyanide derivative (Sp)-10e, followed by quenching with ClPPh2 as the 
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electrophile, gave product (Sp)-15 in 91% yield, thus providing an alternative route to 
ortho-substituted cyanoferrocenes.  
It is worth mentioning that not only the disubstituted ferrocenes 10a–10e and 11a–11d 
but also all derivatives 12–15 can serve as precursors for the preparation of catalyst 
ligands, e.g. for the synthesis of ferrocenyl phosphinooxazolines.
48–52
   
 
3. Conclusion 
A number of 1,2-disubstituted ferrocene derivatives have been prepared starting 
from the monosubstituted and ortho-directing ferrocenyl amines (R)-2, (1R,2S)-3 and 
(R)-4. Quaternisation of their amino-nitrogen with methyl iodide and subsequent 
reduction with sodium borohydride led to the removal of the ortho-directing amino-
substituents to give to 2-substituted chiral, nonracemic methyl- or ethylferrocenes. In 
most cases, ortho-substituents I, Br, COOEt, P(O)Ph2 and CN were found to tolerate 
the reaction conditions used. Furthermore, it was shown in a few examples that 2-
bromo- and, most interestingly, 2-cyano-methyl (or ethyl)ferrocene can be further ortho-
deprotonated next to the bromo and the cyano group by treatment with LiTMP. The 
subsequent reaction of these intermediates with an appropriate electrophile gave chiral, 
nonracemic 1,2,3-substituted ferrocene derivatives. In particular, we consider the 
deaminated 1,2-disubstituted ferrocenes 10a–10e, 11a–11d and similar derivatives to 
be useful starting materials for the synthesis of chiral, nonracemic ferrocenes for use 
as, for example, phosphino- or oxazoline-based catalysts ligands.  
 
4. Experimental 
4.1. General methods 
NMR spectra were recorded on a Bruker DPX-400 spectrometer in CDCl3 or 
DMSO-d6. Chemical shifts (δ) are given relative to CHCl3 (
1H: 7.26 ppm), CDCl3 (
13C: 
77.0 ppm), DMSO (1H: 2.50 ppm), CDCl3 (
13C: 39.5 ppm) or 85% H3PO4 (
31P: 0 ppm). 
The coupling constants in 13C{1H} spectra are due to 13C-31P coupling. For signal 
assignment the following terms were used: s, bs, d, dd, t, q and m refer to singlet, broad 
singlet, doublet, doublet of doublets, triplet, quartet and multiplet, respectively. The 
terms PhA-C were used for phenyl units. In this respect, superscripts A and B were used 
to distinguish between rings attached to phosphorus atoms. A general atom numbering 
scheme used for proton and carbon assignment only is given in Figure 1. Melting points 
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were determined on a Kofler melting point apparatus and are uncorrected. Mass 
spectra were recorded on Finnigan MAT 900 and MAT 95 spectrometers. Optical 
rotations were measured on a Perkin-Elmer 241 polarimeter. All reactions required inert 
conditions and were carried out under an argon atmosphere using standard Schlenk 
techniques. All solvents were dried according to standard procedures and distilled 
before use. Chromatographic separations were performed under gravity either on silica 
(MERCK, 40–63 µm) or on standardized aluminium oxide 90 (MERCK). Petroleum 
ether with a boiling range of 55–65 °C was used for chromatography. Abbreviations: 
PE: petroleum ether, DEE: diethyl ether, EA: ethyl acetate; TEA: triethylamine. 
Fe
R1 R2
R3
R1 = amine, Me or Et
1 2
3
5
4
Cp'
 
Figure 1: Numbering scheme (for NMR signal assignment only) 
 
4.2. Synthesis of ferrocenes (R,Sp)-7a–7e, (1R,2S,Rp)-8a–8e and (R,Rp)-9a, 9c, 9e 
Compounds (R,Sp)-7a,
53 7b,54 7c,55 7d15 were synthesised from (R)-2, (1R,2S,Rp)-8a,
31 
8b31 from (1R,2S)-3, and (R,Rp)-9a,
56 9c57 from (R)-4 according to reported procedures. 
4.2.1. (R,Sp)-N-1-(2-Cyano-ferrocenyleth-1-yl)-N,N-dimethylamine (R,Sp)-7e 
To a solution of (R)-2 (500 mg, 1.94 mmol) in diethyl ether (15 mL) was added dropwise 
a solution of tBuLi in pentane (1.7 M, 1.26 mL, 2.14 mmol) at –78 °C. The reaction 
mixture was stirred at –78 °C for 1 h and then at r.t. for a further 3 h. The mixture was 
added to a solution of tosyl cyanide (703 mg, 3.88 mmol) in THF (10 mL) at –78 °C. 
After 20 min at –78 °C, the solution was allowed to warm up to r.t. and an aqueous 
solution of NaOH (0.5 M, 5 mL) was added. After stirring for an additional 15 min, the 
mixture was poured into a solution of NaOH (1 M, 150 mL). The phases were separated 
and the aqueous phase was extracted with diethyl ether (3 × 50 mL). The combined 
organic phases were washed with brine and dried over MgSO4. The solvents were 
removed under reduced pressure and the residue was purified by chromatography on 
silica with PE/EA/TEA = 30/10/1 as eluent to give the title compound as orange crystals 
(483 mg, 88% yield). mp 85 °C. [α]20λ (nm) = –33.9 (589), –30.4 (578), –6.8 (546) (c 
0.280, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.54 (d, J = 6.8 Hz, 3H, CHCH3), 2.10 [s, 
6H, N(CH3)2], 3.75 (q, J = 6.8 Hz, 1H, CHCH3), 4.27 (s, 5H, Cp'), 4.33 (dd, J = 2.5 Hz, J 
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= 1.3 Hz, 1H, H5), 4.37 (t, J = 2.5 Hz, 1H, H4), 4.64 (dd, J = 2.5 Hz, J = 1.3 Hz, 1H, 
H3). 13C{1H} NMR (100.6 MHz, CDCl3) δ: 17.4 (CHCH3), 41.2 [N(CH3)2], 53.1 (C2), 57.6 
(CHCH3), 69.2 (C5), 69.5 (C4), 70.9 (C3), 71.1 (Cp'), 90.4 (C1), 120.4 (CN). HR-MS (EI, 
30 °C): m/z [M]+ calcd 282.0819 for C15H18FeN2; found 282.0811. 
4.2.2. (1R,2S,Rp)-N-(2-Ethoxycarbonyl-ferrocenylmethyl)-N-methyl-1-methoxy-1-
phenylprop-2-ylamine (1R,2S,Rp)-8c 
A solution of (1R,2S)-3 (5.00 g, 13.25 mmol) in pentane (100 mL) was cooled to –78 °C 
and the resulting suspension was treated with a solution of tBuLi in pentane (1.7 M, 
9.35 mL, 15.90 mmol). Stirring was continued at this temperature for 1.5 h followed by 
warming to –30 °C and stirring for an additional 2.5 h. The mixture was again cooled to 
–78 °C and diethyl carbonate (35 mL) was added in one portion with vigorous stirring. 
The reaction was kept at –78 °C for 30 min and at r.t. for 1 h. Addition of water led to 
phase separation and the aqueous phase was extracted with diethyl ether. The 
combined organic extracts were washed with water and brine, dried over MgSO4 and 
the solvents were evaporated. The crude product was chromatographed on aluminium 
oxide 90 using PE/DE/TEA = 80/20/1 as the eluent to give the title compound as a red 
oil (4.26 g, 72% yield). [α]20λ (nm) = –22.9 (589), –23.5 (578), –27.0 (546) (c 0.808, 
CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.08 (d, J = 6.8 Hz, 3H, CHCH3), 1.32 (t, J = 7.1 
Hz, 3H, CH2CH3), 2.26 (s, 3H, NCH3), 2.88–2.97 (m, 1H, CHCH3), 3.23 (s, 3H, OCH3), 
3.57 (d, J = 13.9 Hz, 1H, CHAHB), 3.99 (d, J = 13.9 Hz, 1H, CHAHB), 4.06 (s, 5H, Cp'), 
4.17–4.28 (m, 5H, H5 + H4 + CH2CH3 + CHOCH3), 4.68–4.72 (m, 1H, H3), 7.17–7.32 
(m, 5H, Ph). 13C{1H} NMR (100.6 MHz, CDCl3) δ: 9.5 (s, CHCH3), 11.6 (s, CH2CH3), 
37.0 (s, NCH3), 53.0 (s, CH
AHB), 56.7 (OCH3), 59.8 (CH2CH3), 63.3 (CHCH3), 69.3 (C4), 
69.4 (C1/C2), 70.2 (Cp'), 70.7 (C3), 73.9 (C5), 85.1 (CHOCH3), 88.8 (C1/C2), 126.9 
(Ph-para), 127.0 (Ph-ortho), 127.9 (Ph-meta), 141.7 (Ph-ipso), 171.9 (C=O). HR-MS 
(ESI): m/z [M + H]+ calcd 450.1732 for C25H32FeNO3; found 450.1713.  
4.2.3. (1R,2S,Rp)-N-(2-Diphenylphosphinyl-ferrocenylmethyl)-N-methyl-1-methoxy-
1-phenylprop-2-ylamine (1R,2S,Rp)-8d 
To a stirred solution of (1R,2S,Rp)-N-(2-diphenylphosphino-ferrocenylmethyl)-N-methyl-
1-methoxy-1-phenylprop-2-ylamine31 (7.44 g, 13.25 mmol) in acetone (100 mL) was 
added a 30% solution of hydrogen peroxide in water (12 mL). Stirring was continued for 
1 h at r.t. and excess peroxide was decomposed by dropwise addition of saturated 
aqueous Na2S2O3 (20 mL). Acetone was then removed under reduced pressure and the 
residue was extracted with dichloromethane (2 × 50 mL). The combined organic 
extracts were washed with water and brine, dried over MgSO4 and the solvents were 
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removed on a rotary evaporator. The crude phosphine oxide was purified by 
chromatography on aluminium oxide 90 using EA as the eluent to give the title 
compound as an orange-yellow semisolid (5.98 g, 78% yield). [α]20λ (nm) = +45.0 (589), 
+45.7 (578), +41.5 (546) (c 1.230, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 0.73 (d, J = 6.8 
Hz, 3H, CHCH3), 1.98 (s, 3H, NCH3), 2.70–2.78 (m, 1H, CHCH3), 3.17 (s, 3H, OCH3), 
3.49 (d, J = 13.9 Hz, 1H, CHAHB), 3.80 (d, J = 13.9 Hz, 1H, CHAHB), 3.79–3.82 (m, 1H, 
H3), 4.06–4.10 (m, 1H, CHOCH3), 4.16 (s, 5H, Cp'), 4.19–4.23 (m, 1H, H4), 4.31–4.34 
(m, 1H, H5), 7.16–7.20 (m, 2H, PhC-ortho), 7.20–7.25 (m, 1H, PhC-para), 7.27–7.36 (m, 
4H, PhB-meta + PhC-meta), 7.37–7.42 (m, 1H, PhB-para), 7.42–7.53 (m, 3H, PhA-meta + 
PhA-para), 7.57–7.64 (m, 2H, PhB-ortho), 7.74–7.81 (m, 2H, PhA-ortho). 13C{1H} NMR 
(100.6 MHz, CDCl3) δ: 8.8 (CHCH3), 35.9 (NCH3), 53.7 (CH
AHB), 56.4 (OCH3), 64.1 
(CHCH3), 69.3 (d, J = 11.3 Hz, C4), 70.2 (Cp'), 71.3 (d, J = 115.0 Hz, C2), 73.6 (d, J = 
15.2 Hz, C3), 73.8 (d, J = 10.0 Hz, C5), 84.8 (CHOCH3), 91.3 (d, J = 10.7 Hz, C1), 
126.69 (PhC-para), 126.74 (PhC-ortho), 127.8 (d, J = 6.1 Hz, PhA/B-meta), 127.88 (PhC-
meta), 127.9 (d, J = 5.6 Hz, PhA/B-meta), 131.0 (d, J = 2.5 Hz, PhA/B-para), 131.1 (d, J = 
2.5 Hz, PhA/B-para), 131.48 (d, J = 9.5 Hz, PhA/B-ortho), 131.51 (d, J = 9.9 Hz, PhA/B-
ortho), 134.1 (d, J = 99.4 Hz, PhA-ipso), 135.2 (d, J = 101.0 Hz, PhB-ipso), 141.9 (s, 
PhC-ipso). 31P NMR (162 MHz, CDCl3) δ: 29.6 (P(O)Ph2). HR-MS (ESI): m/z [M + H]
+ 
calcd 578.1912 for C34H37FeNO2P; found 578.1916.  
4.2.4. (1R,2S,Rp)-N-(2-Cyano-ferrocenyl)-N-methyl-1-methoxy-1-phenylprop-2-
ylamine (1R,2S,Rp)-8e 
A solution of (1R,2S)-3 (5.00 g, 13.25 mmol) in pentane (100 mL) was cooled to –78 °C 
and the resulting suspension was treated with a solution of tBuLi in pentane (1.7 M, 
9.35 mL, 15.90 mmol). Stirring was continued at this temperature for 1.5 h followed by 
warming to 0 °C and stirring was continued for a further 2.5 h. The mixture was again 
cooled to –78 °C and a solution of tosylcyanide (3.60 g, 19.87 mmol) in THF (10 mL) 
was added dropwise with stirring. The reaction was warmed to r.t. and stirred for a 
further 1 h. Addition of water led to phase separation and the aqueous phase was 
extracted with diethyl ether. The combined organic extracts were washed with water 
and brine, dried over MgSO4 and the solvents were evaporated. The crude product was 
chromatographed on silica using DEE as eluent to give the title compound as a dark red 
oil (4.12 g, 77% yield). [α]20λ (nm) = –32.6 (589), –37.9 (578), –57.1 (546) (c 0.298, 
CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.07 (d, J = 6.8 Hz, 3H, CHCH3), 2.25 (s, 3H, 
NCH3), 2.78–2.88 (m, 1H, CHCH3), 3.27 (s, 3H, OCH3), 3.56–3.67 (m, 2H, CH
AHB), 4.23 
(s, 5H, Cp'), 4.24–4.30 (m, 3H, H4 + H5 + CHOCH3), 4.54–4.57 (m, 1H, H3), 7.20–7.27 
(m, 3H, Ph-ortho + Ph-para), 7.28–7.34 (m, 2H, Ph-meta). 13C{1H} NMR (100.6 MHz, 
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CDCl3) δ: 8.9 (CHCH3), 37.6 (NCH3), 52.1 (CH
AHB), 53.3 (C2), 56.7 (OCH3), 63.7 
(CHCH3), 69.7 (C4), 71.0 (Cp'), 71.3 (C3), 72.1 (C5), 85.3 (CHOCH3), 89.5 (C1), 119.8 
(C≡N), 126.9 (Ph-ortho), 127.0 (Ph-para), 128.0 (Ph-meta), 141.4 (Ph-ipso). HR-MS 
(ESI): m/z [M + H]+ calcd 403.1473 for C23H27FeN2O; found 403.1478.  
4.2.5. (R,Rp)-N-(2-Cyano-ferrocenylmethyl)-2-methoxymethyl-pyrrolidine (R,Rp)-9e 
To a stirred solution of (R)-432 (5.00 g, 15.96 mmol) in diethyl ether (80 mL) was added 
dropwise at –78 °C a solution of sBuLi in cyclohexane (1.4 M, 13.7 mL, 19.15 mmol). 
The resulting mixture was stirred for 1.5 h at –78 °C and for an additional 1.5 h at –30 
°C. During this time an orange suspension evolved and this was again cooled to –78 °C 
followed by addition of a solution of tosyl cyanide (4.34 g, 23.94 mmol) in diethyl ether 
(60 mL). Stirring was continued for an additional 30 min at –78 °C. The mixture was 
warmed to r.t. and quenched by the addition of water. The aqueous phase was made 
basic with an aqueous sodium hydroxide solution and the product was extracted with 
diethyl ether (2 × 100 mL). The combined organic extracts were washed with water and 
brine, dried over MgSO4 and the solvents were evaporated. The crude product was 
subjected to chromatography on silica using PE/EA/TEA = 10/1/1 → 2/1/1 as the eluent 
to give the title compound as a red oil (4.88 g, 90% yield). [α]20λ (nm) = +79.6 (589), 
+79.3 (578), +63.5 (546) (c 0.690, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.50–1.75 (m, 
3H, NCH2CH2CHH), 1.75–1.90 (m, 1H, NCH2CH2CHH), 2.18–2.30 (m, 1H, NCHH), 
2.62–2.75 (m, 1H, NCH), 2.95–3.03 (m, 1H, NCHH), 3.29 (dd, J = 9.4 Hz, J = 5.4 Hz, 
1H, CH3OCHH), 3.37 (s, 3H, CH3), 3.42 (dd, J = 9.4 Hz, J = 5.4 Hz, 1H, CH3OCHH), 
3.59 (d, J = 13.5 Hz, 1H, FcCHH), 3.99 (d, J = 13.5 Hz, 1H, FcCHH), 4.28 (s, 5H, Cp'), 
4.30–4.34 (m, 1H, H4), 4.41–4.47 (m, 1H, H5), 4.59–4.64 (m, 1H, H3). 13C{1H} NMR 
(100.6 MHz, CDCl3) δ: 22.7 (NCH2CH2), 28.4 (NCH2CH2CH2), 51.8 (FcCH2), 53.7 (C2), 
54.2 (NCH2), 59.1 (CH3), 61.7 (NCH), 70.0 (C4), 71.0 (Cp'), 71.6 (C3), 72.3 (C5), 76.4 
(CH3OCH2), 87.8 (C1), 119.7 (s, C≡N). HR-MS (ESI): m/z [M + H]
+ calcd 339.1160 for 
C18H23FeN2O; found 339.1158. 
4.3. General procedure for the preparation of the ammonium iodide salts of 
(R,Sp)-7a–7e, (1R,2S,Rp)-8a–8d and (R,Rp)-9a, 9c 
To a solution of amines (R,Sp)-7a–7e, (1R,2S,Rp)-8a–8d or (R,Rp)-9a,9c (10 mmol) in 
anhydrous acetonitrile (50 mL) was added dropwise methyl iodide (30 mmol) and the 
mixture was stirred at r.t. for 1 h. In the cases of 7a, 7b, 8a, 8b and 9a diethyl ether 
(100 mL) was added and a yellow precipitate was formed. After stirring for an additional 
30 min the precipitate was filtered off, washed with diethyl ether and dried under 
vacuum to give a crystalline solid. In the cases of 7c–7e, 8c, 8d and 9c all volatiles 
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were removed, the residues were dried under vacuum and the remaining yellow salts 
were used without further purification.  
4.4. General procedure for the preparation of (Sp)-10a–10e 
The ammonium iodide salts (10 mmol) of (R,Sp)-7a–7e (prepared according to the 
general procedure 4.3.) were suspended in anhydrous acetonitrile (50 mL) and NaBH4 
(30 mmol) was added in portions. The resulting mixture was stirred for 4 h at 80 °C. The 
reaction mixture was cooled to r.t. and was quenched with water (30 mL). Diethyl ether 
was added, the phases were separated and the organic phase was washed with water 
(3×) and brine. After drying with MgSO4 the solvent was removed under reduced 
pressure and the crude product was purified by chromatography on aluminium oxide 
90. 
4.4.1. (Sp)-2-Ethyl-1-iodo-ferrocene (Sp)-10a 
The crude product prepared from the ammonium iodide salt of (R,Sp)-7a (676 mg, 1.29 
mmol) and NaBH4 (146 mg, 3.86 mmol) was purified by chromatography on aluminium 
oxide 90 with eluent PE/EA = 9/1 to give the title compound as a red oil (375 mg, 86% 
yield). [α]20λ (nm) = –5.2 (589), –3.3 (578), +16.6 (546) (c 0.484, CHCl3). 
1H NMR (400 
MHz, CDCl3) δ: 1.16 (t, J = 7.5 Hz, 3H, CH2CH3), 2.32–2.45 (m, 2H, CH2CH3), 4.10 (s, 
5H, Cp'), 4.11–4.14 (m, 2H, H4 + H5), 4.37 (dd, J = 2.3 Hz, J = 1.5 Hz, 1H, H3). 13C{1H} 
NMR (100.6 MHz, CDCl3) δ: 14.5 (CH2CH3), 23.1 (CH2CH3), 45.3 (C2), 66.2 (C5), 67.6 
(C4), 71.4 (Cp'), 73.8 (C3), 91.8 (C1). HR-MS (EI, 30 °C): m/z [M]+ calcd 339.9411 for 
C12H13FeI; found 339.9410. 
4.4.2. (Sp)-1-Bromo-2-ethyl-ferrocene (Sp)-10b
29 
The crude product prepared from the ammonium iodide salt of (R,Sp)-7b (2.74 g, 5.74 
mmol) and NaBH4 (651 mg, 17.20 mmol) was purified by chromatography on aluminium 
oxide 90 with eluent PE/EA = 9/1 to give the title compound as a yellow oil (1.62 g, 96% 
yield). [α]20λ (nm) = –2.5 (589), –1.7 (578), +8.3 (546) (c 0.485, CHCl3). 
1H NMR (400 
MHz, CDCl3) δ: 1.17 (t, J = 7.5 Hz, 3H, CH2CH3), 2.44 (q, J = 7.5 Hz, 2H, CH2CH3), 4.01 
(t, J = 2.5 Hz, 1H, H4), 4.05–4.08 (m, 1H, H5), 4.14 (s, 5H, Cp'), 4.35–4.39 (dd, J = 2.5 
Hz, J = 1.4 Hz, 1H, H3). 13C{1H} NMR (100.6 MHz) δ: 14.4 (CH2CH3), 21.4 (CH2CH3), 
65.1 (C4), 65.6 (C5), 69.4 (C3), 71.0 (Cp'), 79.8 (C2), 89.3 (C1). HR-MS (EI, 30 °C): 
m/z [M]+ calcd 291.9552 for C12H13FeBr; found 291.9553. 
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4.4.3. (Sp)-1-Ethoxycarbonyl-2-ethyl-ferrocene (Sp)-10c 
The crude product prepared from amine (R,Sp)-7c (2 g, 6.075 mmol) and NaBH4 (689 
mg, 18.22 mmol) was purified by chromatography on aluminium oxide 90 with eluent 
PE/EA = 15/1 to give the title compound as a red oil (1.56 g, 90% yield). [α]20λ (nm) = –
15.5 (589), +12.3 (578), +17.8 (546) (c 0.252, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 
1.17 (t, J = 7.3 Hz, 3H, CH2CH3), 1.36 (t, J = 7.3 Hz, 3H, OCH2CH3), 2.61–2.72 (m, 1H, 
CHAHBCH3), 2.74–2.85 (m, 1H, CH
AHBCH3), 4.12 (s, 5H, Cp'), 4.19–4.35 (m, 2H, 
OCH2CH3), 4.24 (t, J = 2.5 Hz, 1H, H4), 4.31–4.33 (m, 1H, H5), 4.75 (dd, J = 2.5 Hz, J = 
1.6 Hz, 1H, H3). 13C{1H} NMR (100.6 MHz, CDCl3) δ: 14.5 (OCH2CH3), 15.0 (CH2CH3), 
21.9 (CH2CH3), 59.7 (OCH2CH3), 68.7 (C4), 69.1 (C2), 70.0 (Cp'), 70.5 (C3), 71.4 (C5), 
93.5 (C1), 172.4 (C=O). HR-MS (ESI): m/z [M]+ calcd 286.0656 for C15H18FeO2; found 
286.0659. 
4.4.4. (Sp)-1-Diphenylphosphinyl-2-ethyl-ferrocene (Sp)-10d
15 
The crude product prepared from amine (R,Sp)-7d (2.285 g, 4.996 mmol) and NaBH4 
(0.582 g, 1.54 mmol) was purified by chromatography on aluminium oxide 90 with EA 
as the eluent to provide the title compound as a yellow solid (1.64 g, 79% yield); mp 
150 °C. [α]20λ (nm) = –115.7 (589), –117.1 (578), –128.8 (546) (c 0.281, CHCl3). 
1H 
NMR (400 MHz, CDCl3) δ: 0.97 (t, J = 7.5 Hz, 3H, CH2CH3), 2.32–2.43 (m, 1H, 
CHAHBCH3), 2.59–2.70 (m, 1H, CH
AHBCH3), 3.73–3.77 (m, 1H, H3), 4.22–4.25 (m, 1H, 
H4), 4.27 (s, 5H, Cp'), 4.39–4.43 (m, 1H, H5), 7.44–7.42 (m, 2H, PhB-meta), 7.43–7.55 
(m, 4H, PhA-meta + PhA-para + PhB-para), 7.57–7.65 (m, 2H, PhB-ortho), 7.71–7.79 (m, 
2H, PhA-ortho). 13C{1H} NMR (100.6 MHz, CDCl3) δ: 15.2 (CH2CH3), 22.2 (CH2CH3), 
69.1 (d, J = 11.5 Hz, C5), 70.0 (Cp'), 71.2 (d, J = 10.4 Hz, C4), 71.7 (d, J = 114.5 Hz, 
C2), 73.5 (d, J = 15.7 Hz, C3), 95.2 (d, J = 11.5 Hz, C1), 128.0 (d, J = 12.3 Hz, PhA-
meta), 128.2 (d, J = 12.3 Hz, PhA-meta), 131.2–131.4 (m, PhA-para + PhB-para), 131.5 
(d, J = 10.0 Hz, 2C-ortho), 131.6 (d, J = 10.0 Hz, 2C-ortho), 133.9 (d, J = 88.8 Hz, PhA- 
ipso), 134.9 (d, J = 88.8 Hz, PhB - ipso). 31P NMR (162.6 MHz, CDCl3) δ: 31.3 
[P(O)PPh2]. HR-MS (EI, 30 °C): m/z [M]
 + calcd 414.0836 for C24H23FePO; found 
414.0823. 
4.4.5. (Sp)-1-Cyano-2-ethyl-ferrocene (Sp)-10e 
The crude product prepared from amine (R,Sp)-7e (2.485 g, 8.81 mmol) and NaBH4 
(999 mg, 26.4 mmol) was purified by chromatography on aluminium oxide 90 with 
eluent PE/EA = 9/1 to give the title compound as a red oil (1.91 g, 91% yield). [α]20λ 
(nm) = +24.3 (589), +34.8 (578), +103.7 (546) (c 0.485, CHCl3). 
1H NMR (400 MHz, 
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CDCl3) δ: 1.23 (t, J = 7.6 Hz, 3H, CH2CH3), 2.46–2.60 (m, 2H, CH2CH3), 4.25–4.27 (m, 
1H, H4), 4.27 (s, 5H, Cp'), 4.29–4.33 (m, 1H, H5), 4.57 (dd, J = 2.5 Hz, J = 1.3 Hz, 1H, 
H3). 13C{1H} NMR (100.6 MHz, CDCl3) δ: 14.9 (CH2CH3), 21.4 (CHCH3), 52.2 (C2), 69.2 
(C5), 69.6 (C3), 70.7 (C4), 70.8 (Cp'), 94.6 (C1), 120.0 (C≡N). HR-MS (ESI): m/z [M]+ 
calcd 239.0397 for C13H13FeN; found 239.0398. 
4.5. General procedure for the preparation of (Rp)-11a–11d 
To a stirred suspension of the ammonium iodide salts of (1R,2S,Rp)-8a–8d and (R,Rp)-
9c (5 mmol, prepared according to the general procedure 4.3., in dimethyl sulfoxide (10 
mL) was added sodium borohydride (15 mmol) in portions. The resulting mixture was 
heated to 100 °C (8a–8d) or 120 °C (9c) for 4 h and was subsequently cooled to r.t., 
diluted with water (200 mL) and extracted with diethyl ether (2 × 100 mL). The 
combined organic extracts were washed with water and brine, dried over MgSO4 and 
the solvents were removed under reduced pressure. The crude product was purified by 
column chromatography on silica or aluminium oxide 90.  
4.5.1. (Rp)-1-Iodo-2-methyl-ferrocene (Rp)-11a 
The crude product obtained from the ammonium iodide salt of (1R,2S,Rp)-8a (1.00 g, 
1.550 mmol) and sodium borohydride (176 mg, 4.650 mmol) in dimethyl sulfoxide (4 mL) 
was purified by filtration through a short plug of aluminium oxide 90 using PE as the 
eluent. The product was obtained as an orange solid (470 mg, 93% yield). mp 44–47 °C. 
[α]20λ (nm) = +29.9 (589), +30.1 (578), +22.9 (546) (c 0.708, CHCl3). 
1H NMR (400 MHz, 
CDCl3) δ: 2.02 (s, 3H, CH3), 4.09 (s, 5H, Cp'), 4.08–4.11 (m, 1H, H4), 4.14–4.17 (m, 1H, 
H5), 4.34–4.37 (m, 1H, H3). 13C{1H} NMR (100.6 MHz, CDCl3) δ: 15.7 (CH3), 46.5 (C2), 
67.7 (C4/C5), 67.9 (C4/C5), 71.6 (Cp'), 73.7 (C3), 85.9 (C1). HR-MS (ESI): m/z [M]+ 
calcd 325.9255 for C11H11FeI; found 325.9248. 
4.5.2. (Rp)-1-Bromo-2-methyl-ferrocene (Rp)-11b
58 
The crude product obtained from the ammonium iodide salt of (1R,2S,Rp)-8b (5.03 g, 
8.409 mmol) and sodium borohydride (1.00 g, 26.43 mmol) in dimethyl sulfoxide (20 mL) 
was purified by filtration through a short plug of aluminium oxide 90 using PE as eluent. 
Traces of methylferrocene were removed by heating the mixture in a bulb to bulb 
distillation apparatus under vacuum at 50 °C for 1 h. The remaining pure product was 
obtained as an orange solid (2.16 g, 92% yield). mp 70–74 °C. [α]20λ (nm) = +26.6 (589), 
+27.0 (578), +24.9 (546) (c 0.957, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 2.05 (s, 3H, 
CH3), 3.97–4.00 (m, 1H, H4), 4.07–4.10 (m, 1H, H5), 4.13 (s, 5H, Cp'), 4.33–4.36 (m, 1H, 
H3). 13C{1H} NMR (100.6 MHz, CDCl3) δ: 13.7 (CH3), 65.1 (C4), 67.4 (C5), 69.2 (C3), 
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71.1 (Cp'), 80.6 (C1/C2), 83.1 (C1/C2). HR-MS (ESI): m/z [M]+ calcd 277.9395 for 
C11H11BrFe; found 277.9393.  
4.5.3. (Rp)-1-Ethoxycarbonyl-2-methyl-ferrocene (Rp)-11c 
The crude product obtained from amine (1R,2S,Rp)-8c (4.172 g, 9.284 mmol) and NaBH4 
(1.054 g, 27.85 mmol) was purified by column chromatography on silica using PE/EA = 
10/1 as the eluent to give the title compound as an orange oil (2.155 g, 85% yield). [α]20λ 
(nm) = +22.1 (589), +18.8 (578), –6.3 (546) (c 0.521, CHCl3). 
1H NMR (400 MHz, CDCl3) 
δ: 1.37 (t, J = 7.1 Hz, 3H, CH2CH3), 2.27 (s, 3H, CH3), 4.12 (s, 5H, Cp'), 4.21–4.23 (m, 
1H, H4), 4.23–4.34 (m, 3H, H5 + CH2CH3), 4.70–4.73 (m, 1H, H3). 
13C{1H} NMR (100.6 
MHz, CDCl3) δ: 14.59, 14.63 (CH2CH3 + CH3), 59.8 (CH2CH3), 68.8 (C4), 69.7 (C2), 70.3 
(C3), 70.4 (Cp'), 73.6 (C5), 87.0 (C1), 172.4 (C=O). HR-MS (ESI): m/z [M]+ calcd 
272.0500 for C14H16FeO2; found 272.0502.  
4.5.4. (Rp)-1-Diphenylphosphinyl-2-methyl-ferrocene (Rp)-11d 
The crude product obtained from amine (1R,2S,Rp)-8d (5.071 g, 8.781 mmol) and NaBH4 
(996 mg, 26.34 mmol) was purified by column chromatography on aluminium oxide 90 
using EA as the eluent to give the title compound as an orange solid (2.495 g, 71% 
yield). mp 130–134 °C. [α]20λ (nm) = +118.9 (589), +120.7 (578), +113.7 (546) (c 0.996, 
CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 2.04 (s, 3H, CH3), 3.70–3.74 (m, 1H, H3), 4.17–
4.21 (m, 1H, H4), 4.24 (s, 5H, Cp'), 4.35–4.39 (m, 1H, H5), 7.34–7.41 (m, 2H, PhB-meta), 
7.41–7.48 (m, 3H, PhA-meta + PhB-para), 7.48–7.54 (m, 1H, PhA-para), 7.54–7.61 (m, 
2H, PhB-ortho), 7.69–7.78 (m, 2H, PhA-ortho). 13C{1H} NMR (100.6 MHz, CDCl3) δ: 14.1 
(CH3), 69.1 (d, J = 11.4 Hz, C4), 70.1 (Cp'), 72.1 (d, J = 115.1 Hz, C2), 73.5 (d, J = 15.4 
Hz, C3), 73.6 (d, J = 10.1 Hz, C5), 88.3 (d, J = 10.9 Hz, C1), 127.9 (d, J = 12.1 Hz, PhA-
meta), 128.2 (d, J = 11.9 Hz, PhB-meta), 131.2–131.3 (m, PhA-para + PhB-para), 131.4 
(d, J = 6.7 Hz, PhA/B-ortho), 131.5 (d, J = 6.8 Hz, PhA/B-ortho), 133.5, 134.2, 134.3, 135.2 
(PhA-ipso + PhB-ipso). 31P NMR (162 MHz, CDCl3) δ: 30.6 (P(O)Ph2). HR-MS (ESI): m/z 
[M + H]+ calcd 401.0758 for C23H22FeOP; found 401.0760.  
4.6. Synthesis of 1,2,3-trisubstituted ferrocenes 
4.6.1. (Rp)-1-Bromo-5-ethyl-2-hydroxycarbonyl-ferrocene (Rp)-12 
To a solution of (Sp)-10b (437 mg, 1.491 mmol) in dry THF (5 mL) was added a solution 
of LiTMP in THF/hexane (0.73 M, 4.08 mL, 2.98 mmol) at –78 °C. After stirring for 30 min 
at –78 °C, the temperature was raised to –30 °C and the mixture was stirred for an 
additional 4 h. The reaction mixture was transferred onto crushed dry ice. After 1 h at r.t. 
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the reaction mixture was dissolved in diethyl ether and extracted with a 10% aqueous 
NaOH solution (50 mL). The basic aqueous phase was extracted with diethyl ether (3 × 
50 mL, organic phases discarded) and the aqueous phase was made acidic with 10% 
phosphoric acid. After extraction with diethyl ether (3 × 50 mL) the combined organic 
phases were washed with brine, dried over MgSO4 and the solvent was removed under 
reduced pressure. The title compound was obtained as a yellow solid (0.386 mg, 77% 
yield). 1H NMR (400 MHz, DMSO-d6) δ: 1.12 (t, J = 7.3 Hz, 3H, CH2CH3), 2.35–2.56 (m, 
2H, CH2CH3), 4.18 (s, 5H, Cp'), 4.47–4.53 (m, 1H, H5), 4.64–4.72 (m, 1H, H4), 12.38 (s, 
1H, COOH). 13C{1H} NMR (100.6 MHz, DMSO-d6) δ: 14.2 (CH2CH3), 21.5 (CH2CH3), 
68.0 (Cq), 68.5 (C5), 68.9 (C2), 72.4 (Cp'), 80.5 (Cq), 92.8 (C1), 170.9 (COOH). HR-MS 
(EI, 30 °C): m/z [M – H]+ calcd 334.9372 for C13H12FeBrO2; found 334.9368. 
4.6.2. (Rp)-1-Bromo-2-ethoxycarbonyl-5-ethyl-ferrocene (Rp)-13 
To a solution of (Rp)-12 (290 mg, 861 mmol) in dichloromethane (23 mL) and methanol 
(2.3 mL) at r.t. was added a solution of diazomethane in diethyl ether (1M, 18 mL, 18 
mmol). The mixture was stirred for 30 min and the solvents were evaporated. The crude 
product was purified by chromatography on aluminium oxide 90 with PE/EA = 5/1 as the 
eluent to give the title compound as an orange solid (2.81 mg, 93% yield). mp 83 °C. 
[α]20λ (nm) = +0.61 (589),+3.1 (578), +26.7 (546) (c 0.330, CHCl3). 
1H NMR (400 MHz, 
CDCl3) δ: 1.17 (t, J = 7.6 Hz, 3H, CH2CH3), 2.40–2.57 (m, 2H, CH2CH3), 3.84 (s, 3H, 
CH3), 4.17 (s, 5H, Cp'), 4.36 (d, J = 2.8 Hz, 1H, H5), 4.73 (d, J = 2.8 Hz, 1H, H4). 
13C 
{1H}NMR (100.6 MHz, CDCl3) δ: 14.0 (CH2CH3), 21.9 (CH2CH3), 51.7 (CH3), 67.8 (C4), 
68.6 (C5), 72.7 (Cp'), 80.1 (Cq), 94.0 (C1), 1 Cq was not observed. HR-MS (EI, 30 °C): 
m/z [M]+ calcd 349.9605 for C14H15BrFeO2; found 349.9606. 
4.6.3. (Sp)-1-Bromo-2-hydroxycarbonyl-5-methyl-ferrocene (Sp)-14 
To a solution of (Rp)-11b (200 mg, 0.7170 mmol) in THF (6 mL) was added dropwise a 
solution of LiTMP in THF/hexane (0.73 M, 1.96 mL, 1.434 mmol) at –78 °C. The resulting 
mixture was stirred at –78 °C for a further 30 min and at –30 °C for 3 h. The solution was 
poured onto crushed dry ice and the heterogeneous mixture was left to warm up to r.t. 
The residue was dissolved in diethyl ether and extracted with 10% aqueous sodium 
hydroxide (50 mL). The basic aqueous phase was extracted twice with diethyl ether 
(organic phases discarded), the aqueous phase was made acidic with 10% phosphoric 
acid and extracted with diethyl ether. The combined organic extracts were washed with 
water and brine, dried over MgSO4 and the solvents were removed under reduced 
pressure. The crude product was obtained as an orange-yellow solid (169 mg, 73% 
yield). mp 145–168 °C (dec.). [α]20λ (nm): +9.8 (589), +5.1 (578), –26.2 (546) (c 0.654, 
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CHCl3). 
1H NMR (400 MHz, DMSO-d6) δ: 2.04 (s, 3H, CH3), 4.16 (s, 5H, Cp'), 4.53 (d, J = 
2.7 Hz, 1H, H5), 4.66 (d, J = 2.7 Hz, 1H, H4), 12.39 (bs, 1H, COOH). 13C{1H} NMR 
(100.6 MHz, DMSO-d6) δ: 13.9 (CH3), 68.0 (C4), 68.6 (Cq), 70.1 (C5), 72.6 (Cp'), 80.6 
(Cq), 86.9 (Cq), 170.9 (COOH). HR-MS (ESI): m/z [M]+ calcd 321.9293 for C12H11BrFeO2; 
found 321.9296. 
4.6.4. (Sp)-2-Cyano-1-diphenylphosphino-3-ethyl-ferrocene (Sp)-15 
To a solution of (Sp)-10e (269 mg, 1.125 mmol) in dry THF/hexane (5 mL) was added 
LiTMP (0.73 M, 3.08 mL, 2.250 mmol) at –78 °C. After stirring for 30 min at –78 °C, the 
temperature was raised to –30 °C and the mixture was stirred for additional 4 h. The 
mixture was cooled to –78 °C and chlorodiphenylphosphine (0.437 mL, 2.363 mmol) was 
added. After 30 min stirring at –78 °C, the reaction mixture was allowed to warm up to r.t. 
Stirring was continued for an additional 16 h and the reaction was quenched by the 
dropwise addition of water (5 mL). Diethyl ether was added and the phases were 
separated. The organic phase was washed with water and brine (3×), dried over MgSO4 
and the solvent was removed under reduced pressure. The crude product was purified 
by chromatography on aluminium oxide 90 with PE/EA = 9/1 as the eluent to give the title 
compound as a yellow solid (433 mg, 91% yield). mp 162 °C. [α]20λ (nm) = –108.1 (589), 
–111.4 (578), –131.9 (546) (c 0.298, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.27 (t, J = 
7.8 Hz, 3H, CH2CH3), 2.59 (q, J = 7.8 Hz, 2H, CH2CH3), 3.95 (dd, J = 2.5 Hz, J = 1.0 Hz, 
1H, H4), 4.45(d, J = 2.5 Hz, 1H, H5), 7.16–7.23 (m, 2H, PhA-ortho), 7.25–7.30 (m, 3H, 
PhA-meta + PhA-para), 7.37–7.43 (m, 3H, PhB-meta + PhB-para), 7.52–7.60 (m, 2H, PhB-
ortho). 13C{1H}NMR (100.6 MHz, CDCl3) δ: 14.5 (CH2CH3), 21.8 (CH2CH3), 58.5 (d, J = 
28.9, 2C Hz, C2), 71.3 (C4), 72.1 (Cp'), 73.6 (d, J = 2.4 Hz, C5), 80.1 (d, J = 14.5 Hz, 
C3), 97.8 (d, J = 2.7 Hz, C1), 119.0 (CN), 128.3 (d, J = 6.2 Hz, PhA-meta), 125.35 (PhA-
para), 128.4 (d, J = 6.9 Hz, PhB-meta), 129. 5 (PhB-para), 132.3 (d, J = 18.3 Hz, PhA-
ortho), 134.8 (d, J = 21.4 Hz, PhB-ortho), 136.5 (d, J = 9.5 Hz, PhB-ipso), 138.4 (d, J = 
10.7Hz, PhA-ipso). HR-MS (EI, 30 °C): m/z [M + H]+ calcd 424.0918 for C25H23FeNP; 
found 424.0923.  
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 4. Summary 
4.1 Ruthenium complexes of phosphino-substituted ferrocenyl-
oxazolines in the asymmetric hydrogenation and transfer 
hydrogenation of ketones: a comparison. 
As described in Chapter 3.1*, a number of phosphino-substituted ferrocenyloxazolines 
with altered structural features were prepared and tested in the ruthenium-catalyzed 
transfer hydrogenation and hydrogenation of ketones. It was one intention of this work to 
investigate correlations in between ligand structure and catalyst performance. 
Furthermore, it was of interest to compare the results of transfer hydrogenations and 
hydrogenations when these reactions were carried out with identical catalyst precursors. 
For this purpose five ligands, 2–4, recently developed in our group plus three newly 
prepared ligands, 5–7, with varied structural features were used (Chart 10). 
Ligand (R,RFc)-5 which lacks the stereogenic center of the oxazoline unit, was 
prepared by the synthesis procedure depicted in Scheme 21. Amino-ester (R,SFc)-9 
which was easily accessible from Ugi’s amine, (R)-8, underwent with the appropriate 
amino alcohol an aluminium mediated transamidation that afforded the corresponding 
amide (R,SFc)-10. In the next step, (R,SFc)-10 was transformed according to Appel’s 
methodology to oxazoline (R,SFc)-11. Subsequently, treatment with methyl iodide in 
acetonitrile and reaction of the crude ammonium salt with diphenylphosphinyl lithium 
generated the phosphinyl-substituted derivative (R,RFc)-12. Reduction of this phosphine 
oxide with polymethylhydrosiloxane (PMHS) in the presence of titanium isopropoxide 
provided the desired phosphine-oxazoline (R,RFc)-5. 
Ligands (SOx,SFc)-6 and (SOx,SFc)-7 which both lack the stereogenic center of the 
side-chain carbon were achieved in only two steps from commercially available 
ferrocenyl oxazoline (SOx)-13. Alcohol (SOx,RFc)-14, easily obtainable from (SOx)-13, was 
transformed with either diphenylphosphine or bis(3,5-dimethylphenyl)phosphine in the 
presence of chlorotrimethylsilane and sodium iodide into ligands (SOx,SFc)-6 and 
(SOx,SFc)-7 (Scheme 22). 
                                               
*
 The substance numbering is adapted from chapter 3. 
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Scheme 21. Synthesis route for ligand (R,RFc)-5. 
 
 
Scheme 22. Synthesis route for ligands (SOx,SFc)-6 and (SOx,SFc)-7. 
Ruthenium complexes of the type [RuCl2PPh3(L)] were prepared from all eight 
bidentate phosphine-oxazoline ligands L = 2–7 plus one reference ligand L = 1 (Chart 
10) and were tested as catalyst precursors in the asymmetric hydrogenation and 
transfer hydrogenation of fourteen ketones. 
In summary, ruthenium complexes [RuCl2PPh3(L)] of eight novel bidentate 
phosphine-oxazoline ligands were synthesized, characterized and screened in transfer 
hydrogenations and hydrogenations of a series of dialkyl and aryl-alkyl ketones. In 
addition, for comparative purposes, the transfer hydrogenations of all substrates were 
carried out with one analogous and well-established FOXAP ruthenium complex (L = 1). 
Two catalysts delivered products with enantiomeric excesses of up to 99% in 
hydrogenation and 98% in transfer hydrogenation. A structural comparison of all ligands 
allowed to deduce that the (S,SOx,SFc) relative configuration constitutes the matching 
configuration while a change of the oxazoline configuration leads to a decrease in 
product enantiomeric excess. Furthermore, a comparison of transfer hydrogenation and 
hydrogenation data showed surprising similarities. In both types of reaction nearly 
identical product e.e.s were obtained when identical catalyst precursors were used and 
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 this fact is likely to be the result of comparable reaction mechanisms. The molecular 
structures of two catalyst precursors and of two corresponding acetonitrile complexes 
were studied by X-ray diffraction. From these structures a transition state model for the 
transfer hydrogenations reactions was deduced that allowed a correlation of ligand and 
product absolute configurations. 
 
Chart 10. Ligands 1–7. 
4.2 Diastereoselective -deprotonations and autocatalytic 
alkylations: synthesis of phosphino-substituted ferrocenyl-
oxazolines 
As reported in chapter 3.2, two novel routes were developed for the synthesis of 
the most efficient phosphino-substituted ferrocenyloxazoline ligands (Raffa-FOX 
ligands) (SOx,SFc)-3 and analogs. As compared to the original synthesis, these novel 
routes avoid the use of two enantiopure starting materials and in addition allow the 
synthesis of previously inaccessible diastereomers. 
Both routes started from easily accessible ferrocenyl-oxazolines and in both 
cases the phosphino-substituted side chain was built up diastereoselectively. In the first 
synthesis sequence, 2-oxazolinyl substituted ferrocene aldehydes were directly arylated 
or alkylated through an auto-activated phenyl or alkyl transfer either from diphenyl zinc 
or from dialkyl zinc reagents and provided alcohols (S,SOx,RFc)-18, 20, 23 and 24 in 
form of single diastereomers. Furthermore, these alcohols were transformed into the 
desired phosphino-oxazolines (S,SOx,SFc)-3, 4 and 22 in enantiomerically pure form all 
having the desired (S,SOx,SFc) relative configuration (Scheme 23). 
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Scheme 23. Synthesis of different phosphino-oxazolines via auto-activated 
phenyl or alkyl transfers. 
In the second sequence, ligands of type (SOx,SFc)-2 were synthesized in three 
straightforward steps from easily accessible and commercially available ferrocenyl 
oxazoline (SOx)-5 (Scheme 24). Subsequently, (SOx,SFc)-2 was oxidized to phosphine 
oxide (SOx,SFc)-26. Diastereoselective -deprotonation of (SOx,SFc)-26 with 
tBuLi in THF 
at –78 °C and quenching with MeI formed (R,SOx,SFc)-17 as the main diastereomer. In 
the next step, reduction of (R,SOx,SFc)-17 resulted in (R,SOx,SFc)-3 which represents the 
side chain epimer of (S,SOx,SFc)-3 (Scheme 25).  
 
Scheme 24. Synthesis of ligands (SOx,SFc)-2 and (SOx,SFc)-11. 
 
 
Scheme 25. Diastereoselective -deprotonation of (SOx,SFc)-26. 
Surprisingly, when (R,SOx,SFc)-17 was reacted with 
tBuLi and when the lithiated 
intermediate was quenched with water, it cleanly epimerized to (S,SOx,SFc)-17. 
151
 Subsequently, reduction of (S,SOx,SFc)-17 resulted in (S,SOx,SFc)-3 which in form of its 
enantiomer (R,ROx,RFc)-3 had performed best in the hydrogenation and transfer 
hydrogenation of ketones (Scheme 26). Furthermore, the -dimethylsubstituted 
ferrocene derivative (SOx,SFc)-27 was obtained by treating (R,SOx,SFc)-17 with 
tBuLi and 
quenching with MeI (Scheme 26). 
 
Scheme 26. Synthesis of (S,SOx,SFc)-3 and (SOx,SFc)-27. 
In summary, two complementary and highly modular synthesis routes for 
ferrocenyl-based phosphino-oxazolines were explored that have the phosphino unit 
attached to a ferrocenylmethyl or a ferrocenylethyl side-chain. Furthermore, a number 
of transfer hydrogenations of ketones were carried out. From a comparison of these 
catalysis results with our previously reported data it is concluded that for this type of 
ligand the (S,SOx,SFc) relative configuration constitutes the matching configuration while 
a change of either the side-chain or the oxazoline configuration leads to less efficient 
transfer hydrogenation catalysts.  
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 4.3 Synthesis of chiral, non-racemic ferrocene derivatives via 
ortho-metallation and partial reductive removal of ortho-directing 
amino groups 
As described in chapter 3.3, a three step sequence for the preparation of chiral, 
nonracemic ferrocene derivatives was explored. In the first step 1,2-disubstituted 
derivatives were synthesized from the well-established ferrocenyl amines (R)-2, 
(1R,2S)-3, and (R)-4 via diastereoselective ortho-directed reactions. In the second step, 
suitable reaction conditions for the reductive removal of the amino substituents were 
developed (Scheme 27). A further ortho-lithiation of derivatives 10b–10e and 11b–11d 
which contain well recognised ortho-directing substituents (Br, COOEt, P(O)Ph2 and 
CN) resulted in chiral non-racemic 1,2,3-trisubstituted ferrocenes (Scheme 28). 
In summary, a very general and highly modular procedure has been developed 
for the synthesis of chiral non-racemic 1,2-di- and 1,2,3-trisubstituted ferrocene 
derivatives which all are inclined to be useful starting materials for the preparation of 
chiral, non-racemic ferrocenes such as phosphino or oxazoline based catalysts ligands. 
 
Scheme 27. Preparation of derivatives 7–11. 
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Scheme 28. Synthesis of 1,2,3-trisubstituted ferrocenes 12–15. 
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